Profile of medicinal plants utilization through patent documents: the andiroba example

Directory of Open Access Journals (Sweden)

Luciene F. Gaspar Amaral

2013-06-01

Full Text Available Today, one of the trends of the pharmaceutical, cosmetic and food market is the development of products with components of natural origin, rationally exploiting biodiversity. Brazilian population makes secular use of medicinal plants including andiroba, whose oil is used in folk medicine as febrifuge, pain-relieving, anti-parasitic, anti-allergic as well as insect repellant. The present study attempts to evaluate the profile of utilization of andiroba by analyzing the patenting trends based on information collected on the databases of the World Intellectual Property Organization, European Patent Office and Brazilian National Institute of Industrial Property in the period from 1990 to 2011. The following parameters were analyzed: chronological aspect of the applications, countries of priority, international patent classification, technologies and actors in the technological platform. The temporal analysis of the applications shows an evident increase despite a discontinuous evolution of the number of applications. Pharmaceutical, chemical and cosmetic areas were identified as the main areas for commercial application of the plant. Brazil is the country with the largest number of applications even though the majority of the patent technologies are already in public domain, indicating that the technological information contained in these documents could be used for research and investment in several areas.

Patent Medicine Vendors in Rural Areas of Lagos Nigeria ...

African Journals Online (AJOL)

Purpose: To determine the compliance of patent medicine vendors (PMVs) in rural areas of Lagos State, Nigeria with set guidelines to regulate their practice and its implications for malaria control. Methods: A baseline cross-sectional study was conducted as part of an intervention study in two rural local government areas ...

George Fulford and Victorian patent medicine men: Quack mercenaries or Smilesian entrepreneurs?

Science.gov (United States)

Loeb, L

1999-01-01

In the early twentieth century, a time when patent medicine men were stereotyped as evil and dishonest, G. T. Fulford of Brockville, Ontario made his fortune from an iron pill called Dr. Williams' Pink Pills for Pale People. Once successful, Fulford remained in Brockville where he served on the town council and gave generously to charities. In 1900 he was appointed by Laurier to the Senate. When he died in 1905 he was remembered as a kind and ethical man. His story, like that of several other prominent patent medicine men, conforms more with the ideals of Samuel Smiles than with the popular image of disrepute.

Radioactive legacies from medicine and industry

International Nuclear Information System (INIS)

Linder, R.; Rodriguez, J.

2005-01-01

Due to the unintended disposal of radioactive legacies (waste from medicine, industry or private persons) radioactive material occasionally enters the disposal ways of conventional waste. The Swiss Federal Office of Public Health (SFOPH) and the Swiss accident Insurance Fund (Swiss) are the licensing authorities and regulatory agencies of the handling with radioactive materials for non-nuclear use. The aim is to avoid such incidents with concrete measures and so to preserve men and environment from the negative effect of not correctly disposed radioactive waste. (orig.)

[Preliminary study on general safe medication regularity of Chinese patent orthopedic medicines based on adverse reaction/event literature analysis].

Science.gov (United States)

Wang, Yu-guang; Shi, Xin-yuan; Jin, Rui; Li, Hong-yan; Kong, Xiang-wen; Qiao, Yan-jiang

2015-03-01

Chinese patent orthopedic medicines feature complex components, mainly including desperate and toxic herbal pieces, narrow safety window, more clinical contraindications and frequent adverse drug reaction/events (ADR/ADE). To study the general safe medication regularity of Chinese patent orthopedic medicines, define key points in the medication education and ensure rational clinical medication, the authors took 80 types of commonly used Chinese patent orthopedic medicines as the study objects, collect 237 cases from 164 ADR/ADE documents through a system retrieval strategy, make a multidimensional literature analysis to determine the common risk factors for safe and rational medication of Chinese patent orthopedic medicines and establish an ADR/ADE prevention regularity. First, in the aspect of clinical symptoms, skin allergy is the most common ADR/ADE and closely related to the toxic ingredients, particularly accumulated liver or kidney damage caused by some drugs. Second, there are three time nodes in the ADR/ADE occurrence; The ADR/ADE occurred in 30 minutes is closely related to the idiosyncrasy; the ADR/ADE occurred between several months and half a year is related to the drug-induced liver and kidney damages; The most common ADR/ADE was observed within 7 days and predictable according to the pharmacological actions; Third, toxicity is an important factor in the occurrence of ADR/ADE of Chinese patent orthopedic medicines. Fourth, emphasis shall be given to the special medication factors, such as the combination with western medicines and Chinese herbal decoctions, overdose and long-course medication and self-medical therapy. In conclusion, the general ADR/ADE prevention regularity for Chinese patent orthopedic medicines was summarized to provide supports for clinicians in safe and rational medication and give the guidance for pharmacist in medication education.

Plant biotechnology patents: applications in agriculture and medicine.

Science.gov (United States)

Hefferon, Kathleen

2010-06-01

Recent advances in agricultural biotechnology have enabled the field of plant biology to move forward in great leaps and bounds. In particular, recent breakthroughs in molecular biology, plant genomics and crop science have brought about a paradigm shift of thought regarding the manner by which plants can be utilized both in agriculture and in medicine. Besides the more well known improvements in agronomic traits of crops such as disease resistance and drought tolerance, plants can now be associated with topics as diverse as biofuel production, phytoremediation, the improvement of nutritional qualities in edible plants, the identification of compounds for medicinal purposes in plants and the use of plants as therapeutic protein production platforms. This diversification of plant science has been accompanied by the great abundance of new patents issued in these fields and, as many of these inventions approach commercial realization, the subsequent increase in agriculturally-based industries. While this review chapter is written primarily for plant scientists who have great interest in the new directions being taken with respect to applications in agricultural biotechnology, those in other disciplines, such as medical researchers, environmental scientists and engineers, may find significant value in reading this article as well. The review attempts to provide an overview of the most recent patents issued for plant biotechnology with respect to both agriculture and medicine. The chapter concludes with the proposal that the combined driving forces of climate change, as well as the ever increasing needs for clean energy and food security will play a pivotal role in leading the direction for applied plant biotechnology research in the future.

Radioactive waste management of the nuclear medicine services

International Nuclear Information System (INIS)

Barboza, Alex

2009-01-01

Radioisotope applications in nuclear medicine services, for diagnosis and therapy, generate radioactive wastes. The general characteristics and the amount of wastes that are generated in each facility are function of the number of patients treated, the procedures adopted, and the radioisotopes used. The management of these wastes embraces every technical and administrative activity necessary to handle the wastes, from the moment of their generation, till their final disposal, must be planned before the nuclear medicine facility is commissioned, and aims at assuring people safety and environmental protection. The regulatory framework was established in 1985, when the National Commission on Nuclear Energy issued the regulation CNEN-NE-6.05 'Radioactive waste management in radioactive facilities'. Although the objective of that regulation was to set up the rules for the operation of a radioactive waste management system, many requirements were broadly or vaguely defined making it difficult to ascertain compliance in specific facilities. The objective of the present dissertation is to describe the radioactive waste management system in a nuclear medicine facility and provide guidance on how to comply with regulatory requirements. (author)

Quality Control of the Traditional Patent Medicine Yimu Wan Based on SMRT Sequencing and DNA Barcoding

Science.gov (United States)

Jia, Jing; Xu, Zhichao; Xin, Tianyi; Shi, Linchun; Song, Jingyuan

2017-01-01

Substandard traditional patent medicines may lead to global safety-related issues. Protecting consumers from the health risks associated with the integrity and authenticity of herbal preparations is of great concern. Of particular concern is quality control for traditional patent medicines. Here, we establish an effective approach for verifying the biological composition of traditional patent medicines based on single-molecule real-time (SMRT) sequencing and DNA barcoding. Yimu Wan (YMW), a classical herbal prescription recorded in the Chinese Pharmacopoeia, was chosen to test the method. Two reference YMW samples were used to establish a standard method for analysis, which was then applied to three different batches of commercial YMW samples. A total of 3703 and 4810 circular-consensus sequencing (CCS) reads from two reference and three commercial YMW samples were mapped to the ITS2 and psbA-trnH regions, respectively. Moreover, comparison of intraspecific genetic distances based on SMRT sequencing data with reference data from Sanger sequencing revealed an ITS2 and psbA-trnH intergenic spacer that exhibited high intraspecific divergence, with the sites of variation showing significant differences within species. Using the CCS strategy for SMRT sequencing analysis was adequate to guarantee the accuracy of identification. This study demonstrates the application of SMRT sequencing to detect the biological ingredients of herbal preparations. SMRT sequencing provides an affordable way to monitor the legality and safety of traditional patent medicines. PMID:28620408

Life after Myriad: the uncertain future of patenting biomedical innovation and personalised medicine in an international context

DEFF Research Database (Denmark)

M. Schwartz, Robert; Minssen, Timo

2015-01-01

On June 13, 2013, the U.S. Supreme Court decided the Myriad gene patent case. In a unanimous judgment the Court held that patent claims directed to isolated genomic DNA are identical to the naturally occurring sequence and thus unpatentable “products of nature”. This decision affects all isolated...... with the situation in Australia and in the EU.   Keywords: biotechnology, comparative patent law, US, Europe, Australia, DNA, Myriad, patent-eligibility,personalized medicine, genetic diagnostics, USPTO 2014 Guidelines, methods,innovation, Unified Patent Court....... of these decisions on the biomedical sector and personalized medicine,as well the methodology used by the generalist Supreme Court in reversing a specialized CAFC judgment is particularly interesting from a comparative perspective. This paper analyses and discusses these U.S. developments, and compares them...

[Research on collaborative innovation in traditional Chinese medicine of China based on patent cooperation network].

Science.gov (United States)

Li, Bei; Chen, Xiang-dong

2015-03-01

In the situation of global completion, collaborative innovation is becoming increasingly important because its advantage in risk avoiding and innovation efficiency. In order to explore the model of collaborative innovation and its evolution in traditional Chinese medicine of China, the cooperation in traditional Chinese medicine patents of China from 1985 to 2013 has been analyzed by using the method of scientometrics and social network analysis. It is proved that, though the number of grated cooperative patents has increased sharply during the last thirty years, the degree of cooperation innovation in traditional Chinese medicine of China is still not high. Moreover, in spite of the individual subject' s leading role in the past domestic collaborative innovation in traditional Chinese medicine of China, the institutions have been more and more powerful and achieved great improvement. At last, core institutions, represented by universities have played an important role in the collaborative innovation of domestic institutions, because they are key links between many institutions and promote the transferring and diffusion of knowledge.

Canada's Patented Medicine Notice of Compliance regulations: balancing the scales or tipping them?

Directory of Open Access Journals (Sweden)

Lexchin Joel

2011-03-01

Full Text Available Abstract Background In order to comply with the provisions of the North American Free Trade Agreement, in 1993 the Canadian federal government introduced the Patented Medicine Notice of Compliance Linkage Regulations. These regulations were meant to achieve a balance between the timely entry of generic medicines and the rights of patent holders. The regulations tied the regulatory approval of generic medicines to the patent status of the original brand-name product. Discussion Since their introduction the regulations have been a source of contention between the generic and the brand-name industry. While the regulations have generated a considerable amount of work for the Federal Court of Canada both sides dispute the interpretation of the "win rate" in the court cases. Similarly, there is no agreement on whether multiple patents on single drugs represent a legitimate activity by the brand-name industry or an "evergreening" tactic. The generic industry's position is that the regulations are being abused leading to the delay in the introduction of lower cost generic products by as much as 8 years. The brand-name companies counter that the regulations are necessary because injunctions against the introduction of generic products are frequently unavailable to them. The regulations were amended in 2006 and again in 2008 but both sides continue to claim that the regulations favour the other party. The battle around the regulations also has an international dimension with interventions by PhRMA, the trade association representing the United States based multinational companies, arguing that the regulations are not stringent enough and that Canada needs to be placed on the U.S. Priority Watch List of countries. Finally, there are multiple costs to Canadian society as a result of the NOC regulations. Summary Despite the rhetoric there has been almost no empiric academic research done into the effect of the regulations. In order to develop rational policy

The pharmaceutical sector, patents and access to medicines in the South

Directory of Open Access Journals (Sweden)

Xabier Barrutia Etxebarría

2003-12-01

Full Text Available This article deals with the lack of access to drug treatments experienced by the poor in the economic South. First, it studies the extraordinarily profitable pharmaceutical industry, whose research forgets about the illnesses typical of the South, given its greatbusiness and market concentration in the countries of the North, where marketing is decisive. Then, it deals with the relationship between the high prices of medicines and a patent system which is greatly strengthened by the rules of the WTO and which clasheswith people’s right to health, as revealed by the case of HIV-AIDS treatment in the countries of the South. The paper concludes by underscoring the need for an active intervention by the public sector, both at a national and international level, which wouldlimit the patents on drugs and promote research on the forgotten diseases.

Regulation on the manufacture of radioactive medicines

International Nuclear Information System (INIS)

1977-01-01

This is the latest revision of the regulation which provides for the control of the manufacture of the said medicines in accordance with the Medical Drugs Act (Law No. 145, 1960). Schedule 1 to Article 1 which specifies the items of the radioactive medicines has been modified: several substances including their compounds and medicines made from them are added to, or omitted from the Schedule, such as; (added to) 11 C, 13 N, 15 O, sup(85m)Kr, 81 Rb and 123 I, (omitted from) 89 Sr, 91 y and 137 Cs. (Matsushima, A.)

Radioactive isotopes in clinical medicine and research. Abstracts

International Nuclear Information System (INIS)

2005-01-01

The contribution displays 44 abstracts and 35 posters from the 27th International Symposium on ''radioactive isotopes in clinical medicine and research'', organized by the Austrian society of nuclear medicine and the department of nuclear medicine and the center for biomedical engineering and physics of the Vienna medical university. The abstracts are sorted according to lecture headers: radiopharmaceutical sciences, endocrinology, clinical PET, neurology, oncology, physics and instrumentation, cardiology, inflammation, therapy and varia. (uke)

Statutory instruments: 1984 No. 1261 Medicines - The Medicines (Committee on Radiation from Radioactive Medicinal Products) (Revocation) Order 1984

International Nuclear Information System (INIS)

1984-01-01

This Order, which came into force on 6 September 1984, revokes the Medicines (Committee on Radiation from Radioactive Medicinal Products) Order 1978 thereby abolishing the Committee, which was established for the purpose of giving advice on safety, quality and efficacy in relation to radiation involving any substance or article for human use to which the Medicins Act 1968 is applicable. (NEA) [fr

Development and tuning of an original search engine for patent libraries in medicinal chemistry.

Science.gov (United States)

Pasche, Emilie; Gobeill, Julien; Kreim, Olivier; Oezdemir-Zaech, Fatma; Vachon, Therese; Lovis, Christian; Ruch, Patrick

2014-01-01

The large increase in the size of patent collections has led to the need of efficient search strategies. But the development of advanced text-mining applications dedicated to patents of the biomedical field remains rare, in particular to address the needs of the pharmaceutical & biotech industry, which intensively uses patent libraries for competitive intelligence and drug development. We describe here the development of an advanced retrieval engine to search information in patent collections in the field of medicinal chemistry. We investigate and combine different strategies and evaluate their respective impact on the performance of the search engine applied to various search tasks, which covers the putatively most frequent search behaviours of intellectual property officers in medical chemistry: 1) a prior art search task; 2) a technical survey task; and 3) a variant of the technical survey task, sometimes called known-item search task, where a single patent is targeted. The optimal tuning of our engine resulted in a top-precision of 6.76% for the prior art search task, 23.28% for the technical survey task and 46.02% for the variant of the technical survey task. We observed that co-citation boosting was an appropriate strategy to improve prior art search tasks, while IPC classification of queries was improving retrieval effectiveness for technical survey tasks. Surprisingly, the use of the full body of the patent was always detrimental for search effectiveness. It was also observed that normalizing biomedical entities using curated dictionaries had simply no impact on the search tasks we evaluate. The search engine was finally implemented as a web-application within Novartis Pharma. The application is briefly described in the report. We have presented the development of a search engine dedicated to patent search, based on state of the art methods applied to patent corpora. We have shown that a proper tuning of the system to adapt to the various search tasks

A critique of an argument against patent rights for essential medicines

DEFF Research Database (Denmark)

Sønderholm, Jørn

2014-01-01

holds, namely that patent rights for essential medicines are morally unjustified per se. Throughout this paper, ‘the strong view’ refers to this view. The strong view is one that enjoys considerable support both within and outside the academic community. This paper critically discusses one specific......Thomas Pogge has recently argued that the way in which research and development of essential medicines is incentivized, under existing World Trade Organization rules, should be supplemented with an additional incentivizing mechanism. One might hold a stronger view than the one that Pogge currently...... view also have some grounds for believing that the argument is sound. This belief comes, however, with what is arguably a too high cost, namely that the global institutional order becomes very demanding on taxpaying citizens of high-income countries if it is to be just. One may find acceptance...

Expert Consensus on the Treatment of Hypertension with Chinese Patent Medicines

Directory of Open Access Journals (Sweden)

Li Ying Wang

2013-01-01

Full Text Available Objectives. This study was aimed to determine the therapeutic principle and identify Chinese Patent Medicine (CPM with corresponding indications for hypertension treatment. Methods. Three rounds of Delphi survey were mailed among 40 cardiovascular integrative medicine specialists. Items with agreement of more than 80% respondents were included in the consensus. Results. According to majority of the panelists, CPM is suitable for most hypertensive patients and should be used according to traditional Chinese medicine pattern classification. CPM could be used alone for grade 1 hypertension and could be used in combination with Western biomedicine (WM for both grade 2 and grade 3 hypertension. It is recommended that less than two CPMs are used simultaneously. For the treatment of grade 2 and 3 hypertension, CPM and WM should be taken separately. Recommended CPMs included Tianma Gouteng granule, Qiju Dihuang capsule, Jinkui Shenqi pill, Yinxingye tablet, Niuhuang Jiangya pill and Banxia Tianma pill. The indications of 4 CPMs were specified with symptoms related to TCM pattern classification by the experts. Conclusions. An expert consensus on CMP application was formed for the treatment of hypertension in the form of integrative medicine. A flow of IM hypertension management was proposed based on the results of the survey.

An advanced search engine for patent analytics in medicinal chemistry.

Science.gov (United States)

Pasche, Emilie; Gobeill, Julien; Teodoro, Douglas; Gaudinat, Arnaud; Vishnykova, Dina; Lovis, Christian; Ruch, Patrick

2012-01-01

Patent collections contain an important amount of medical-related knowledge, but existing tools were reported to lack of useful functionalities. We present here the development of TWINC, an advanced search engine dedicated to patent retrieval in the domain of health and life sciences. Our tool embeds two search modes: an ad hoc search to retrieve relevant patents given a short query and a related patent search to retrieve similar patents given a patent. Both search modes rely on tuning experiments performed during several patent retrieval competitions. Moreover, TWINC is enhanced with interactive modules, such as chemical query expansion, which is of prior importance to cope with various ways of naming biomedical entities. While the related patent search showed promising performances, the ad-hoc search resulted in fairly contrasted results. Nonetheless, TWINC performed well during the Chemathlon task of the PatOlympics competition and experts appreciated its usability.

[Method of traditional Chinese medicine formula design based on 3D-database pharmacophore search and patent retrieval].

Science.gov (United States)

He, Yu-su; Sun, Zhi-yi; Zhang, Yan-ling

2014-11-01

By using the pharmacophore model of mineralocorticoid receptor antagonists as a starting point, the experiment stud- ies the method of traditional Chinese medicine formula design for anti-hypertensive. Pharmacophore models were generated by 3D-QSAR pharmacophore (Hypogen) program of the DS3.5, based on the training set composed of 33 mineralocorticoid receptor antagonists. The best pharmacophore model consisted of two Hydrogen-bond acceptors, three Hydrophobic and four excluded volumes. Its correlation coefficient of training set and test set, N, and CAI value were 0.9534, 0.6748, 2.878, and 1.119. According to the database screening, 1700 active compounds from 86 source plant were obtained. Because of lacking of available anti-hypertensive medi cation strategy in traditional theory, this article takes advantage of patent retrieval in world traditional medicine patent database, in order to design drug formula. Finally, two formulae was obtained for antihypertensive.

[Rapid determination of illicit beta2-agonist additives in health foods and traditional Chinese patent medicines with DCBI-MS/MS method].

Science.gov (United States)

Hou, Yu-Lan; Wu, Shuang; Wang, Hua; Zhao, Yong; Liao, Peng; Tian, Qing-Qing; Sun, Wen-Jian; Chen, Bo

2013-01-01

A novel rapid method for detection of the illicit beta2-agonist additives in health foods and traditional Chinese patent medicines was developed with the desorption corona beam ionization mass spectrometry (DCBI-MS) technique. The DCBI conditions including temperature and sample volume were optimized according to the resulting mass spectra intensity. Matrix effect on 9 beta2-agonists additives was not significant in the proposed rapid determination procedure. All of the 9 target molecules were detected within 1 min. Quantification was achieved based on the typical fragment ion in MS2 spectra of each analyte. The method showed good linear coefficients in the range of 1-100 mg x L(-1) for all analytes. The relative deviation values were between 14.29% and 25.13%. Ten claimed antitussive and antiasthmatic health foods and traditional Chinese patent medicines from local pharmacies were analyzed. All of them were negative with the proposed DCBI-MS method. Without tedious sample pretreatments, the developed DCBI-MS is simple, rapid and sensitive for rapid qualification and semi-quantification of the illicit beta2-agonist additives in health foods and traditional Chinese patent medicines.

Development of RadRob15, A Robot for Detecting Radioactive Contamination in Nuclear Medicine Departments

Directory of Open Access Journals (Sweden)

Shafe A.

2016-09-01

Full Text Available Accidental or intentional release of radioactive materials into the living or working environment may cause radioactive contamination. In nuclear medicine departments, radioactive contamination is usually due to radionuclides which emit high energy gamma photons and particles. These radionuclides have a broad range of energies and penetration capabilities. Rapid detection of radioactive contamination is very important for efficient removing of the contamination without spreading the radionuclides. A quick scan of the contaminated area helps health physicists locate the contaminated area and assess the level of activity. Studies performed in IR Iran shows that in some nuclear medicine departments, areas with relatively high levels of activity can be found. The highest contamination level was detected in corridors which are usually used by patients. To monitor radioactive contamination in nuclear medicine departments, RadRob15, a contamination detecting robot was developed in the Ionizing and Non-ionizing Radiation Protection Research Center (INIRPRC. The motor vehicle scanner and the gas radiation detector are the main components of this robot. The detection limit of this robot has enabled it to detect low levels of radioactive contamination. Our preliminary tests show that RadRob15 can be easily used in nuclear medicine departments as a device for quick surveys which identifies the presence or absence of radioactive contamination.

Quality assurance for radioactive measurement in nuclear medicine

International Nuclear Information System (INIS)

2006-01-01

The field of nuclear medicine continues to grow around the world, owing in part to a number of successful programmes carried out by the IAEA to enhance the use of nuclear medicine techniques in Member States. The implementation of quality assurance (QA) programmes to ensure the safe application of radiopharmaceuticals has, however, been variable in many Member States. One possible reason is the lack of a unified set of principles regarding the establishment of such programmes. This publication addresses the issue of QA programmes for radioactivity measurement in nuclear medicine. A group of experts consulted by the IAEA recommended in 2002 that unified principles concerning QA and quality control (QC) procedures for the measurement of radioactivity in nuclear medicine be developed because of its importance in controlling the safety and effectiveness of the use of radiopharmaceuticals. This publication is the result of advice provided to the IAEA by experts in the fields of radionuclide metrology, medical physics and radiopharmacy. This report can be considered to be a more detailed and updated version of IAEA-TECDOC-602, Quality Control of Nuclear Medicine Instruments, published in 1991. Advances in the field of nuclear instrumentation since that report was published, particularly in imaging, and the increased emphasis on QA and QC prompted the need for an update. Moreover, it was realized that the activity measurement and imaging aspects had each become so specialized as to be better treated in separate publications. The present report focuses on the factors affecting radioactivity measurement and the implementation of QA and QC programmes to ensure accurate and consistent results. The IAEA has developed a safety standard on The Management System for Facilities and Activities (IAEA Safety Standards Series No. GS-R-3), which replaces the IAEA publications on QA issued as Safety Series No. 50-C/SG-Q (1996). In GS-R-3, the management system is described as a set of

Successful private-public funding of paediatric medicines research: lessons from the EU programme to fund research into off-patent medicines.

Science.gov (United States)

Ruggieri, L; Giannuzzi, V; Baiardi, P; Bonifazi, F; Davies, E H; Giaquinto, C; Bonifazi, D; Felisi, M; Chiron, C; Pressler, R; Rabe, H; Whitaker, M J; Neubert, A; Jacqz-Aigrain, E; Eichler, I; Turner, M A; Ceci, A

2015-04-01

The European Paediatric Regulation mandated the European Commission to fund research on off-patent medicines with demonstrated therapeutic interest for children. Responding to this mandate, five FP7 project calls were launched and 20 projects were granted. This paper aims to detail the funded projects and their preliminary results. Publicly available sources have been consulted and a descriptive analysis has been performed. Twenty Research Consortia including 246 partners in 29 European and non-European countries were created (involving 129 universities or public-funded research organisations, 51 private companies with 40 SMEs, 7 patient associations). The funded projects investigate 24 medicines, covering 10 therapeutic areas in all paediatric age groups. In response to the Paediatric Regulation and to apply for a Paediatric Use Marketing Authorisation, 15 Paediatric Investigation Plans have been granted by the EMA-Paediatric Committee, including 71 studies of whom 29 paediatric clinical trials, leading to a total of 7,300 children to be recruited in more than 380 investigational centres. Notwithstanding the EU contribution for each study is lower than similar publicly funded projects, and also considering the complexity of paediatric research, these projects are performing high-quality research and are progressing towards the increase of new paediatric medicines on the market. Private-public partnerships have been effectively implemented, providing a good example for future collaborative actions. Since these projects cover a limited number of off-patent drugs and many unmet therapeutic needs in paediatrics remain, it is crucial foreseeing new similar initiatives in forthcoming European funding programmes.

Analysis on the Application and Characteristics of Chinese Patent Medicines Containing Dried Rehmanniae Radix

Science.gov (United States)

Guo, Hui; Miao, Yanyan; Miao, mingsan

2018-01-01

Dried Rehmanniae Radix has sweet taste, and its drug property is cold.It acts on heart, liver and kidney.It has the effect of clearing heat and cooling blood, nourishing yin and promoting fluid production.The active constituents of dried Rehmanniae Radix are mainly iridoid glycosides, polysaccharides, oligosaccharides and so on.This article sorted and analyzed the application forms, efficacy, applicable symptomsh and the frequency of the use of single traditional Chinese medicine in the Chinese patent medicines containing dried Rehmanniae Radix in the Chinese Pharmacopoeia of 2015. This method provides a train of thought for the further study of the pharmacological constituents of dried Rehmanniae Radix, and supplements the pharmacodynamics of Chinese herbal medicine of dried Rehmanniae Radix. It also provides ideas for the improvement of dried Rehmanniae Radix prescription and the new usage of its old prescription.

Radioactive isotopes in clinical medicine and research. Abstracts

International Nuclear Information System (INIS)

2007-01-01

The review on the International Symposium on radioactive isotopes in clinical medicine and research in Bad Hofgastein, Austria, 9-12 January 2008, contains 42 papers and 29 poster contributions on the following topics: radiopharmaceutical sciences; radiopharmaceutical sciences in oncology and cardiology; therapy; endocrinology; molecular imaging; clinical PET; physics: image processing; instrumentation, neurology, psychiatry

Radioactive isotopes in clinical medicine and research. Abstracts

Energy Technology Data Exchange (ETDEWEB)

NONE

2007-07-01

The review on the International Symposium on radioactive isotopes in clinical medicine and research in Bad Hofgastein, Austria, 9-12 January 2008, contains 42 papers and 29 poster contributions on the following topics: radiopharmaceutical sciences; radiopharmaceutical sciences in oncology and cardiology; therapy; endocrinology; molecular imaging; clinical PET; physics: image processing; instrumentation, neurology, psychiatry.

Using Patents to Protect Traditional Knowledge on the Medicinal Uses of Plants in South Africa

Directory of Open Access Journals (Sweden)

Emeka Polycarp Amechi

2015-06-01

Full Text Available The movement towards the protection of traditional knowledge particularly on the medicinal uses of plants (TKMUP in South Africa reflects a global albeit belated interest in the protection of traditional knowledge associated with biological resources. Hence, it was not surprising South Africa like most developing nation, sought in response to instances of the misappropriation of its TKMUP and other TK associated with its biological resources, to provide a measure of protection for such knowledge using the intellectual property (IP system. This is evident in the adoption of the Policy Framework for the Protection of Indigenous Knowledge through the Intellectual Property System in 2008 which identified patent as one of the major IP tools in the protection of the TK. The Policy Framework represents a paradigmatic shift from South Africa’s earlier sceptical and dialectical approach to, and experience with the IP system in context of TK. This paper therefore examines the benefits and challenges involved in using the patent system in the protection of TK particularly those relating to the medicinal uses of plants (TKMUP. Such examination became necessary as South Africa’s natural capital of biological diversity, together with its wealth of indigenous TK, has been recognised as an important resource base for promoting economic growth through biological innovations under the recently adopted Bio-economy Strategy. It finds that patents offer a great potential in not only protecting TKMUP from misappropriation, but also in promoting the commercialisation of innovative TKMUP or inventions based on or derived from TKMUP in South Africa. However, this can only be possible if the challenges identified in this paper can be successfully navigated.

Management of radioactive waste generated in nuclear medicine; Gestion de los residuos radiactivos generados en medicina nuclear

Energy Technology Data Exchange (ETDEWEB)

Lorenz Perez, P.

2015-07-01

Nuclear medicine is a clinical specialty in which radioactive material is used in non-encapsulated form, for the diagnosis and treatment of patients. Nuclear medicine involves administering to a patient a radioactive substance, usually liquid, both diagnostic and therapeutic purposes. This process generates solid radioactive waste (syringes, vials, gloves) and liquid (mainly the patient's urine). (Author)

International guidance on the establishment of quality assurance programmes for radioactivity measurement in nuclear medicine

Energy Technology Data Exchange (ETDEWEB)

Zimmerman, B.E. [Dosimetry and Medical Radiation Physics Section, Division of Human Health, International Atomic Energy Agency, Wagramer Strasse 5, P.O. Box 200, A-1400 Vienna (Austria)]. E-mail: b.zimmerman@iaea.org; Herbst, C. [Department of Medical Physics, University of the Free State, Geneeskundige Fisika G 68, Bloemfontein 9300 (South Africa); Norenberg, J.P. [College of Pharmacy, 2502 Marble, NE MSC09 5360, University of New Mexico, Albuquerque 87131 (United States); Woods, M.J. [Ionizing Radiation Consultants, Ltd., 152 Broom Road, Teddington, Middlesex TW11 9PQ (United Kingdom)

2006-10-15

A new guidance document for the implementation of quality assurance (QA) programmes for nuclear medicine radioactivity measurement, produced by the International Atomic Energy Agency, is described. The proposed programme is based on the principles of ISO 17025 and will enable laboratories, particularly in developing countries, to provide consistent, safe and effective radioactivity measurement services to the nuclear medicine community.

International guidance on the establishment of quality assurance programmes for radioactivity measurement in nuclear medicine

International Nuclear Information System (INIS)

Zimmerman, B.E.; Herbst, C.; Norenberg, J.P.; Woods, M.J.

2006-01-01

A new guidance document for the implementation of quality assurance (QA) programmes for nuclear medicine radioactivity measurement, produced by the International Atomic Energy Agency, is described. The proposed programme is based on the principles of ISO 17025 and will enable laboratories, particularly in developing countries, to provide consistent, safe and effective radioactivity measurement services to the nuclear medicine community

Law-medicine interfacing: patenting of human genes and mutations.

Science.gov (United States)

Fialho, Arsenio M; Chakrabarty, Ananda M

2011-08-01

Mutations, Single Nucleotide Polymorphisms (SNPs), deletions and genetic rearrangements in specific genes in the human genome account for not only our physical characteristics and behavior, but can lead to many in-born and acquired diseases. Such changes in the genome can also predispose people to cancers, as well as significantly affect the metabolism and efficacy of many drugs, resulting in some cases in acute toxicity to the drug. The testing of the presence of such genetic mutations and rearrangements is of great practical and commercial value, leading many of these genes and their mutations/deletions and genetic rearrangements to be patented. A recent decision by a judge in the Federal District Court in the Southern District of New York, has created major uncertainties, based on the revocation of BRCA1 and BRCA2 gene patents, in the eligibility of all human and presumably other gene patents. This article argues that while patents on BRCA1 and BRCA2 genes could be challenged based on a lack of utility, the patenting of the mutations and genetic rearrangements is of great importance to further development and commercialization of genetic tests that can save human lives and prevent suffering, and should be allowed.

Radioactive properties of medicinal plants

International Nuclear Information System (INIS)

Ahmedova, G.A.

2003-01-01

Full text: A complicated cycle of various compounds' synthesis is provided by plants in the process of their development. The synthesized compounds are necessary to maintain the life of all living organisms both in water and on the land. Together with the organic compounds all known natural radionuclides are accumulated by the plants. Many plants possess the ability to accumulate some elements, whose concentration in the plants may be much higher than that in the soils and water sources. It is well known that the plants are basic or initial raw materials for producing numerous food products, as well as medicinal preparations. The radionuclides, accumulated in the plants, may pass to the human organism through the products and drugs, and may become a source of internal radiation. Accumulation of the radionuclides in various human organs above the maximal acceptable concentration (MAC) may lead to various pathologic changes. That is why it is a necessary and urgent problem to carry out investigations of the radioactive properties of the plants (i.e. to determine their radioecological cleanliness) before using the medicinal plant for pharmacological purposes. In the present work we investigated the radioactive processes of kinds of medicinal plants by the method of semi-conductor gamma-spectrometry. Measurements of the gamma-spectra of the plants' leach were carried out with the help of a gamma-spectrometer with a Ge(Li) detector accompanied by a 4096-channel analyzer. Responsive volume of the detector was 40 cm 3 , energy resolution with respect to 1333 keV 60 Co line was 3 keV. In the measured spectra we observed clearly photo-peaks belonging to uranium-238 family: 186 keV 226 Ra; 295, 351 keV 214 Pb; 609, 1120, 1764 keV 214 Bi; and those belonging to thorium - 232 family: 339, 911, 968 keV 2 28 Ac; 583, 2614 keV 208 Te; as well as the photo-peak of the natural radionuclide 40 K with the energy 1460 keV. From the proper gamma-lines, observed in the spectra, we

Preliminary survey of radioactivity level in Thai medicinal herb plants

International Nuclear Information System (INIS)

Kranrod, C; Chanyotha, S; Kritsananuwat, R; Ploykrathok, T; Pengvanich, P; Tumnoi, Y; Thumvijit, T; Sriburee, S

2017-01-01

In this research, the natural radioactivity concentrations and their respective annual effective dose of the naturally occurring radionuclides 226 Ra, 228 Ra and 40 K in selected medicinal herb plants were investigated. Seven kinds of popular Thai medicinal herb plants had been studied: turmeric, ginger, safflower, moringa, gotu kola, garlic and alexandria senna. The radiological risk associated with the use of these medicinal plants was assessed. The activity concentrations of 226 Ra, 228 Ra and 40 K were determined using the gamma-ray spectrometry technique. The radioactivity concentrations were found to range from less than 0.20 to 6.67 Bqkg -1 for 226 Ra, less than 0.10 to 9.69 Bqkg -1 for 228 Ra, and from 159.42 to 1216.25 Bqkg -1 for 40 K. Gotu kola showed the highest activity concentrations of 226 Ra and 228 Ra, while ginger showed the highest activity concentration of 40 K. The total annual effective dose due to ingestion of these herb plants were found to range from 0.0028 to 0.0097 mSvy -1 with an average value of 0.0060±0.0001 mSvy -1 . The results conclude that the Thai medicinal herb plants samples from this research are considered safe in terms of the radiological hazard. (paper)

Preliminary survey of radioactivity level in Thai medicinal herb plants

Science.gov (United States)

Kranrod, C.; Chanyotha, S.; Kritsananuwat, R.; Ploykrathok, T.; Pengvanich, P.; Tumnoi, Y.; Thumvijit, T.; Sriburee, S.

2017-06-01

In this research, the natural radioactivity concentrations and their respective annual effective dose of the naturally occurring radionuclides 226Ra, 228Ra and 40K in selected medicinal herb plants were investigated. Seven kinds of popular Thai medicinal herb plants had been studied: turmeric, ginger, safflower, moringa, gotu kola, garlic and alexandria senna. The radiological risk associated with the use of these medicinal plants was assessed. The activity concentrations of 226Ra, 228Ra and 40K were determined using the gamma-ray spectrometry technique. The radioactivity concentrations were found to range from less than 0.20 to 6.67 Bqkg-1 for 226Ra, less than 0.10 to 9.69 Bqkg-1 for 228Ra, and from 159.42 to 1216.25 Bqkg-1 for 40K. Gotu kola showed the highest activity concentrations of 226Ra and 228Ra, while ginger showed the highest activity concentration of 40K. The total annual effective dose due to ingestion of these herb plants were found to range from 0.0028 to 0.0097 mSvy-1 with an average value of 0.0060±0.0001 mSvy-1. The results conclude that the Thai medicinal herb plants samples from this research are considered safe in terms of the radiological hazard.

Radioactivity appearing at landfills in household trash of nuclear medicine patients: much ado about nothing?

Science.gov (United States)

Siegel, Jeffry A; Sparks, Richard B

2002-03-01

The U.S. NRC in 1997 removed its arbitrary 1.11 GBq (30 mCi) rule, which had been in existence for almost 50 y, and now many more patients receiving radionuclide therapy in nuclear medicine can be treated as outpatients. However, another problem has the potential to limit the short-lived reality of outpatient treatment unless nuclear medicine practitioners and the health physics community gets involved. Radioactive articles in the household trash of nuclear medicine patients are appearing at solid waste landfills that have installed radiation monitors to prevent the entry of any detectable radioactivity, and alarms are going off around the country. These monitors are set to alarm at extremely low activity levels. Some states may actually hold licensees responsible if a patient's radioactive household trash is discovered in a solid waste stream; this is another major reason [along with continued use of the 1.11 GBq (30 mCi) rule] why many licensees are still not releasing their radionuclide therapy patients. This is in spite of the fact that the radioactivity contained in released nuclear medicine therapy patients, let alone the much lower activity level contained in their potentially radioactive household wastes, poses a minimal hazard to the public health and safety or to the environment. Currently, there are no regulations governing the disposal of low-activity, rapidly-decaying radioactive materials found in the household trash of nuclear medicine patients, the performance of landfill radiation monitors, or the necessity of spectrometry equipment. Resources are, therefore, being unnecessarily expended by regulators and licensees in responding to radiation monitor alarms that are caused by these unregulated short-lived materials that may be mixed with municipal trash. Recommendations are presented that would have the effect of modifying the existing landfill regulations and practices so as to allow the immediate disposal of such wastes.

Reforming South Africa's procedures for granting patents to improve ...

African Journals Online (AJOL)

requires SA to grant 20 years of patent protection on products and processes ... 2010 in SA. However, secondary, evergreening patents prevented generic versions from being brought to the market at a 30% price reduction when the initial patent expired. ... and new uses (new clinical uses of medicines other than those for.

Manual of use and accounting of radioactive material and procedures of radiological protection for nuclear medicine

International Nuclear Information System (INIS)

Chavez, Miguel

1997-03-01

This manual of use and accounting of material radioactive and procedures of radiological safety tries to facilitate workings of protection of material radioactive in services of medicine nuclear, during diagnosis (examinations with x-rays, or those that are made in nuclear medicine), or during the processing of diseases, mainly of the carcinomas (x-ray)

Investigation of radiation safety management at nuclear medicine facilities in Japan. Contamination of radioactivity in the draining-water system

International Nuclear Information System (INIS)

Endo, Keigo; Koizumi, Mitsuru; Kinoshita, Fujimi; Nakazawa, Keiji

1999-01-01

Radiation-safety management condition in Japanese nuclear medicine facilities were investigated by the questionnaire method. The first questionnaire was asked in all Japanese 1,401 Nuclear Medicine facilities. Answers from 624 institutes (44.5%) were received and analyzed. The radiation-safety management in nuclear medicine institutes was considered to be very well performed everyday. Opinion for the present legal control of nuclear medicine institutes was that the regulation in Japan was too strict for the clinical use of radionuclides. The current regulation is based on the assumption that 1% of all radioactivity used in nuclear medicine institutes contaminates into the draining-water system. The second questionnaire detailing the contamination of radioactivity in the draining-water system was sent to 128 institutes, and 64 answers were received. Of them, 42 institutes were considered to be enough to evaluate the contamination of radioactivity in the draining-water system. There was no difference between 624 institutes answered to the first questionnaire and 42 institutes, where the radioactivity in the draining-water system measured, in the distribution of the institute size, draining-water system equipment and the radioactivity measuring method, and these 42 institutes seemed to be representative of Japanese nuclear medicine institutes. Contamination rate of radioactivity into the draining system was calculated by the value of radioactivity in the collecting tank divided by the amount of radionuclides used daily in each institute. The institutes were divided into two categories on the basis of nuclear medicine practice pattern; type A: in-vivo use only and type B: both in-vivo and in-vitro use. The contamination rate in 27 type A institutes did not exceed 0.01%, whereas in 15 type B institutes the contamination rate distributed widely from undetectable to above 1%. These results indicated that the present regulation for the draining-water system, which assumed

Quality assurance in nuclear medicine radioactivity measurements

International Nuclear Information System (INIS)

Sahagia, Maria; Razdolescu Anamaria Cristina

2007-01-01

The paper presents some recent results of the Radionuclide Metrology Laboratory (RML) from IFIN-HH, in the assurance of quality in radioactivity measurements for nuclear medicine. Three aspects are treated: (i) Participation of the RML in the frame of the IAEA Coordinated Research Program (CRP), E 2.10.05; (ii) Improvement of the secondary standard, based on a CENTRONIC IG12/20A ionization chamber; (iii) Implementation of the quality management, according to the SR EN ISO/IEC 17025:2005. (authors)

Patent protection and licensing in microfluidics.

Science.gov (United States)

Yetisen, Ali K; Volpatti, Lisa R

2014-07-07

Microfluidic devices offer control over low-volume samples in order to achieve high-throughput analysis, and reduce turnaround time and costs. Their efficient commercialisation has implications for biomedical sciences, veterinary medicine, environmental monitoring and industrial applications. In particular, market diffusion of microfluidic laboratory and point-of-care diagnostic devices can contribute to the improvement of global health. In their commercialisation, consultancy and patent protection are essential elements that complement academic publishing. The awareness of knowledge transfer strategies can help academics to create value for their research. The aim of this article is to provide a guidance to (1) overview the terminology in patent law, (2) elucidate the process of filing a patent in the US, EU, Japan and internationally, (3) discuss strategies to licence a patent, and (4) explain tactics to defend a patent in a potential infringement. Awareness of the patent law and rights allows obtaining optimised, valid and valuable patents, while accelerating implementation to market route. Striking a balance between academic publishing, consultancy to industry and patent protection can increase commercial potential, enhance economic growth and create social impact.

The Medicines (Radioactive Substances) Order 1978 (S.I. no.1004)

International Nuclear Information System (INIS)

1978-01-01

This Order extends the application of specified provisions of the Medicines Act 1968 to certain articles and substances that are, contain or generate radioactive substances. These provisions include section 60 of that Act which enables regulations to be made prohibiting the sale, supply or administration of medicinal products specified in the regulations except by practitioners holding a certificate issued for the purposes of section 60. The Order also modifies the definition of 'administer' for the purposes of the Order [fr

[Research advances in secondary development of Chinese patent medicines based on quality by design concept].

Science.gov (United States)

Gong, Xing-Chu; Chen, Teng; Qu, Hai-Bin

2017-03-01

Quality by design (QbD) concept is an advanced pharmaceutical quality control concept. The application of QbD concept in the research and development of pharmaceutical processes of traditional Chinese medicines (TCM) mainly contains five parts, including the definition of critical processes and their evaluation criteria, the determination of critical process parameters and critical material attributes, the establishment of quantitative models, the development of design space, as well as the application and continuous improvement of control strategy. In this work, recent research advances in QbD concept implementation methods in the secondary development of Chinese patent medicines were reviewed, and five promising fields of the implementation of QbD concept were pointed out, including the research and development of TCM new drugs and Chinese medicine granules for formulation, modeling of pharmaceutical processes, development of control strategy based on industrial big data, strengthening the research of process amplification rules, and the development of new pharmaceutical equipment.. Copyright© by the Chinese Pharmaceutical Association.

A method for conditioning radioactive-wastes

International Nuclear Information System (INIS)

Cuaz, Daniel; Thiery, Daniel.

1974-01-01

Description is given of a method for conditioning radioactive-wastes, according to the main patent. This method is characterized in that the radioactive wastes are constituted by radio-elements incorporated with filtration and/or floculation promoters. This can be applied to radioactive effluent processing [fr

Patent Medicine Sellers: How Can They Help Control Childhood Malaria?

Directory of Open Access Journals (Sweden)

Rosamund M. Akuse

2010-01-01

Full Text Available Roll Back Malaria Initiative encourages participation of private health providers in malaria control because mothers seek care for sick children from them. This study investigated Patent Medicine Sellers (PMS management of presumptive malaria in children in order to identify how they can assist malaria control. A cross-sectional survey of 491 PMS in Kaduna, Nigeria, was done using interviews and observation of shop activities. Most (80% customers bought drugs without prescriptions. Only 29.5% were given instructions about doses. Between 40–100% doses of recommended antimalarials were incorrect. Some (22% PMS did not ask questions about illness for which they were consulted. Most children treated in shops received injections. PMS facilitate homecare but have deficiencies in knowledge and practice. Interventions must focus on training them to accurately determine doses, give advice about drug administration, use oral medication, and ask about illness. Training should be made a prerequisite for registering and reregistering shops.

Radioactive waste management of the nuclear medicine services; Gestao de rejeitos radioativos em servicos de medicina nuclear

Energy Technology Data Exchange (ETDEWEB)

Barboza, Alex

2009-07-01

Radioisotope applications in nuclear medicine services, for diagnosis and therapy, generate radioactive wastes. The general characteristics and the amount of wastes that are generated in each facility are function of the number of patients treated, the procedures adopted, and the radioisotopes used. The management of these wastes embraces every technical and administrative activity necessary to handle the wastes, from the moment of their generation, till their final disposal, must be planned before the nuclear medicine facility is commissioned, and aims at assuring people safety and environmental protection. The regulatory framework was established in 1985, when the National Commission on Nuclear Energy issued the regulation CNEN-NE-6.05 'Radioactive waste management in radioactive facilities'. Although the objective of that regulation was to set up the rules for the operation of a radioactive waste management system, many requirements were broadly or vaguely defined making it difficult to ascertain compliance in specific facilities. The objective of the present dissertation is to describe the radioactive waste management system in a nuclear medicine facility and provide guidance on how to comply with regulatory requirements. (author)

Radioactive waste management of the nuclear medicine services; Gestao de rejeitos radioativos em servicos de medicina nuclear

Energy Technology Data Exchange (ETDEWEB)

Barboza, Alex

2009-07-01

Radioisotope applications in nuclear medicine services, for diagnosis and therapy, generate radioactive wastes. The general characteristics and the amount of wastes that are generated in each facility are function of the number of patients treated, the procedures adopted, and the radioisotopes used. The management of these wastes embraces every technical and administrative activity necessary to handle the wastes, from the moment of their generation, till their final disposal, must be planned before the nuclear medicine facility is commissioned, and aims at assuring people safety and environmental protection. The regulatory framework was established in 1985, when the National Commission on Nuclear Energy issued the regulation CNEN-NE-6.05 'Radioactive waste management in radioactive facilities'. Although the objective of that regulation was to set up the rules for the operation of a radioactive waste management system, many requirements were broadly or vaguely defined making it difficult to ascertain compliance in specific facilities. The objective of the present dissertation is to describe the radioactive waste management system in a nuclear medicine facility and provide guidance on how to comply with regulatory requirements. (author)

Natural compounds for solar photoprotection: a patent review.

Science.gov (United States)

Serafini, Mairim R; Guimarães, Adriana G; Quintans, Jullyana S S; Araújo, Adriano A S; Nunes, Paula S; Quintans-Júnior, Lucindo J

2015-04-01

Ultraviolet irradiation has deleterious effects on human skin, including tanning, sunburn, cancer and connective tissue degradation (photoaging). Botanical antioxidants have been shown to be associated with reduced incidence of photocarcinogenesis and photoaging through their photoprotective profile. Here, the authors summarized therapeutic patent applications concerning the employment of medicinal plants on the technological development of a formulation with photoprotective or photoaging application. So, the patent search was conducted in the databases WIPO, Espacenet, USPTO and Derwent, using the keywords - photoaging, photoprotection and the IPC A61K 8/97 (cosmetics or similar cleaning supplies obtained from vegetable origin, for example, plant extracts) and A61K 36/00 (medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, for example, traditional herbal medicines). We found 180 patents, out of which 25 were evaluated using inclusion criteria as application of natural products with photoprotective or photoaging application. We found that some patents related to the cosmetic compositions for improving skin wrinkle and either preventing or reducing the signs of photoaging and sunburn. The cosmetic compositions are manufactured in the form of a lotion, gel, soluble liquid, cream, essence, oil-in-water-type or water-in-oil-type formulation, containing the vegetal extracts as an active ingredient.

National audit of radioactivity measurements in Nuclear Medicine Centres

International Nuclear Information System (INIS)

Ravindra, Anuradha; Kulkarni, D.B.; Joseph, Leena; Babu, D.A.R.

2014-01-01

Routine activity measurements of radiopharmaceutical solutions in Nuclear Medicine Centres (NMC) are carried out with the help of radionuclide calibrators (RC). These solutions are either ingested or injected to the patient for diagnosis or therapy. However, for the realization of an optimized examination, the activity of these radiopharmaceuticals must be determined accurately before administering it to patients. The primary standards are maintained by Radiation Standards Section, Radiological Physics and Advisory Division. National audit programmes of Iodine -131 activity measurements with RCs are conducted biannually to establish traceability to national standards and to check the status of nuclear medicine practice followed at the NMC. The results of fifteenth audit of 131 I activity measurements with RC are presented in this paper. Questionnaires were sent to two hundred and thirty three NMCs in-the country. One hundred and nine NMC's agreed for participation and accordingly, glass vials containing radioactive 131 I solution of nominal activity of 100 MBq were procured from Board of Radiation and Isotope Technology, Mumbai. The radioactivity in each vial was determined with high pressure re-entrant gamma ionisation chamber (GIC), a secondary standard maintained by this laboratory. The sensitivity coefficient of GIC is traceable to the primary standard. The standardized radioactive solution of 131 I in glass vial was sent to each participant. Measurements results were reported in the reporting form sent. This audit was conducted in four schedules in Jan 2013. One hundred and sixty six results were received from one hundred and nine participants as many participants took measurements on more than one isotope calibrator

'Government Patent Use': A Legal Approach To Reducing Drug Spending.

Science.gov (United States)

Kapczynski, Amy; Kesselheim, Aaron S

2016-05-01

The high cost of patent-protected brand-name drugs can strain budgets and curb the widespread use of new medicines. An example is the case of direct-acting antiviral drugs for the treatment of hepatitis C. While prices for these drugs have come down in recent months, they still create barriers to treatment. Additionally, prescribing restrictions imposed by insurers put patients at increased risk of medical complications and contribute to transmission of the hepatitis C virus. We propose that the federal government invoke its power under an existing "government patent use" law to reduce excessive prices for important patent-protected medicines. Using this law would permit the government to procure generic versions of patented drugs and in exchange pay the patent-holding companies reasonable royalties to compensate them for research and development. This would allow patients in federal programs, and perhaps beyond, to be treated with inexpensive generic medicines according to clinical need-meaning that many more patients could be reached for no more, and perhaps far less, money than is currently spent. Another benefit would be a reduction in the opportunity for companies to extract monopoly profits that far exceed their risk-adjusted costs of research and development. Project HOPE—The People-to-People Health Foundation, Inc.

Japan's patent issues relating to life science therapeutic inventions.

Science.gov (United States)

Tessensohn, John A

2014-09-01

Japan has made 'innovation in science and technology' as one of its central pillars to ensure high growth in its next stage of economic development and its life sciences market which hosts regenerative medicine was proclaimed to be 'the best market in the world right now.' Although life science therapeutic inventions are patentable subject matter under Japanese patent law, there are nuanced obviousness and enablement challenges under Japanese patent law that can be surmounted in view of some encouraging Japanese court developments in fostering a pro-patent applicant environment in the life sciences therapeutic patent field. Nevertheless, great care must be taken when drafting and prosecuting such patent applications in the world's second most important life sciences therapeutic market.

Medicinal Chemistry Insights into Novel HDAC Inhibitors: An Updated Patent Review (2012-2016).

Science.gov (United States)

Zhan, Peng; Wang, Xueshun; Liu, Xinyong; Suzuki, Takayoshi

2017-01-01

Many laboratories have made intensive efforts to develop potent, selective, and orally bioavailable HDAC inhibitors (HDACIs). Novel HDACIs are being developed with the objective of improving potency and selectivity against specific types of cancers or non-cancer diseases. This updated patent review is an attempt to compile the work of various researchers of HDACIs from 2012 to mid 2016, and to enlighten and surprise both newcomers in this field and devoted medicinal chemists. According to the literature research and the writers' own research experience in the discovery of HDAC inhibitors. The inhibitors possessing new chemical scaffolds have attracted immense interest because they have the ability to improve HDAC isoform specificity and pharmaceutical properties. Focus is given to emerging medicinal chemistry principles and insights into the discovery and development of HDAC inhibitors. The development of effective HDACIs is shifting from trial-and-error approaches to sophisticated strategies. Effective profiling technologies will continue to have important utility. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Annotated chemical patent corpus: A gold standard for text mining

NARCIS (Netherlands)

S.A. Akhondi (Saber); A.G. Klenner (Alexander G.); C. Tyrchan (Christian); A.K. Manchala (Anil K.); K. Boppana (Kiran); D. Lowe (Daniel); M. Zimmermann (Marc); S.A.R.P. Jagarlapudi (Sarma A. R. P.); R. Sayle (Roger); J.A. Kors (Jan); C. Muresan (Cornelia)

2014-01-01

textabstractExploring the chemical and biological space covered by patent applications is crucial in early-stage medicinal chemistry activities. Patent analysis can provide understanding of compound prior art, novelty checking, validation of biological assays, and identification of new starting

India changes patent law to meet WTO treaty, making new medicines less available to most citizens, other countries.

Science.gov (United States)

James, John S

2004-01-01

India changed its pharmaceutical patent law to conform to the U.S.-European system, just ahead of a Jan. 1 World Trade Organization deadline--meaning that most new medicines (patentable in 1995 or later) will be priced out of reach of the great majority of people in India--and in Africa and other poor regions as well. "The real issue for the multinational corporations is not the poor-country markets, which are financially small and unattractive, but the poor-country examples. How would thousands of people in rich countries, especially the U.S., be persuaded to accept death from cancer and other diseases because they cannot pay tens of thousands of dollars a year for a new generation of treatments that could save their lives--if companies in India could manufacture and sell the same treatments for a small fraction of the price?"

An in-depth study of patent medicine sellers' perspectives on malaria in a rural Nigerian community

Directory of Open Access Journals (Sweden)

Okafor Henrietta U

2006-11-01

Full Text Available Abstract Background Malaria remains a major cause of mortality among under five children in Nigeria. Most of the early treatments for fever and malaria occur through self-medication with antimalarial drugs bought from medicine sellers. These have led to increasing calls for interventions to improve treatment obtained in these outlets. However, information about the current practices of these medicine sellers is needed before such interventions. This study aims to determine the medicine sellers' perspectives on malaria and the determinants that underlie their dispensing patterns of antimalarial drugs. Methods The study was conducted in Ugwugo-Nike, a rural community in south-east Nigeria. It involved in-depth interviews with 13 patent medicine sellers. Results A majority of the medicine sellers were not trained health professionals and malaria is recognized as a major health problem by them. There is poor knowledge and poor dispensing behaviour in relation to childhood malaria episodes. Although referral of severe malaria is common, there are those who will not refer. Verbal advice is rarely given to the care-givers. Conclusion More action research and interventions to improve prescription and referral practices and giving verbal advice to care-givers is recommended. Ways to integrate the drug sellers in the health system are also recommended.

A critique of an argument against patent rights for essential medicines

Directory of Open Access Journals (Sweden)

Jorn Sonderholm

2014-09-01

Full Text Available Thomas Pogge has recently argued that the way in which research and development of essential medicines is incentivized, under existing World Trade Organization rules, should be supplemented with an additional incentivizing mechanism. One might hold a stronger view than the one that Pogge currently holds, namely that patent rights for essential medicines are morally unjustified per se. Throughout this paper, ‘the strong view’ refers to this view. The strong view is one that enjoys considerable support both within and outside the academic community. This paper critically discusses one specific argument in favor of the strong view. This argument is named the ‘Poggean argument’. This denominator is appropriate because a number of the essential premises of the argument are constituted by propositions that Pogge at some point has defended. The Poggean argument is valid, and defenders of the strong view also have some grounds for believing that the argument is sound. This belief comes, however, with what is arguably a too high cost, namely that the global institutional order becomes very demanding on taxpaying citizens of high-income countries if it is to be just. One may find acceptance of this cost relatively unproblematic, but this cost is, it is argued, unacceptable to anyone who has views on distributive justice that are sympathetic to the core tenets of libertarianism.

Verification of radioactive waste management of nuclear medicine clinics in the city of Recife

International Nuclear Information System (INIS)

Silva, V.C.B.; Lopes-Filho, F.J.; Passos, R.S.; Lira, R.F.; Santos, M.A.P.; Belo, I.B.; Lima, F.R.A.; Vieira, J.W.; Ferreira-Filho, A.

2010-01-01

The increasing use of ionizing radiation in various areas can not be dissociated from the concerns of safety and radiation security. In Nuclear Medicine, this concern becomes higher, because of the radionuclides used in diagnosis and therapy of radiation sources are not sealed. Their use inevitably produces radioactive waste that must be controlled through proper management, according to the normative standards established in Brazil by the National Commission of Nuclear Energy (CNEN). The management of radioactive waste seeks to lower the occupational doses besides the environmental preservation. In the work carried out by the Regional Center of Nuclear Sciences Northeast (CRCN-NE) and the Federal Office for Education, Science and Technology (OPSI), we see the systems management of radioactive waste from Nuclear Medicine in the city of Recife. The results were obtained from the preparation of a sheet of compliance and its implementation in eight clinics. (author)

Decoding Patent Information Using Patent Maps

OpenAIRE

Liu, Chen-Yuan; Yang, James Chingyu

2008-01-01

Patent information is a derivative product from the legal patent system. This information, which includes patent applications, patent descriptions, patent gazettes, patent abstracts, and patent data, is prepared in exact compliance with the regulations and specifications of the patent acts. Patent information, different from other published circulating information, is legally well protected. For convenience, this study classifies patent information into bibliographic and numeric data to creat...

Device and method for traditional chinese medicine diagnosis using radioactive tracer method

Energy Technology Data Exchange (ETDEWEB)

Wu, Shanling; Shen, Miaohe

1997-05-29

Disclosed is a device and method for traditional chinese medicine diagnosis using radioactive-tracer method. At least two nuclear radiation probes are arranged apart along the channels to detect the changing with time and on space of the intensity of radioactivity of the nuclear radioactive tracer which has been injected into the body in the channel position. The detected signals are amplified by amplifiers, and the outputs of the amplifiers are applied to data processing means which monitor the whole detecting process in real time and analyse and process the detected information about the changing of the intensity of radioactivity with time and on space indicating the operating of vital energy and blood, and obtain state parameters about operating of vital energy and blood in the body which is then output through data output means. (author) figs.

METRICS DEVELOPMENT FOR PATENTS.

Science.gov (United States)

Veiga, Daniela Francescato; Ferreira, Lydia Masako

2015-01-01

To develop a proposal for metrics for patents to be applied in assessing the postgraduate programs of Medicine III - Capes. From the reading and analysis of the 2013 area documents of all the 48 areas of Capes, a proposal for metrics for patents was developed to be applied in Medicine III programs. Except for the areas Biotechnology, Food Science, Biological Sciences III, Physical Education, Engineering I, III and IV and Interdisciplinary, most areas do not adopt a scoring system for patents. The proposal developed was based on the criteria of Biotechnology, with adaptations. In general, it will be valued, in ascending order, the deposit, the granting and licensing/production. It will also be assigned higher scores to patents registered abroad and whenever there is a participation of students. This proposal can be applied to the item Intellectual Production of the evaluation form, in subsection Technical Production/Patents. The percentage of 10% for academic programs and 40% for Masters Professionals should be maintained. The program will be scored as Very Good when it reaches 400 points or over; Good, between 200 and 399 points; Regular, between 71 and 199 points; Weak up to 70 points; Insufficient, no punctuation. Desenvolver uma proposta de métricas para patentes a serem aplicadas na avaliação dos Programas de Pós-Graduação da Área Medicina III - Capes. A partir da leitura e análise dos documentos de área de 2013 de todas as 48 Áreas da Capes, desenvolveu-se uma proposta de métricas para patentes, a ser aplicada na avaliação dos programas da área. Constatou-se que, com exceção das áreas Biotecnologia, Ciência de Alimentos, Ciências Biológicas III, Educação Física, Engenharias I, III e IV e Interdisciplinar, a maioria não adota sistema de pontuação para patentes. A proposta desenvolvida baseou-se nos critérios da Biotecnologia, com adaptações. De uma forma geral, foi valorizado, em ordem crescente, o depósito, a concessão e o

[Study on building index system of risk assessment of post-marketing Chinese patent medicine based on AHP-fuzzy neural network].

Science.gov (United States)

Li, Yuanyuan; Xie, Yanming; Fu, Yingkun

2011-10-01

Currently massive researches have been launched about the safety, efficiency and economy of post-marketing Chinese patent medicine (CPM) proprietary Chinese medicine, but it was lack of a comprehensive interpretation. Establishing the risk evaluation index system and risk assessment model of CPM is the key to solve drug safety problems and protect people's health. The clinical risk factors of CPM exist similarities with the Western medicine, can draw lessons from foreign experience, but also have itself multi-factor multivariate multi-level complex features. Drug safety risk assessment for the uncertainty and complexity, using analytic hierarchy process (AHP) to empower the index weights, AHP-based fuzzy neural network to build post-marketing CPM risk evaluation index system and risk assessment model and constantly improving the application of traditional Chinese medicine characteristic is accord with the road and feasible beneficial exploration.

Quinoxaline derivatives: a patent review (2006--present).

Science.gov (United States)

González, Mercedes; Cerecetto, Hugo

2012-11-01

Quinoxaline scaffold is included in a large number of therapeutic agents because of its physicochemical properties that make the difference between them and the carbono analogue, naphthalene. This review of patented products presents the quinoxaline heterocycle as part of the structural patent claims from a medicinal chemistry perspective. We centred our discussion in the various drug patent applications of the quinoxaline and its derivatives. The applications are based firstly in the specific enzyme target with very low development in the disease treatment. Only for cancer and antimicrobial agents they were specifically determined but little is mentioned in order to insight in the last development activities.

Google Patents: The global patent search engine

OpenAIRE

Noruzi, Alireza; Abdekhoda, Mohammadhiwa

2014-01-01

Google Patents (www.google.com/patents) includes over 8 million full-text patents. Google Patents works in the same way as the Google search engine. Google Patents is the global patent search engine that lets users search through patents from the USPTO (United States Patent and Trademark Office), EPO (European Patent Office), etc. This study begins with an overview of how to use Google Patent and identifies advanced search techniques not well-documented by Google Patent. It makes several sug...

Biotechnological Patents Applications of the Deuterium Oxide in Human Health.

Science.gov (United States)

da S Mariano, Reysla M; Bila, Wendell C; Trindade, Maria Jaciara F; Lamounier, Joel A; Galdino, Alexsandro S

2017-01-01

Deuterium oxide is a molecule that has been used for decades in several studies related to human health. Currently, studies on D2O have mobilized a "Race for Patenting" worldwide. Several patents have been registered from biomedical and technological studies of D2O showing the potential of this stable isotope in industry and health care ecosystems. Most of the patents related to the applications of the deuterium oxide in human health have been summarized in this review. The following patents databases were consulted: European Patent Office (Espacenet), the United States Patent and Trademark Office (USPTO), the United States Latin America Patents (LATIPAT), Patent scope -Search International and National Patent Collections (WIPO), Google Patents and Free Patents Online. With this review, the information was collected on recent publications including 22 patents related to deuterium oxide and its applications in different areas. This review showed that deuterium oxide is a promising component in different areas, including biotechnology, chemistry and medicine. In addition, the knowledge of this compound was covered, reinforcing its importance in the field of biotechnology and human health. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Patent indicators: a window to pharmaceutical market success.

Science.gov (United States)

Guo, Yang; Hu, Yuanjia; Zheng, Mingli; Wang, Yitao

2013-07-01

Pharmaceutical success in the market is the best reward for pharmaceutical investors undergoing the lengthy, costly and risky process of pharmaceutical Research and Development (R&D). Drugs with high market revenues trigger fierce competition between pharmaceutical enterprises, as is demonstrated by the increasing Mergers & Acquisitions (M&A) cases focusing on seizing the best-selling products. On the other hand, patents, as the best shield for innovative drugs against generic drugs, become a powerful weapon for pharmaceutical enterprises to win the substantial returns generated by market exclusivity. Patents seem to be directly responsible for the commercial success of new medicines. In this context, it is of great significance to find out the empirical associations between pharmaceutical commercial success and patents. By comprehensively analysing 127 drugs marketed in the USA and their 621 American patents, this article identifies the evidence to link various patent indicators with pharmaceutical sales in actual market.

Modern Medicine Environment and Adaptation of Korean Trader for Medicinal Herbs From the Late 19th Century to the Early 20th Century

Directory of Open Access Journals (Sweden)

YANG Jeongpil

2006-12-01

Full Text Available Since the late 18th century, the Korean traditional medicine trade witnessed a steady growth. There were lots of stores which sold Korean medicinal herbs in Seoul and every major towns had at least one or more stores in Korea, which led to a subsequent growth of people involved in the trade. However, Korean medicine merchants encountered a new environment with the influx of western medicines after the Opening of Ports and the execution of modern medicine policies. Such change of atmosphere led the merchants to seek new breakthroughs. Some of the merchants found the answer in producing and selling patent medicine. The people in the industry had little knowledge of western medicine, so that they had little choice but to combine their experience of Korean medicine with whatever information they had about western counterpart. Such resolution generated a new kind of medicine known as patent medicine. Patent medicine businessmen observed the new medicine policies of the Korean Empire. Some visionary ones even sought to eagerly utilize the trademark system to secure the selling route. The Japanese colonial government strengthened the medicine policies. It revised the legislature and mobilized administrative powers to manage and control the industry. However, such colonial policies in the 1910s implicated certain limits due to its lack of understanding of Korean medicine industry. Also, the colonial government showed poor efforts in introducing modern medicine facilities and systems, so that the ground was set for the patent medicine business to flourish. Patent medicine enjoyed a high turnover. So, the entrepreneurs endeavored to promote the sales in whatever means necessary. The most basic form of advertisement was through the newspaper. Indirect promotion through newspaper articles, issuing medicine flyers, free gift draw, reputation of an influential expert were widely used for its sales. Consequently, patent medicine industry in the 1910s saw a

Huangqi injection (a traditional Chinese patent medicine for chronic heart failure: a systematic review.

Directory of Open Access Journals (Sweden)

Shufei Fu

2011-05-01

Full Text Available Chronic heart failure (CHF is a global public health problem. Therefore, novel and effective drugs that show few side-effects are needed. Early literature studies indicated that Huangqi injection is one of the most commonly used traditional Chinese patent medicines for CHF in China. As a large number of clinical studies has been carried out and published, it is essential to evaluate the effectiveness and safety of Huangqi injection. Therefore, we carried out this systematic review under the support of the framework of the Joint Sino-Italian Laboratory (JoSIL.To evaluate the efficacy and safety of Huangqi injection for CHF according to the available scientific knowledge.An extensive search including PubMed, EMBASE, CBM, the Cochrane Library and Chinese literature databases was performed up to July 2008. Clinical trials regarding Huangqi injection for the treatment of CHF were searched for, irrespective of languages. The quality of each trial was assessed according to the Cochrane Reviewers' Handbook 5.0, and RevMan 5.0 provided by the Cochrane Collaboration and STATA 9.2 were used for data analysis.After selection of 1,205 articles, 62 RCTs and quasi-RCTs conducted in China and published in Chinese journals were included in the review. The methodological quality of the trials was low. In most trials inclusion and exclusion criteria were not specified. Furthermore, only one study evaluated the outcomes for drug efficacy after an adequate period of time. For these reasons and because of the different baseline characteristics we did not conduct a meta-analysis.Although available studies are not adequate to draw a conclusion on the efficacy and safety of Huangqi injection (a traditional Chinese patent medicine, we hope that our work could provide useful experience on further studies on Huangqi injections. The overall level of TCM clinical research needs to be improved so that the efficacy of TCM can be evaluated by the international community and

Huangqi injection (a traditional Chinese patent medicine) for chronic heart failure: a systematic review.

Science.gov (United States)

Fu, Shufei; Zhang, Junhua; Menniti-Ippolito, Francesca; Gao, Xiumei; Galeotti, Francesca; Massari, Marco; Hu, Limin; Zhang, Boli; Ferrelli, Rita; Fauci, Alice; Firenzuoli, Fabio; Shang, Hongcai; Guerra, Ranieri; Raschetti, Roberto

2011-05-06

Chronic heart failure (CHF) is a global public health problem. Therefore, novel and effective drugs that show few side-effects are needed. Early literature studies indicated that Huangqi injection is one of the most commonly used traditional Chinese patent medicines for CHF in China. As a large number of clinical studies has been carried out and published, it is essential to evaluate the effectiveness and safety of Huangqi injection. Therefore, we carried out this systematic review under the support of the framework of the Joint Sino-Italian Laboratory (JoSIL). To evaluate the efficacy and safety of Huangqi injection for CHF according to the available scientific knowledge. An extensive search including PubMed, EMBASE, CBM, the Cochrane Library and Chinese literature databases was performed up to July 2008. Clinical trials regarding Huangqi injection for the treatment of CHF were searched for, irrespective of languages. The quality of each trial was assessed according to the Cochrane Reviewers' Handbook 5.0, and RevMan 5.0 provided by the Cochrane Collaboration and STATA 9.2 were used for data analysis. After selection of 1,205 articles, 62 RCTs and quasi-RCTs conducted in China and published in Chinese journals were included in the review. The methodological quality of the trials was low. In most trials inclusion and exclusion criteria were not specified. Furthermore, only one study evaluated the outcomes for drug efficacy after an adequate period of time. For these reasons and because of the different baseline characteristics we did not conduct a meta-analysis. Although available studies are not adequate to draw a conclusion on the efficacy and safety of Huangqi injection (a traditional Chinese patent medicine), we hope that our work could provide useful experience on further studies on Huangqi injections. The overall level of TCM clinical research needs to be improved so that the efficacy of TCM can be evaluated by the international community and possibly some

How patent experts create patent breadth

DEFF Research Database (Denmark)

Beukel, Karin

2014-01-01

Science as an input to patented inventions is a fundamental of economic growth. However, our understanding of how science is transformed into patents is limited. In the present paper I seek to fill this gap by examining the micro-foundations of science-patent transformations. Using an inductive......, grounded theory approach to study the transformation of 12 scientific discoveries into patents I recast the relationship between science and patents: I show it as a particular process that affects patent breadth. Exploiting surplus patent breadth depends on the processes of abstraction and cognitive...... variety, which can be mobilized by patenting experts. The theory is tested using a recently published algebraic interpretive method for examining causal relationships in small-N studies....

How patent experts create patent breadth

DEFF Research Database (Denmark)

Beukel, Karin

2018-01-01

Science as an input to patented inventions is a fundamental of economic growth. However, our understanding of how science is transformed into patents is limited. In the present paper I seek to fill this gap by examining the micro-foundations of science-patent transformations. Using an inductive......, grounded theory approach to study the transformation of 12 scientific discoveries into patents I recast the relationship between science and patents: I show it as a particular process that affects patent breadth. Exploiting surplus patent breadth depends on the processes of abstraction and cognitive...... variety, which can be mobilized by patenting experts. The theory is tested using a recently published algebraic interpretive method for examining causal relationships in small-N studies....

An overview of radioactive waste disposal procedures of a nuclear medicine department.

Science.gov (United States)

Ravichandran, R; Binukumar, J P; Sreeram, Rajan; Arunkumar, L S

2011-04-01

Radioactive wastes from hospitals form one of the various types of urban wastes, which are managed in developed countries in a safe and organized way. In countries where growth of nuclear medicine services are envisaged, implementations of existing regulatory policies and guidelines in hospitals in terms of handling of radioactive materials used in the treatment of patients need a good model. To address this issue, a brief description of the methods is presented. A designed prototype waste storage trolley is found to be of great help in decaying the I-131 solid wastes from wards before releasing to waste treatment plant of the city. Two delay tanks with collection time of about 2 months and delay time of 2 months alternately result in 6 releases of urine toilet effluents to the sewage treatment plant (STP) of the hospital annually. Samples of effluents collected at releasing time documented radioactive releases of I-131 much below recommended levels of bi-monthly release. External counting of samples showed good statistical correlation with calculated values. An overview of safe procedures for radioactive waste disposal is presented.

An overview of radioactive waste disposal procedures of a nuclear medicine department

International Nuclear Information System (INIS)

Ravichandran, R.; Binukumar, J.P.; Sreeram, Rajan; Arunkumar, L.S.

2011-01-01

Radioactive wastes from hospitals form one of the various types of urban wastes, which are managed in developed countries in a safe and organized way. In countries where growth of nuclear medicine services are envisaged, implementations of existing regulatory policies and guidelines in hospitals in terms of handling of radioactive materials used in the treatment of patients need a good model. To address this issue, a brief description of the methods is presented. A designed prototype waste storage trolley is found to be of great help in decaying the 131 I solid wastes from wards before releasing to waste treatment plant of the city. Two delay tanks with collection time of about 2 months and delay time of 2 months alternately result in 6 releases of urine toilet effluents to the sewage treatment plant (STP) of the hospital annually. Samples of effluents collected at releasing time documented radioactive releases of 131 I- much below recommended levels of bi-monthly release. External counting of samples showed good statistical correlation with calculated values. An overview of safe procedures for radioactive waste disposal is presented. (author)

Searching bioremediation patents through Cooperative Patent Classification (CPC).

Science.gov (United States)

Prasad, Rajendra

2016-03-01

Patent classification systems have traditionally evolved independently at each patent jurisdiction to classify patents handled by their examiners to be able to search previous patents while dealing with new patent applications. As patent databases maintained by them went online for free access to public as also for global search of prior art by examiners, the need arose for a common platform and uniform structure of patent databases. The diversity of different classification, however, posed problems of integrating and searching relevant patents across patent jurisdictions. To address this problem of comparability of data from different sources and searching patents, WIPO in the recent past developed what is known as International Patent Classification (IPC) system which most countries readily adopted to code their patents with IPC codes along with their own codes. The Cooperative Patent Classification (CPC) is the latest patent classification system based on IPC/European Classification (ECLA) system, developed by the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO) which is likely to become a global standard. This paper discusses this new classification system with reference to patents on bioremediation.

Radioactive isotopes are use wide in medicine

International Nuclear Information System (INIS)

Vargas, Celso

2011-01-01

The radioactive isotopes are used in medicine to view the status of an organ under different conditions; especially in the evolution of an organism after treatment of a cancer. In this process, three key areas have combined; first, the production of isotopes by developing of accelerators or reactors both linear accelerator and cyclotrons. Second, the use of suitable equipment such as PET (Positron emission tomography) for accurate scan of internal organs at physiological and biochemical level or molecular for diagnosis and effective treatment of diseases such as cancer. Currently, the trend has been to combine PET with other technologies such as CAT (computed axial tomographic) or SPECT (Single photon emission computer tomography). Third and finally, the development of molecules increasingly specific that have allowed to obtain several chemical compounds for different uses [es

Patent office governance and patent system quality

OpenAIRE

PICARD, Pierre M.; VAN POTTELSBERGHE DE LA POTTERIE, Bruno

2011-01-01

The present paper discusses the role of quality in patent systems from the perspective of patent offices' behavior and organization. After documenting original stylized facts, the paper presents a model in which patent offices set patent fees and the quality level of their examination processes. Various objectives of patent offices' governors are considered. We show that the quality of the patent system is maximal for the patent offices that maximises either the social welfare or its own prof...

[Post-marketing re-evaluation about usage and dosage of Chinese medicine based on human population pharmacokinetics].

Science.gov (United States)

Jiang, Junjie; Xie, Yanming

2011-10-01

The usage and dosage of Chinese patent medicine are determined by rigorous evaluation which include four clinical trail stages: I, II, III. But the usage and dosage of Chinese patent medicine are lacked re-evaluation after marketing. And this lead to unchanging or fixed of the usage and dosage of Chinese patent medicine instead of different quantity based on different situations in individual patients. The situation of Chinese patent medicine used in clinical application is far away from the idea of the "Treatment based on syndrome differentiation" in traditional Chinese medicine and personalized therapy. Human population pharmacokinetics provides data support to the personalized therapy in clinical application, and achieved the postmarking reevaluating of the usage and dosage of Chinese patent medicine. This paper briefly introduced the present situation, significance and the application of human population pharmacokinetics about re-evaluation of the usage and dosage of Chinese patent medicine after marketing.

Guidance on radioactive waste management legislation for application to users of radioactive materials in medicine, research and industry

International Nuclear Information System (INIS)

1992-04-01

This document, addressed primarily to developing countries, is restricted to management of radioactive wastes arising from uses of radionuclides in medicine, industry and research. It does not deal with wastes from the nuclear fuel cycle. Safeguards and physical protection are also outside the scope even though in some special cases it may be relevant; for instance, when fissile material is handled at research establishments. Information on nuclear fuel cycle waste management and waste transport can be found in a number of IAEA publications. The main aim of this document is to give guidance on legislation required for safe handling, treatment, conditioning and release or disposal of radioactive waste. It covers all steps from the production or import of radioactive material, through use, treatment, storage and transport, to the release or disposal of the waste either as exempted material or in special repositories. Management of radioactive wastes as a whole is optimized and kept at acceptable levels in accordance with the basic ICRP recommendations and the IAEA Basic Safety Standards. As a result of the new ICRP recommendations of 1991, the Agency is revising its Basic Safety Standards, the results of which may have some impact on the national regulations and necessitate updating of this document. 16 refs, 1 fig

U Y 105 standard use of non sealed radioactive sources in nuclear medicine: approve for Industry energy and Mining Ministry 28/6/2002 Resolution

International Nuclear Information System (INIS)

2002-01-01

Establish minimal requirements radiological safety for use non sealed radioactive sources in nuclear medicine.The present standard is used in operation or nuclear medicine practices using non sealed radioactive sources with diagnostic and therapeutic purposes in vivo and in vitro

Proposal of a monitoring program of occupational exposure by incorporation of radioactive material for nuclear medicine services in the Caja Costarricense del Seguro Social

International Nuclear Information System (INIS)

Badilla Segura, Mirta

2013-01-01

A monitoring program of the occupational exposure by incorporation of radioactive material is proposed. Nuclear medicine services of the Caja Costarricense del Seguro Social (CCSS) are evaluated. The monitoring program is based on the provisions of the International Atomic Energy Agency and of study of nuclear medicine services of the CCSS. Radionuclides are determined for monitoring of the occupational exposure, according to the radioactive material that is worked in nuclear medicine services of the CCSS. The appropriate and alternative techniques are established for the monitoring of the occupational exposure by incorporation of radioactive material, depending on the type of radionuclide that is worked in nuclear medicine services. The worker occupationally exposed (TOE) should be subject of monitoring and how often should be realized the monitoring of the occupational exposure. The monitoring of the radiation by radioactive material must be applied to personnel working in radiopharmacies and the worker has carried out therapeutic procedures for handling of significant amounts of 13 1 I. The calculation of the committed effective dose is proposed by incorporation of radioactive material with the TOE [es

Radioactive waste processing and disposal

International Nuclear Information System (INIS)

1980-01-01

This compilation contains 4144 citations of foreign and domestic reports, journal articles, patents, conference proceedings, and books pertaining to radioactive waste processing and disposal. Five indexes are provided: Corporate Author, Personal Author, Subject, Contract Number, and Report Number

An overview of radioactive waste disposal procedures of a nuclear medicine department

Science.gov (United States)

Ravichandran, R.; Binukumar, J. P.; Sreeram, Rajan; Arunkumar, L. S.

2011-01-01

Radioactive wastes from hospitals form one of the various types of urban wastes, which are managed in developed countries in a safe and organized way. In countries where growth of nuclear medicine services are envisaged, implementations of existing regulatory policies and guidelines in hospitals in terms of handling of radioactive materials used in the treatment of patients need a good model. To address this issue, a brief description of the methods is presented. A designed prototype waste storage trolley is found to be of great help in decaying the I-131 solid wastes from wards before releasing to waste treatment plant of the city. Two delay tanks with collection time of about 2 months and delay time of 2 months alternately result in 6 releases of urine toilet effluents to the sewage treatment plant (STP) of the hospital annually. Samples of effluents collected at releasing time documented radioactive releases of I-131 much below recommended levels of bi-monthly release. External counting of samples showed good statistical correlation with calculated values. An overview of safe procedures for radioactive waste disposal is presented. PMID:21731225

An overview of radioactive waste disposal procedures of a nuclear medicine department

Directory of Open Access Journals (Sweden)

R Ravichandran

2011-01-01

Full Text Available Radioactive wastes from hospitals form one of the various types of urban wastes, which are managed in developed countries in a safe and organized way. In countries where growth of nuclear medicine services are envisaged, implementations of existing regulatory policies and guidelines in hospitals in terms of handling of radioactive materials used in the treatment of patients need a good model. To address this issue, a brief description of the methods is presented. A designed prototype waste storage trolley is found to be of great help in decaying the I-131 solid wastes from wards before releasing to waste treatment plant of the city. Two delay tanks with collection time of about 2 months and delay time of 2 months alternately result in 6 releases of urine toilet effluents to the sewage treatment plant (STP of the hospital annually. Samples of effluents collected at releasing time documented radioactive releases of I-131 much below recommended levels of bi-monthly release. External counting of samples showed good statistical correlation with calculated values. An overview of safe procedures for radioactive waste disposal is presented.

Annotated chemical patent corpus: a gold standard for text mining.

Directory of Open Access Journals (Sweden)

Saber A Akhondi

Full Text Available Exploring the chemical and biological space covered by patent applications is crucial in early-stage medicinal chemistry activities. Patent analysis can provide understanding of compound prior art, novelty checking, validation of biological assays, and identification of new starting points for chemical exploration. Extracting chemical and biological entities from patents through manual extraction by expert curators can take substantial amount of time and resources. Text mining methods can help to ease this process. To validate the performance of such methods, a manually annotated patent corpus is essential. In this study we have produced a large gold standard chemical patent corpus. We developed annotation guidelines and selected 200 full patents from the World Intellectual Property Organization, United States Patent and Trademark Office, and European Patent Office. The patents were pre-annotated automatically and made available to four independent annotator groups each consisting of two to ten annotators. The annotators marked chemicals in different subclasses, diseases, targets, and modes of action. Spelling mistakes and spurious line break due to optical character recognition errors were also annotated. A subset of 47 patents was annotated by at least three annotator groups, from which harmonized annotations and inter-annotator agreement scores were derived. One group annotated the full set. The patent corpus includes 400,125 annotations for the full set and 36,537 annotations for the harmonized set. All patents and annotated entities are publicly available at www.biosemantics.org.

Medical irradiation, radioactive waste and misinformation. A press release from the French Academy of Medicine

International Nuclear Information System (INIS)

The, G. de; Tubiana, M.

2002-01-01

The Academy of Medicine, worried by the problems that poses for public opinion the medical irradiation, the radioactive wastes and some erroneous information that these subjects give rise to, considers useful to give an advice based on objective data. (N.C.)

[Development strategy of Paris based on combination of domestic patent and current resource application and development].

Science.gov (United States)

Zhao, Fei-Ya; Tao, Ai-En; Xia, Cong-Long

2018-01-01

Paris is a commonly used traditional Chinese medicine (TCM), and has antitumor, antibacterial, sedative, analgesic and hemostatic effects. It has been used as an ingredient of 81 Chinese patent medicines, with a wide application and large market demand. Based on the data retrieved from state Intellectual Property Office patent database, a comprehensive analysis was made on Paris patents, so as to explore the current features of Paris patents in the aspects of domestic patent output, development trend, technology field distribution, time dimension, technology growth rate and patent applicant, and reveal the development trend of China's Paris industry. In addition, based on the current Paris resource application and development, a sustainable, multi-channel and multi-level industrial development approach was built. According to the results, studies of Paris in China are at the rapid development period, with a good development trend. However, because wild Paris resources tend to be exhausted, the studies for artificial cultivation technology should be strengthened to promote the industrial development. Copyright© by the Chinese Pharmaceutical Association.

Using radioactivity

International Nuclear Information System (INIS)

1982-10-01

The leaflet discusses the following: radioactivity; radioisotopes; uses of ionising radiations; radioactivity from (a) naturally occurring radioactive elements, and (b) artificially produced radioisotopes; uses of radioactivity in medicine, (a) clinical diagnostic, (b) therapeutic (c) sterilization of medical equipment and materials; environmental uses as tracers; industrial applications, e.g. tracers and radiography; ensuring safety. (U.K.)

Therapeutic effect of Chinese herbal medicines for post stroke recovery: A traditional and network meta-analysis.

Science.gov (United States)

Han, Shi-You; Hong, Zhi-You; Xie, Yu-Hua; Zhao, Yong; Xu, Xiao

2017-12-01

Stroke is a condition with high morbidity and mortality, and 75% of stroke survivors lose their ability to work. Stroke is a burden to the family and society. The purpose of this study was to evaluate the effectiveness of Chinese herbal patent medicines in the treatment of patients after the acute phase of a stroke. We searched the following databases through August 2016: PubMed, Embase, Cochrane library, China Knowledge Resource Integrated Database (CNKI), China Science Periodical Database (CSPD), and China Biology Medicine disc (CBMdisc) for studies that evaluated Chinese herbal patent medicines for post stroke recovery. A random-effect model was used to pool therapeutic effects of Chinese herbal patent medicines on stroke recovery. Network meta-analysis was used to rank the treatment for each Chinese herbal patent medicine. In our meta-analysis, we evaluated 28 trials that included 2780 patients. Chinese herbal patent medicines were effective in promoting recovery after stroke (OR, 3.03; 95% CI: 2.53-3.64; P herbal patent medicines significantly improved neurological function defect scores when compared with the controls (standard mean difference [SMD], -0.89; 95% CI, -1.44 to -0.35; P = .001). Chinese herbal patent medicines significantly improved the Barthel index (SMD, 0.73; 95% CI, 0.53-0.94; P herbal medicines most likely to improve stroke recovery when combined with acupuncture. Our research suggests that the Chinese herbal patent medicines were effective for stroke recovery. The most effective treatments for stroke recovery were MLC601, Shuxuetong, and BuchangNaoxintong. However, to clarify the specific effective ingredients of Chinese herbal medicines, a well-designed study is warranted.

37 CFR 1.5 - Identification of patent, patent application, or patent-related proceeding.

Science.gov (United States)

2010-07-01

... UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES General Provisions General Information and Correspondence § 1.5 Identification of patent, patent... benefit of the date of deposit with the United States Postal Service. If the returned correspondence is...

The role of patent and non-patent databases in patent research in universities

Science.gov (United States)

Tolstaya, A. M.; Suslina, I. V.; Tolstaya, P. M.

2017-01-01

This studies deal with the description and systematization of the popular patent retrieval resources. The importance of the non-patent information when conducting patent research for the intellectual property created in educational and scientific activity of the university is highlighted. The differences in the patent and non-patent information are found out. Based on the databases` analysis the authors conducted the patent research on "Wireless endoscopic capsules" (development of the NRNU MEPhI). This study can be used to facilitate the university work on the new product development in order to improve the efficiency of the process of the commercialization of the intellectual activity results, including the entering the international market.

[The patents game. Generic and biosimilar drugs].

Science.gov (United States)

Villamañán, E; González, D; Armada, E; Ruano, M; Álvarez-Sala, R; Herrero, A

2016-01-01

The protection provided by patents on medicines has a limited duration. The expiry of patents expiration allows copies of the drugs to be released, competing with original. At first, they were identical to the original, known as generic drugs, but in recent years, due to the marketing of biological therapies and the expiry of many of their patents, biosimilar drugs have also emerged. These are not exact copies of the original, but, like generic drugs, biosimilar drugs have to demonstrate equivalence to the reference drugs in quality, safety and efficacy. Nevertheless, despite their importance and contribution to sustainability of health system, doctors are sometimes unaware of differences between them, and their impact in terms of clinical and economic effects. An attempt is made to review and clarify certain aspects often unknown by physicians, despite their involvement in their use. Copyright © 2015 SECA. Published by Elsevier Espana. All rights reserved.

广州市中药专利质量分析%Analysis of Traditional Chinese Medicine Patents Quality in Guangzhou Literatures

Institute of Scientific and Technical Information of China (English)

刘子志; 叶倩姝

2012-01-01

Objective To study the situation and characteristics of applications of traditional Chinese medicine in Guangzhou, and to raise suggestions for promotion. Methods By analyzing the effective dada from 2001 to 2010 in the PRC full-text database of The State Intellectual Property Office, the patent data was analyzed, based on Soopat online patent analysis system. Results In 978 eligible patents, 976 are inventions, the other 2 are patents of utility model. Among them, 396 patents get the right, 196 are under verification, 384 are unauthorized. Conclusion The application number is rising year by year, but most of the applicants are from colleges and universities. This causes unideal conversion rate, patents distribution and protection.%目的 研究广州市中药产业专利质量现状和特点,得出现况评价,并对弱势项提出相关对策建议.方法 检索国家知识产权局专利全文数据库,导出2001-2010年中药专利申请文献数据,通过soopat在线专利分析系统和药品专利质量评价指标体系,对导出数据中有意义专利检索结果进行专利分析.结果 共得到978项符合检索条件的中药发明专利和实用新型专利,其中976项为发明,2项为实用新型,拥有专利权的为396项,在审查中的为196项,未获权的专利文献为384项.结论 目前广州地区中药专利申请量逐年攀升,但申请人集中于高校等单一科研机构导致专利转化率不理想,以组方为主的中药专利申请造成专利结构不佳、保护力度有限.

Innovative Strategy in Treating Angina Pectoris with Chinese Patent Medicines by Promoting Blood Circulation and Removing Blood Stasis: Experience from Combination Therapy in Chinese Medicine.

Science.gov (United States)

Xiong, Xing-Jiang; Wang, Zhong; Wang, Jie

2015-01-01

Coronary heart disease (CHD) is one of the leading causes of death worldwide. Moreover, angina pectoris is one of the most important types of CHD. Therefore, prevention and effective treatment of angina pectoris is of utmost importance in both China and western countries. However, undesirable effects of antianginal therapy do influence treatment adherence to a certain extent. Therefore, it's not surprising that, complementary and alternative medicine (CAM), including Chinese medicine (CM), are widely welcomed among patients with CHD, hoping that it might complement western medicine. In our previous studies, blood stasis syndrome (BSS) (Xueyu Zheng) was the main syndrome (Zheng-hou) of angina pectoris. Currently, China Food and Drug Administration authoritatively recommended more than 200 Chinese patent medicines (CPMs) as complementary or adjunctive therapies for symptom management and enhancing quality of life along with mainstream care on angina pectoris management in mainland China. This paper reviewed 4 kinds of most frequently-used CPMs by promoting blood circulation and removing blood stasis in the treatment of angina pectoris. It aims to evaluate the current evidence of CPMs in combination therapy for angina pectoris. This review indicated that CPMs as adjunctive treatment to routine antianginal therapy play an active role in reducing the incidence of primary endpoint events, decreasing anginal attack rate, and improving electrocardiogram. Additionally, CPMs have been proven relatively safe. Further rigorously designed clinical trials should be conducted to confirm the results.

Patent Ductus Arteriosus Treatment in Very Preterm Infants

DEFF Research Database (Denmark)

Edstedt Bonamy, Anna-Karin; Gudmundsdottir, Anna; Maier, Rolf F

2017-01-01

BACKGROUND: Spontaneous closure of patent ductus arteriosus (PDA) occurs frequently in very preterm infants and despite the lack of evidence for treatment benefits, treatment for PDA is common in neonatal medicine. OBJECTIVES: The aim of this work was to study regional variations in PDA treatment...

Medical treatment methods, medical indication claims and patentability: A quest into the rationale of the exclusion and patentability in the context of the future of personalised medicine

NARCIS (Netherlands)

Bostyn, S.J.R.

2016-01-01

This contribution discusses the thorny issue of the rationale of the exclusion from patentability of medical treatment methods and the patentability of medical indications. This quest is the consequence of our earlier findings that medical indication patents present a real life risk for many players

Exploring sets of molecules from patents and relationships to other active compounds in chemical space networks

Science.gov (United States)

Kunimoto, Ryo; Bajorath, Jürgen

2017-09-01

Patents from medicinal chemistry represent a rich source of novel compounds and activity data that appear only infrequently in the scientific literature. Moreover, patent information provides a primary focal point for drug discovery. Accordingly, text mining and image extraction approaches have become hot topics in patent analysis and repositories of patent data are being established. In this work, we have generated network representations using alternative similarity measures to systematically compare molecules from patents with other bioactive compounds, visualize similarity relationships, explore the chemical neighbourhood of patent molecules, and identify closely related compounds with different activities. The design of network representations that combine patent molecules and other bioactive compounds and view patent information in the context of current bioactive chemical space aids in the analysis of patents and further extends the use of molecular networks to explore structure-activity relationships.

High-level radioactive wastes

International Nuclear Information System (INIS)

Grissom, M.C.

1982-10-01

This bibliography contains 812 citations on high-level radioactive wastes included in the Department of Energy's Energy Data Base from January 1981 through July 1982. These citations are to research reports, journal articles, books, patents, theses, and conference papers from worldwide sources. Five indexes are provided: Corporate Author, Personal Author, Subject, Contract Number, and Report Number

The lifespan of semiconductor patents by assignee and patent characteristics

Directory of Open Access Journals (Sweden)

Chang Shu-Hao

2017-01-01

Full Text Available Evaluating the values of patents is critical for both managers and investors. Patent maintenance time is an ideal proxy indicator for evaluating commercial patent value. This study investigated the survival rates of patents in the semiconductor industry by using a survival analysis and incorporated a predictive model for patent maintenance times. The technical characteristics of the patents, the assignee factors, and the statuses of the patents were used as the predictive factors for patent maintenance time. The results revealed a small entity size and the number of assignees are the risk factors that increase the likelihood of the maintenance time of a patent decreasing. The litigation status of a patent and the number of its international patent classifications, claims, forward citations, and assignments were determined to be the protection factors that raise the likelihood of its maintenance time extending. Additionally, substantial differences were noted between small entities and nonsmall entities and between being litigated and not in their effects on the survival rates of patents. This study examined the factors that affect the survival rates of patents and provides a reference for the managers and investors of intellectual property rights to use when assessing technical and commercial patent values.

Lovely but dangerous: The impact of patent citations on patent duration

OpenAIRE

Maurseth, Per Botolf

2001-01-01

- What is the impact of patent citations on patent renewal behaviour? Patent citations are commonly used as an indicator of technology spillovers. For cited patents therefore, patent citations have a potentially ambiguous impact. On the one hand, patent citations may indicate a scientific breakthrough, a high value of the cited patent and therefore a long survival period. On the other hand, patent citations may indicate competing innovations that render the cited patent obsolete. By discri...

Test Collections for Patent-to-Patent Retrieval and Patent Map Generation in NTCIR-4 Workshop

OpenAIRE

Fujii, Atsushi; Iwayama, Makoto; Kando, Noriko

2004-01-01

This paper describes the Patent Retrieval Task in the Fourth NTCIR Workshop, and the test collections produced in this task. We perform the invalidity search task, in which each participant group searches a patent collection for the patents that can invalidate the demand in an existing claim. We also perform the automatic patent map generation task, in which the patents associated with a specific topic are organized in a multi-dimensional matrix.

Patenting human genes: Chinese academic articles' portrayal of gene patents.

Science.gov (United States)

Du, Li

2018-04-24

The patenting of human genes has been the subject of debate for decades. While China has gradually come to play an important role in the global genomics-based testing and treatment market, little is known about Chinese scholars' perspectives on patent protection for human genes. A content analysis of academic literature was conducted to identify Chinese scholars' concerns regarding gene patents, including benefits and risks of patenting human genes, attitudes that researchers hold towards gene patenting, and any legal and policy recommendations offered for the gene patent regime in China. 57.2% of articles were written by law professors, but scholars from health sciences, liberal arts, and ethics also participated in discussions on gene patent issues. While discussions of benefits and risks were relatively balanced in the articles, 63.5% of the articles favored gene patenting in general and, of the articles (n = 41) that explored gene patents in the Chinese context, 90.2% supported patent protections for human genes in China. The patentability of human genes was discussed in 33 articles, and 75.8% of these articles reached the conclusion that human genes are patentable. Chinese scholars view the patent regime as an important legal tool to protect the interests of inventors and inventions as well as the genetic resources of China. As such, many scholars support a gene patent system in China. These attitudes towards gene patents remain unchanged following the court ruling in the Myriad case in 2013, but arguments have been raised about the scope of gene patents, in particular that the increasing numbers of gene patents may negatively impact public health in China.

Natural and artificial radioactivity determination of some medicinal plants

International Nuclear Information System (INIS)

Desideri, Donatella; Meli, Maria Assunta; Roselli, Carla

2010-01-01

Several medicinal plants used in Italy were analysed to determine natural and artificial radioactivity in those parts (leaves, fruits, seeds, roots, peduncles, flowers, barks, berries, thallus) used generally as remedies. The radionuclides were determined by alpha ( 238 U, 210 Po) and gamma ( 214 Pb-Bi, 210 Pb, 40 K and 137 Cs) spectrometry. 238 U ranged between dry -1 ; 210 Po between dry -1 ; 214 Pb- 214 Bi between dry -1 ; 210 Pb between dry -1 ; 40 K between 66.2 and 3582.0 Bq kg dry -1 ; 137 Cs between dry -1 . The percentage of 210 Po extraction in infusion and decoction was also determined; the arithmetical mean value of percentage of 210 Po extraction resulted 20.7 ± 7.5.

Litigation-proof patents: avoiding the most common patent mistakes

National Research Council Canada - National Science Library

Goldstein, Larry M

2014-01-01

"Litigation-Proof Patents: Avoiding the Most Common Patent Mistakes explains the principles of excellent patents, presents the ten most common errors in patents, and details a step-by-step method for avoiding these common errors...

How Patent Function Integration with R&D Influence the Value of Patents

DEFF Research Database (Denmark)

Beukel, Karin; Valentin, Finn

Patent strategies are endogenous to firm appropriability. However, to what extent does firm’s R&D teams’ engagement with patent experts influence the value of patents? We estimate the relationship between firm’s R&D use of patent functions on patent value in Biotech firms. Controlling...... for characteristics of scientific team, firm effects, and other patent value indicators, we find that having a firm specific (in-house) internal patent function is a driver of patent value. In addition, we find that the way in which patent functions create patent value differs dependent on whether the firm has...... internal patent function or not. In-house patent functions create value through narrow patents, whereas, firms with no in-house patent function create valuable patents by the use of broader scoped patents. Our results point to a strong effect of firm specific patent functions, but also explain how firms...

Biological diversity in the patent system.

Directory of Open Access Journals (Sweden)

Paul Oldham

Full Text Available Biological diversity in the patent system is an enduring focus of controversy but empirical analysis of the presence of biodiversity in the patent system has been limited. To address this problem we text mined 11 million patent documents for 6 million Latin species names from the Global Names Index (GNI established by the Global Biodiversity Information Facility (GBIF and Encyclopedia of Life (EOL. We identified 76,274 full Latin species names from 23,882 genera in 767,955 patent documents. 25,595 species appeared in the claims section of 136,880 patent documents. This reveals that human innovative activity involving biodiversity in the patent system focuses on approximately 4% of taxonomically described species and between 0.8-1% of predicted global species. In this article we identify the major features of the patent landscape for biological diversity by focusing on key areas including pharmaceuticals, neglected diseases, traditional medicines, genetic engineering, foods, biocides, marine genetic resources and Antarctica. We conclude that the narrow focus of human innovative activity and ownership of genetic resources is unlikely to be in the long term interest of humanity. We argue that a broader spectrum of biodiversity needs to be opened up to research and development based on the principles of equitable benefit-sharing, respect for the objectives of the Convention on Biological Diversity, human rights and ethics. Finally, we argue that alternative models of innovation, such as open source and commons models, are required to open up biodiversity for research that addresses actual and neglected areas of human need. The research aims to inform the implementation of the 2010 Nagoya Protocol on Access to Genetic Resources and the Equitable Sharing of Benefits Arising from their Utilization and international debates directed to the governance of genetic resources. Our research also aims to inform debates under the Intergovernmental Committee on

The Effects of Oral Ibuprofen on Medicinal Closure of Patent Ductus Arteriosus in Full-Term Neonates in the Second Postnatal Week.

Science.gov (United States)

Alipour, Mohammad Reza; Mozaffari Shamsi, Mansooreh; Namayandeh, Seyedeh Mahdieh; Pezeshkpour, Zohreh; Rezaeipour, Fatemeh; Sarebanhassanabadi, Mohammadtaghi

2016-08-01

The arterial ductus is a major communicative pathway which is naturally patent in the fetus, connecting the body of the major pulmonary artery to the descending aorta. Although usually closing on its own, the patent ductus arteriosus (PDA) may remain open in the second postnatal week due to a lack of prompt diagnosis in the initial days of life or an absence of prompt treatment. To prevent the untoward sequelae of patency of the ductus arteriosus, and to avoid invasive surgery at higher ages, the researchers in the present study embarked on determining the effects of oral ibuprofen during the second postnatal week on newborns with patent ductus arteriosus. In this study, 70 neonates aged eight to 14 days, presenting at Khatam-al-Anbia clinic and the NICU ward of Shahid Sadoughi hospital in Yazd, Iran, who were diagnosed with PDA through auscultation of heart murmurs and echocardiography, were randomly assigned to two groups. The experimental group received oral ibuprofen of 10 mg/kg in day 1, 5 mg/kg in day 2, and 5 mg/kg in day 3 administered by their parents. The control group did not receive any drug. Parents were informed of the potential drug complications and side effects and asked to report them to the researchers if any occurred. After intervention, the patent ductus arteriosus was closed in 62.9% of the neonates in the experimental group (35 newborns) who received oral ibuprofen, while it was closed in 54.3% of the control neonates (35 newborns) who did not receive any drug (P = 0.628). No complications were observed in either of the neonatal groups. Our findings showed that administration of oral ibuprofen had no significant effect on the medicinal closure of PDA in full-term neonates during the second postnatal week.

"To patent or not to patent? the case of Novartis' cancer drug Glivec in India".

Science.gov (United States)

Gabble, Ravinder; Kohler, Jillian Clare

2014-01-06

Glivec (imatinib mesylate), produced by the pharmaceutical company Novartis, is prescribed in the case of chronic myeloid leukemia, one of the most common blood cancers in eastern countries. After more than a decade of legal battles surrounding its patentability, the Supreme Court of India gave its final decision on April 1st of 2013, rejecting the appeal of the Swiss giant drug manufacturer. In 2006, the Indian Patent Office first refused Glivec's patent under Section 3(d) of the Indian Patent Act arguing that it was only a modified version of an existing drug, Imatinib, and therefore that the drug was not innovative. Novartis replied filing legal challenges against the Indian government but the final verdict in April of 2013 ends the battle. Indeed, the Supreme Court stated that even if the bioavailability of the drug was improved, it did not demonstrate enhanced efficacy and that Glivec was not patentable. The research primarily focused on journal, newspaper and magazine articles relevant to the time frame of the lawsuit (from 1994 to 2013) as well as news searches through Google, Factiva, ProQuest, PubMed, and YouTube where press articles from court verdicts were obtained by using the following keywords: "India", "Novartis", "Glivec", "Patent", "Novartis Case", and "Supreme Court of India". The data sources were interpreted and analyzed according to the authors' own prior knowledge and understanding of the exigencies of the TRIPS Agreement. This case illuminates how India is interpreting international law to fit domestic public health needs. The Novartis case arguably sets an important precedent for the global pharmaceutical industry and ideally will help improve access to lifesaving medicines in the developing world by demanding that patient health needs supersede commercial interests. The Supreme Court of India's decision may affect the interpretation of the article of the TRIPS Agreement, which states members shall be free to determine the appropriate method

A evolução do sistema internacional de propriedade intelectual: proteção patentária para o setor farmacêutico e acesso a medicamentos Evolution of the international intellectual property rights system: patent protection for the pharmaceutical industry and access to medicines

Directory of Open Access Journals (Sweden)

Gabriela Costa Chaves

2007-02-01

Full Text Available O artigo discute a evolução do sistema internacional de direitos de propriedade intelectual em três fases e as implicações para saúde pública, especialmente para a implementação de políticas de acesso a medicamentos. Durante a primeira fase, caracterizada pelas Convenções de Paris e de Berna, os países signatários determinavam os campos tecnológicos que seriam protegidos ou não. Na segunda fase, com a implementação do Acordo TRIPS pela OMC, os países são obrigados a garantir proteção patentária a todos os campos tecnológicos, inclusive para a indústria farmacêutica. Dentro das suas respectivas legislações nacionais, os países também têm a oportunidade de implementar o acesso às flexibilidades do TRIPS para medicamentos. Com a terceira fase, caracterizada pela negociação e assinatura de acordos comerciais bilaterais e regionais, os países terão que implementar medidas TRIPS-plus que podem ter implicações negativas para as flexibilidades do TRIPS e para políticas de acesso a medicamentos. Os autores concluem que a proposta atual de sistema internacional de direitos de propriedade intelectual favorece os direitos dos detentores de patentes, que deveriam estar em equilíbrio com os direitos à saúde para a população.This article discusses the evolution of the international intellectual property rights system in three phases and the implications for public health, especially for the implementation of policies for access to medicines. During the first phase, characterized by the Paris and Berne Convention, signatory countries defined which technological fields should be protected (or not. Under the second phase, with the enforcement of the WTO TRIPS Agreement, countries are obliged to grant patent protection for all technological fields, including for the pharmaceutical industry. Within their national legislations, countries also have the opportunity to implement access to TRIPS flexibilities for medicines

Nuclear Medicine

Science.gov (United States)

... Parents/Teachers Resource Links for Students Glossary Nuclear Medicine What is nuclear medicine? What are radioactive tracers? ... funded researchers advancing nuclear medicine? What is nuclear medicine? Nuclear medicine is a medical specialty that uses ...

Patent Assessment Quality

DEFF Research Database (Denmark)

Burke, Paul F.; Reitzig, Markus

2006-01-01

The increasing number of patent applications worldwide and the extension of patenting to the areas of software and business methods have triggered a debate on "patent quality". While patent quality may have various dimensions, this paper argues that consistency in the decision making on the side...... of the patent office is one important dimension, particularly in new patenting areas (emerging technologies). In order to understand whether patent offices appear capable of providing consistent assessments of a patent's technological quality in such novel industries from the beginning, we study the concordance...... of the European Patent Office's (EPO's) granting and opoposition decisions for individual patents. We use the historical example of biotech patens filed between 1978 until 1986, the early stage of the industry. Our results indicate that the EPO shows systematically different assessments of technological quality...

Radioactivity of natural medicinal preparations contained extracts from peat mud available in retail trade used externally.

Science.gov (United States)

Karpińska, Maria; Kapała, Jacek; Raciborska, Agnieszka; Kulesza, Grzegorz; Milewska, Anna; Mnich, Stanisław

2017-08-01

In this work were identified and measured the activity of radioactive isotopes present in medicinal preparations from peat mud and estimated the doses obtained from them during therapy. Radioactivity of 22 preparations from peat mud and 20 water samples from water of the North-East region of Poland was studied. The median of the total activity was 24.8 Bq kg -1 . Total maximal isotope activity was observed in the Iwonicka Cube 146 Bq kg -1 while considerable amounts of isotopes were found in the Kolobrzeska Peat Mud Paste 112 Bq kg -1 . The doses obtained during therapy were within the range of 11 nSv-13 μSv depending on extracts of medicinal preparations from peat mud. The probability that such a small dose would stimulate biological effects is low. However, some clinicians believe that one of the possible therapeutic mechanisms in the treatment of rheumatoid disorders is the induction of immune response by ionising radiation.

Patent first, ask questions later: morality and biotechnology in patent law.

Science.gov (United States)

Bagley, Margo A

2003-12-01

This Article explores the U.S. "patent first, ask questions later" approach to determining what subject matter should receive patent protection. Under this approach, the U.S. Patent and Trademark Office (USPTO or the Agency) issues patents on "anything under the sun made by man," and to the extent a patent's subject matter is sufficiently controversial, Congress acts retrospectively in assessing whether patents should issue on such interventions. This practice has important ramifications for morally controversial biotechnology patents specifically, and for American society generally. For many years a judicially created "moral utility" doctrine served as a type of gatekeeper of patent subject matter eligibility. The doctrine allowed both the USTPO and courts to deny patents on morally controversial subject matter under the fiction that such inventions were not "useful." The gate, however, is currently untended. A combination of the demise of the moral utility doctrine, along with expansive judicial interpretations of the scope of patent-eligible subject matter, has resulted in virtually no basis on which the USTPO or courts can deny patent protection to morally controversial, but otherwise patentable, subject matter. This is so despite position statements by the Agency to the contrary. Biotechnology is an area in which many morally controversial inventions are generated. Congress has been in react-mode following the issuance of a stream of morally controversial biotech patents, including patents on transgenic animals, surgical methods, and methods of cloning humans. With no statutory limits on patent eligibility, and with myriad concerns complicating congressional action following a patent's issuance, it is not Congress, the representative of the people, determining patent eligibility. Instead, it is patent applicants, scientific inventors, who are deciding matters of high public policy through the contents of the applications they file with the USTPO. This Article

Radioactive tracer system to indicate drill bit wear or failure

International Nuclear Information System (INIS)

Fries, B.A.

1975-01-01

A radioactive tracer system for indicating drill bit wear or failure utilizing radioactive krypton 85 in clathrate form, in the form of water-soluble kryptonates, or dissolved grease, is described. Preferably the radioactive krypton is placed so that when drill bit wear or failure occurs, the radioactive krypton 85 is relased and effectively becomes diffused in the circulating drilling fluid. At the surface, the radioactive krypton 85 gas is separated from the circulating drilling fluid by gas-mud separating means and is transported as a gas to a counting chamber where an accurate radioactivity count of beta rays released from the krypton is obtained. (Patent Office Record)

Enforcement costs: some humanitarian alternatives to stronger patent rights.

Science.gov (United States)

Trotter, Andrew

2012-01-01

Diseases that cause comparatively few problems in developed countries kill millions of people in the Third World each year. In many cases, people die because they cannot afford the medication needed to save their lives. In others, there are simply no drugs available because there are no wealthy western patients to justify pharmaceutical companies investing in a cure. This reveals a deep-seated problem within the patent system and the pharmaceutical industry that emphasises markets and profits at the expense of health and global welfare. Global efforts have seen substantial improvements in access to medicines in isolated areas, but with international agreements driving towards stronger patent protection and the expiry date for the TRIPS grace period fast approaching, it is time to consider alternatives which will allow the patent system to work for the humanitarian cause rather than against it. This paper considers two such problems in the patent system and pharmaceutical industry - prohibitive pricing and misdirected incentives - to offer a mode of regulation and enforcement that will support both a viable pharmaceutical industry and the human right to health and medication.

Patentability of inventions under the Nigeria's patents and designs act

African Journals Online (AJOL)

Patentability of inventions under the Nigeria's patents and designs act: an examination. ... AFRICAN JOURNALS ONLINE (AJOL) · Journals · Advanced Search · USING ... The Nigerian Patent Registry refuses patent applications for Software or ...

The standardization methods of radioactive sources (125I, 131I, 99mTc, and 18F) for calibrating nuclear medicine equipment in Indonesia

International Nuclear Information System (INIS)

Wurdiyanto, G; Candra, H

2016-01-01

The standardization of radioactive sources ( 125 I, 131 I, 99m Tc and 18 F) to calibrate the nuclear medicine equipment had been carried out in PTKMR-BATAN. This is necessary because the radioactive sources used in the field of nuclear medicine has a very short half-life in other that to obtain a quality measurement results require special treatment. Besides that, the use of nuclear medicine techniques in Indonesia develop rapidly. All the radioactive sources were prepared by gravimetric methods. Standardization of 125 I has been carried out by photon- photon coincidence methods, while the others have been carried out by gamma spectrometry methods. The standar sources are used to calibrate a Capintec CRC-7BT radionuclide calibrator. The results shows that calibration factor for Capintec CRC-7BT dose calibrator is 1,03; 1,02; 1,06; and 1,04 for 125 I, 131 I, 99m Tc and 18 F respectively, by about 5 to 6% of the expanded uncertainties. (paper)

The standardization methods of radioactive sources (125I, 131I, 99mTc, and 18F) for calibrating nuclear medicine equipment in Indonesia

Science.gov (United States)

Wurdiyanto, G.; Candra, H.

2016-03-01

The standardization of radioactive sources (125I, 131I, 99mTc and 18F) to calibrate the nuclear medicine equipment had been carried out in PTKMR-BATAN. This is necessary because the radioactive sources used in the field of nuclear medicine has a very short half-life in other that to obtain a quality measurement results require special treatment. Besides that, the use of nuclear medicine techniques in Indonesia develop rapidly. All the radioactive sources were prepared by gravimetric methods. Standardization of 125I has been carried out by photon- photon coincidence methods, while the others have been carried out by gamma spectrometry methods. The standar sources are used to calibrate a Capintec CRC-7BT radionuclide calibrator. The results shows that calibration factor for Capintec CRC-7BT dose calibrator is 1,03; 1,02; 1,06; and 1,04 for 125I, 131I, 99mTc and 18F respectively, by about 5 to 6% of the expanded uncertainties.

The patent, object of research in Information Science and Communication

Directory of Open Access Journals (Sweden)

Luc Quoniam

2014-04-01

Full Text Available In this study are addressed some dimensions of intellectual property, especially patents and their way of making some tangible outcomes of research and development, playing a key role in the field of strategy, involving the returns on investments and exploration rights to certain inventions. However, the general objective of this study is to present aspects of the information available in patent applications and the possibility of using them to transfer technology between countries, organizations, contribute to the research of social responsibility, valuing natural resources and provide access to medicines, once these are aspects little attention in the literature. Considering the patent as an object of study in the humanities and social sciences, is evidenced by the cases cited, the potential contribution to innovation, research and development organizations, regions and countries.

Low-level radioactive waste

International Nuclear Information System (INIS)

McLaren, L.H.

1983-03-01

This bibliography contains information on low-level radioactive waste included in the Department of Energy's Energy Data Base for January through December 1982. The abstracts are grouped by subject category as shown in the table of contents. Entries in the subject index also facilitate access by subject, e.g., Low-Level Radioactive Wastes/Transport. Within each category the arrangement is by report number for reports, followed by nonreports in reverse chronological order. These citations are to research reports, journal articles, books, patents, theses, and conference papers from worldwide sources. Five indexes, each proceded by a brief description, are provided: Corporate Author, Personal Author, Subject, Contract Number, and Report Number. 492 references

Spatiotemporal PET Imaging of Dynamic Metabolic Changes After Therapeutic Approaches of Induced Pluripotent Stem Cells, Neuronal Stem Cells, and a Chinese Patent Medicine in Stroke.

Science.gov (United States)

Zhang, Hong; Song, Fahuan; Xu, Caiyun; Liu, Hao; Wang, Zefeng; Li, Jinhui; Wu, Shuang; YehuaShen; Chen, Yao; Zhu, Yunqi; Du, Ruili; Tian, Mei

2015-11-01

This study aimed to use spatiotemporal PET imaging to investigate the dynamic metabolic changes after a combined therapeutic approach of induced pluripotent stem cells (iPSCs), neuronal stem cells (NSCs), and Chinese patent medicine in a rat model of cerebral ischemia-reperfusion injury. Cerebral ischemia was established by the middle cerebral artery occlusion approach. Thirty-six male rats were randomly assigned to 1 of the 6 groups: control phosphate-buffered saline (PBS), Chinese patent medicine (Qing-kai-ling [QKL]), induced pluripotent stem cells (iPSCs), combination of iPSCs and QKL, neuronal stem cells (NSCs), and combination of NSCs and QKL. Serial (18)F-FDG small-animal PET imaging and neurofunctional tests were performed weekly. Autoradiographic imaging and immunohistochemical and immunofluorescent analyses were performed at 4 wk after stem cell transplantation. Compared with the PBS control group, significantly higher (18)F-FDG accumulations in the ipsilateral cerebral infarction were observed in 5 treatment groups from weeks 1-4. Interestingly, the most intensive (18)F-FDG accumulation was found in the NSCs + QKL group at week 1 but in the iPSCs + QKL group at week 4. The neurofunctional scores in the 5 treatment groups were significantly higher than that of the PBS group from week 3 to 4. In addition, there was a significant correlation between the PET imaging findings and neurofunctional recovery (P PET imaging with (18)F-FDG demonstrated dynamic metabolic and functional recovery after iPSCs or NSCs combined with QKL in a rat model of cerebral ischemia-reperfusion injury. iPSCs or NSCs combined with Chinese medicine QKL seemed to be a better therapeutic approach than these stem cells used individually. © 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

The Medicines (Administration of Radioactive Substances) Regulations 1978 (S.I. no.1006)

International Nuclear Information System (INIS)

1978-01-01

These regulations prohibit the administration of radioactive medicinal products except by doctors or dentists holding a certificate issued by the Health Ministers for such purpose. They also lay down the procedure for the grant of such certificates and provide for the appointment of a Committee to advise the authorities on these matters. The Regulations were made in pursuance of Council Directive 76/579/Euratom which lays down the revised standards for the health protection of the general public and workers against the dangers of ionizing radiation. (NEA) [fr

Human induced pluripotent stem cells: a review of the US patent landscape.

Science.gov (United States)

Georgieva, Bilyana P; Love, Jane M

2010-07-01

Human induced pluripotent stem (iPS) cells and human embryonic stem cells are cells that have the ability to differentiate into a variety of cell types. Embryonic stem cells are derived from human embryos; however, by contrast, human iPS cells can be obtained from somatic cells that have undergone a process of 'reprogramming' via genetic manipulation such that they develop pluripotency. Since iPS cells are not derived from human embryos, they are a less complicated source of human pluripotent cells and are considered valuable research tools and potentially useful in therapeutic applications in regenerative medicine. Worldwide, there are only three issued patents concerning iPS cells. Therefore, the patent landscape in this field is largely undefined. This article provides an overview of the issued patents as well as the pending published patent applications in the field.

Radioactivity

International Nuclear Information System (INIS)

Chelet, Y.

2006-01-01

The beginning of this book explains the why and how of the radioactivity, with a presentation of the different modes of disintegration. Are tackled the reports between radioactivity and time before explaining how the mass-energy equivalence appears during disintegrations. Two chapters treat natural radioisotopes and artificial ones. This book makes an important part to the use of radioisotopes in medicine (scintigraphy, radiotherapy), in archaeology and earth sciences (dating) before giving an inventory of radioactive products that form in the nuclear power plants. (N.C.)

Natural products against cancer: A comprehensive bibliometric study of the research projects, publications, patents and drugs

Directory of Open Access Journals (Sweden)

Jian Du

2014-01-01

Full Text Available Objectives: To analyze multi-source data including awards, publications, patents and drugs, and try to draw the whole landscape of the research and development community in the area of natural products (NPs against cancer. Materials and Methods: Awards, publications, patents and drugs data from National Institute of Health/Natural Science Foundation of China (NIH/NSFC, PubMed, Derwent Innovation Index and Cortellis were collected. Bibliometric methodologies and technology are used to investigate publications/patents/drugs, their contents and relationships. Results: NIH and NSFC respectively demonstrated a stable and sustained expenditure growth in this area. The number of publications is continuously increasing. Yet the annual patent applications worldwide and FDA drug approvals were little changed or not obviously fluctuated in 2003-2013. USA and several Asia-pacific countries/territories are important contributing powers. We described the evolution of major research topics by those MeSH Major Topics indexed in PubMed with the largest growth range in three intervals, and analyzed hot research topics in the recent 10 years which include NPs or NPs derivatives, cell line/animal model, laboratory technologies and activation mechanisms. Conclusions: China published the most publications and received the most patent applications, but drug discovery performance is no better than USA and Japan. Research on anti-neoplastic structures and compounds originated from Chinese traditional medicine (TCM, medicinal plants, herbal medicine and marine NPs are major research topics in the recent 10 years. There still exits translational gap between basic research and drug discovery. Translational research should be undertaken to strengthen the applicability of NPs.

The patentability of living organisms between science, law and ethics.

Science.gov (United States)

Frati, L; Foà, R; Frati, P

1999-01-01

The approval on May 1998 of the European Union (EU) directive on the legal protection of biotechnological inventions has aligned Europe to the international trend about the patenting of biotechnologies. Many questions are still unresolved, i.e. the differences between the article 53b of the European Patent Convention (EPC), which prohibits patenting of plants and animal varieties, whereas the directive states that Oinvention whose object are plants or animals may be patented if the practicability of the invention is not technically confined to a particular plant or animal varietyO (article 12). Again, the interpretation of plants or animal species specificity and that on the threatening public order and morality (which inhibits patenting) may have doubtful interpretations, according to the different EU States morality and law (e.g. Denmark does not admit patentability of transgenic animals). Despite difficulties, biotechnology Research and Development for applications to medicine, veterinary sciences, agriculture and foods is continuously growing. Bioethical independent evaluations of the applications of biotechnologies and of their side-effects (risk for biodiversity of plants and animals, safety of procedures to save mankind, respect of human dignity and of fundamental human rights, etc.) are mandatory to link the interests of science and industrial productions together with those of mankind. This is the original meaning given by van Potter to the word bioethics, as a bridge to the future.

Radiation protection in nuclear medicine

International Nuclear Information System (INIS)

Chougule, Arun

2014-01-01

The branch of medical science that utilizes the nuclear properties of the radioactivity and stable nuclides to make diagnostic evaluation of anatomical and/or physiological conditions of the body and provide therapy with unsealed radioactive sources is called Nuclear Medicine (NM). The use of unsealed radionuclides in medicine is increasing throughout the world for diagnosis and treatment. As per UNSCEAR report more than 6 million nuclear medicine procedures are conducted in a year. However we know that radiation is double edged sword and if not used carefully will be harmful to patient as well as staff and therefore a nuclear medicine procedure should be undertaken only after proper justification and optimization. Nuclear medicine procedures are different than the X-ray diagnostic procedures as in NM, radioisotope is administered to patient and patient becomes radioactive. The NM staff is involved in unpacking radioactive material, activity measurements, storage of sources, internal transports of sources, preparation of radiopharmaceuticals, administration of radiopharmaceutical, examination of the patient, care of the radioactive patient, handling of radioactive waste and therefore receives radiation dose. This talk will discuss the various steps for radiation safety of patient, staff and public during Nuclear Medicine procedures so as to implementing the ALARA concept. (author)

[How much does the backlog on drug patents cost for health in Brazil?

Science.gov (United States)

Jannuzzi, Anna Haydée Lanzillotti; Vasconcellos, Alexandre Guimarães

2017-08-21

The backlog in processing patent applications in Brazil has persisted since the enactment of Law 9,279/1996, when the country resumed granting patents on drugs. The agencies responsible for granting such patents, namely the Brazilian National Patent and Trademark Office (INPI) and the Brazilian National Health Surveillance Agency (Anvisa) cite technical and administrative reasons for the backlog. However, little research has focused on the economic impacts for health due to the inefficiency of the Brazilian patent system. The current study thus proposes a methodology to estimate the extent to which government procurement of medicines is burdened by the backlog in drug patent applications. According to the results, a total of more than BRL 14 million (USD 4.5 million) is spent unnecessarily per year by the Federal Government on just one antiretroviral drug due to the extension of the respective patent's life. Measures to resolve this situation are urgently needed in the three branches of government. These include hiring more staff for the INPI, analysis of bills of law under review in the two houses of the Brazilian Congress to amend the Industrial Property Law, and ruling on direct class action claims of unconstitutionality to suppress the legal mechanisms that allow extending the life of patents.

Generic and biosimilar medicines: quid?

Directory of Open Access Journals (Sweden)

Steven Simoens

2012-12-01

Full Text Available Once intellectual property protection, data and marketing exclusivity of reference medicines have expired, generic medicines and biosimilar medicines can enter the off-patent market. This market entry is conditional on the approval of marketing authorization, pricing and reimbursement. Given that there tends to be confusion surrounding generic and biosimilar medicines, this Editorial introduces basic concepts related to generic and biosimilar medicines and presents the different studies and articles included in this supplement dedicated to generic and biosimilar medicines.

Evaluation of management of radioactive waste in nuclear medicine department of radiation and isotopes center, Khartoum

International Nuclear Information System (INIS)

Ahmed, Amel Bushra Abaker

2001-01-01

Evaluation of management of radioactive waste in nuclear medicine department of radiation and isotopes center in Khartoum, Sudan, was conducted using radiation survey meter. The purpose of this study is to provide protection of workers, patients, co patients, an the environment by introducing good practice in management of radioactive waste generated in this lab. In this work measurement of radiation effective dose at different locations in the department were carried out. These locations were selected around the radioactive liquid and solid waste disposal position. It was found that the effective doses per year from radioactive wastes obtained through this work using the survey meter RDS-120 at these locations, are 1.47 mSv/y at the neighbouring patients room, 5.47 mSv/y at the hot lab., 0.09 mSv/y at the neighbouring toilet, 0.321 mSv/y at the water closet, and 1.4 mSv/y at the place down water closet. The results obtained shows that the dose levels waste at the location not exceed the recommended dose limits for workers 20 mSv/y, that set by basic safety standards (Bss 115) which published by the international atomic energy agency. Also it s comply with the national regulation, regulation on basic radiation protection requirement and dose limits 1996, issued by sudan atomic energy commission act 1996. The annual dose calculated for the patients and co-patients at rooms around the nuclear medicine department, the results shows that dose are fairly high. Measure should taken to improve the waste management in the department for better protection of workers, patients and co patients. (Author)

Apparatus for waste disposal of radioactive hazardous waste

International Nuclear Information System (INIS)

Burack, R.D.; Stenger, W.J.; Wolfe, C.R.

1992-01-01

This patent describes an apparatus for concentrating dissolved and solid radioactive materials carried in a waste water solution containing a hazardous chelating agent used for cleaning nuclear equipment. It comprises oxidizing chamber means, separator means coupled to the oxidizing chamber means; ion exchange means containing an ion exchange resin; dryer means for receiving the radioactive solids from the separator means and for producing dry solids; and packaging means for receiving the dry solids and spent ion exchange resins containing the removed dissolved radioactive materials and for packaging the dry solids and spent resins in solid form

General Nuclear Medicine

Science.gov (United States)

... Resources Professions Site Index A-Z General Nuclear Medicine Nuclear medicine imaging uses small amounts of radioactive ... of General Nuclear Medicine? What is General Nuclear Medicine? Nuclear medicine is a branch of medical imaging ...

The knowledge of emergency contraception and dispensing practices of Patent Medicine Vendors in South West Nigeria.

Science.gov (United States)

Fayemi, Mojisola M; Oduola, Olufemi L; Ogbuji, Queen C; Osinowo, Kehinde A; Oyewo, Adejoke E; Osiberu, Olabimpe M

2010-09-01

Patent Medicine Vendors (PMVs) can play a critical role in increasing access to emergency contraceptive pills (ECPs) in developing countries, but few studies have examined their knowledge and dispensing practices. Using cluster sampling, the authors selected and interviewed 97 PMVs (60.8 per cent female) in Oyo and Ogun States of Nigeria to assess their knowledge, dispensing practices, and referral for ECPs. About one-third (27.8 per cent) of respondents were not aware of ECPs, and only half knew that ECPs could prevent pregnancy. Forty per cent had ever dispensed ECPs. Reasons proffered by those who do not dispense ECPs included barriers from the State Ministry of Health, police, other regulatory agencies, and religious beliefs. Only 50.5 per cent have referral arrangements for clients. Strategies to increase access to ECPs through PMVs include training on counseling techniques and referral, effective government regulation, and community involvement. Where unsafe abortion is a major cause of maternal mortality, these strategies offer protection for many women in the future.

Children's (Pediatric) Nuclear Medicine

Medline Plus

Full Text Available ... Nuclear Medicine Children’s (pediatric) nuclear medicine imaging uses small amounts of radioactive materials called radiotracers, a special ... is a branch of medical imaging that uses small amounts of radioactive material to diagnose and determine ...

Ethical limitations in patenting biotechnological inventions.

Science.gov (United States)

Lugagnani, V

1999-01-01

In order to connect ethical considerations with practical limits to patentability, the moral judgement should possibly move from the exploitation of the invention to the nature and/or objectives of Research and Development (R&D) projects which have produced it: in other words, it appears quite reasonable and logical that Society is not rewarding unethical R&D activities by granting intellectual property rights. As far as biotechnology R&D is concerned, ethical guidance can be derived from the 1996 Council of EuropeOs OConvention for the protection of human rights and dignity of the human being with regard to the application of biology and medicineO, whose Chapter V - Scientific research - provides guidelines on: i. protection of persons undergoing research (e.g. informed consent); ii. protection of persons not able to consent to research; iii. research on embryos in vitro. As far as the specific point of patenting biotechnology inventions is concerned, the four exclusions prescribed by Directive 98/44/EC (i.e. human cloning, human germ-line gene therapy, use of human embryos for commercial purposes, unjustified animal suffering for medical purposes) are all we have in Europe in terms of ethical guidance to patentability. In Italy, in particular, we certainly need far more comprehensive legislation, expressing SocietyOs demand to provide ethical control of modern biotechnology. However it is quite difficult to claim that ethical concerns are being raised by currently awarded biotechnology patents related to living organisms and material thereof; they largely deal with the results of genomic R&D, purposely and usefully oriented toward improving health-care and agri-food processes, products and services. ONo patents on lifeOO can be an appealing slogan of militants against modern biotechnology, but it is far too much of an over-simplified abstraction to become the Eleventh Commandment our Society.

Patents in INIS

International Nuclear Information System (INIS)

Scheel, H.; Breitfeld, B.

1983-01-01

Proceeding from the INIS rules for collecting, characterizing, and making available patent documents, results of an analysis are presented, which concern timeliness, origin, and classification of patents according to the INIS subject categories and the International Patent Classification. GDR's capabilities for SDI services and retrospective searches are outlined taking into account patents. For a selected subject area (IPC G21) the coverage of patents announced by INIS was found to be about 30%

Patents and access to drugs in developing countries: an ethical analysis.

Science.gov (United States)

Sterckx, Sigrid

2004-05-01

More than a third of the world's population has no access to essential drugs. More than half of this group of people live in the poorest regions of Africa and Asia. Several factors determine the accessibility of drugs in developing countries. Hardly any medicines for tropical diseases are being developed, but even existing drugs are often not available to the patients who need them. One of the important determinants of access to drugs is the working of the patent system. This paper first maps out some facts about the global patent regime that has emerged as a consequence of the conclusion of the WTO-TRIPs Agreement in 1994. Attempts to construct a moral justification of the patent system have been based on three grounds: natural rights, distributive justice, and utilitarian arguments. This paper examines to what extent and on which grounds drug patents can be justified. The final section looks at the so-called 'Doha Declaration on the TRIPs Agreement and Public Health', which was adopted by the WTO Ministerial Conference two years ago, recognising the primacy of public health over the interests of patent proprietors.

Radioactivity handbook. Volume 2: radioactive disintegrations, radiations-matter interactions, applications of radioactivity

International Nuclear Information System (INIS)

Foos, J.; Bonfand, E.; Rimbert, J.N.

1994-01-01

This volume is the second one of a group of three. The first one exposed nuclides, with neutrons and protons in a stable building: atomic nucleus. Here is the second one with unstable, radioactive nucleus. After the description of different kinds of disintegrations, it is justified to follow radiations in matter and modifications attached to them; different uses of radioactivity are developed in medicine, age determination, industrial utilization and biology

Patents and nanomedicine.

Science.gov (United States)

Bawa, Raj

2007-06-01

Big pharma's business model, which relies on a few blockbusters to generate profits, is clearly broken. Patent expiration on numerous blockbusters in recent years is already altering the drug landscape. Drug companies are also facing other challenges that necessitate development and implementation of novel R&D strategies, including those that focus on nanotechnology and miniaturization. Clearly, there is enormous excitement and expectation regarding nanomedicine's potential impact. However, securing valid and defensible patent protection will be critical. Although early forecasts for nanomedicine commercialization are encouraging, there are numerous bottlenecks as well. One of the major hurdles is an emerging thicket of patent claims, resulting primarily from patent proliferation as well as continued issuance of surprisingly broad patents by the US Patent and Trademark Office (PTO). Adding to this confusion is the fact that the US National Nanotechnology Initiative's widely cited definition of nanotechnology is inaccurate and irrelevant from a nanomedicine perspective. It is also the cause of the inadequate patent classification system that was recently unveiled by the PTO. All of this is creating a chaotic, tangled patent landscape in various sectors of nanomedicine where the competing players are unsure of the validity and enforceability of numerous issued patents. If this trend continues, it could stifle competition and limit access to some inventions. Therefore, reforms are urgently needed at the PTO to address problems ranging from poor patent quality and questionable examination practices to inadequate search capabilities, rising attrition, poor employee morale and a skyrocketing patent application backlog. Only a robust patent system will stimulate the development of commercially viable nanomedicine products that can drastically improve a patient's quality of life and reduce healthcare costs.

The liquidation of liquid radioactive waste on nuclear medicine departments

International Nuclear Information System (INIS)

Fueriova, A.

1995-01-01

The most serious problems for Clinic of Nuclear Medicine of National Oncological Institute, Bratislava (CNM) is the localization of CNM in the downtown, inside the hospital area with the dilution water deficit. This department is the only one in Slovak Republic performing therapeutical applications. To be able to perform the necessary amount of therapies and also to introduce a new therapeutical methods, in 1992-1994 the old liquidation waste disposal station (LWDS) was reconstructed with the aim to satisfy the newest requirements of radiation hygiene. LWDS is the 5-floor object partly underground which satisfied the requirements for liquidation of radioactive liquid waste from diagnostic procedures(annually 5000 patients) and also from 200 therapeutical applications annually (15 beds, 720 GBq iodine-131). The capacity of LWDS is able to store about 90 m 3 liquid radioactive waste. Part of the underground spaces are used for the storage of solid radioactive trash. The liquid waste from CNM is collected through isolated metal sewage system to the storage with continuous observation of water specific activity. According to the activity, the liquid waste is placed to the 5 decay storages with the volume about 15 m 3 . The six one serves for the case of technical accident. When the activity declines, the liquid waste is diluted with non active medical trash to the level which is acceptable by low about radiation hygiene protection. The storage walls are made from barium-concrete 25-50 cm thick which is enough for sufficient protection of operation staff and also for walking around persons. Double-layer high quality chemical material prevents the water leak and diffusion of radionuclides into the concrete. Technology consists of cast-iron drains, powerful slush pumps, operation valves, regulation technology from dosimetric system for continuous monitoring of specific activity, for managing system with powerful industrial computer

The liquidation of liquid radioactive waste on nuclear medicine departments

Energy Technology Data Exchange (ETDEWEB)

Fueriova, A [National Oncological Institue, Bratislava (Slovakia). Hospital St. Elis, Clinic of Nuclear Medicine

1996-12-31

The most serious problems for Clinic of Nuclear Medicine of National Oncological Institute, Bratislava (CNM) is the localization of CNM in the downtown, inside the hospital area with the dilution water deficit. This department is the only one in Slovak Republic performing therapeutical applications. To be able to perform the necessary amount of therapies and also to introduce a new therapeutical methods, in 1992-1994 the old liquidation waste disposal station (LWDS) was reconstructed with the aim to satisfy the newest requirements of radiation hygiene. LWDS is the 5-floor object partly underground which satisfied the requirements for liquidation of radioactive liquid waste from diagnostic procedures(annually 5000 patients) and also from 200 therapeutical applications annually (15 beds, 720 GBq iodine-131). The capacity of LWDS is able to store about 90 m{sup 3} liquid radioactive waste. Part of the underground spaces are used for the storage of solid radioactive trash. The liquid waste from CNM is collected through isolated metal sewage system to the storage with continuous observation of water specific activity. According to the activity, the liquid waste is placed to the 5 decay storages with the volume about 15 m{sup 3}. The six one serves for the case of technical accident. When the activity declines, the liquid waste is diluted with non active medical trash to the level which is acceptable by low about radiation hygiene protection. The storage walls are made from barium-concrete 25-50 cm thick which is enough for sufficient protection of operation staff and also for walking around persons. Double-layer high quality chemical material prevents the water leak and diffusion of radionuclides into the concrete. Technology consists of cast-iron drains, powerful slush pumps, operation valves, regulation technology from dosimetric system for continuous monitoring of specific activity, for managing system with powerful industrial computer.

Comprehensive Quantitative Analysis of 32 Chemical Ingredients of a Chinese Patented Drug Sanhuang Tablet

OpenAIRE

Hau-Yee Fung; Yan Lang; Hing-Man Ho; Tin-Long Wong; Dik-Lung Ma; Chung-Hang Leung; Quan-Bin Han

2017-01-01

Sanhuang Tablet (SHT) is a Chinese patented drug commonly used for the treatment of inflammations of the respiratory tract, gastrointestinal tract, and skin. It contains a special medicinal composition including the single compound berberine hydrochloride, extracts of Scutellariae Radix and Rhei Radix et Rhizoma, as well as the powder of Rhei Radix et Rhizoma. Despite advances in analytical techniques, quantitative evaluation of a Chinese patented drug like SHT remains a challenge due to the ...

Modern evaluation of patents

Science.gov (United States)

Ignat, V.

2016-08-01

The number of patents is not so important as the market value. The market value is especially important for licensing of patents, make-or-buy decisions for technology procurement, corporate finance. Patents can be used as collateral for financing. Patents and credit approvals: without patents only 46% and with patents 54%. The value share of knowledge-based components to industrial products already reached 50% and it is still rising. OECD called these developments under the slogan "knowledge economy”. German Norm-DIN 77100 provides a working method for monetary evaluation of a patent. The value of a patent arises from its use. A patent can be used to protect or to earn licensing revenues. An evaluation expertise is required in areas, such as marketing, finance, R & D and strategic planning. As an indicator of the value of a patent is often used the number of citations. The number of a patent citation refers to its meaning and value. Other indicators would be: size of the patent family, validity of the patent, result of objections against patent application, number and quality of claims. The analysis of 9.000 patents resulted that only 7.2% worth over 10 million euro and 68% below 1 million euro. The cost method: it is considered the cost that would be incurred for the development and patenting of a similar invention. The market method: are used the prices that have been achieved in comparable with recently transactions. The Income method: the potential reward is measured, which can arise from a patent. The evaluation will be in the following areas: legal status, technology, market conditions, finance and strategy. Each question relates to a different parameter of a value.

Current Energy Patents

International Nuclear Information System (INIS)

Kelly, R.C.

1982-01-01

Current Energy Patents (CEP) provides abstracting and indexing coverage of the international patent literature, including patent applications, that concerns any aspect of energy production, conservation, and utilization

Management of Radioactive Wastes in Developing Countries

International Nuclear Information System (INIS)

Abdel Ghani, A.H.

1999-01-01

The management of radioactive wastes is one area of increasing interest especially in developing countries having more and more activities in the application of radioisotopes in medicine, research and industry. For a better understanding of radioactive waste management in developing countries this work will discuss the following items:Classification of countries with respect to waste management programs. Principal Radionuclides used in medicine, biological research and others and the range of radioactivity commonly used. Estimation of radioactive waste volumes and activities. Management of liquid wastes Collection. Treatment. Management of small volumes of organic liquid waste. Collection Treatment. Packaging and storage of radioactive wastes

Cross-Border Patent Disputes: Unified Patent Court or International Commercial Arbitration?

OpenAIRE

Alba Betancourt, Ana

2016-01-01

Currently, the enforcement of a patent that is registered in several countries involves the risk of getting different and conflicting decisions from the national courts. In 2013, 25 European countries entered in an agreement that aims to homogenise the patent system by creating the European patent with unitary effect and a Unified Patent Court (UPC). This article focuses on the UPC, which aims to have a single court proceeding for cross-border patent conflicts. Does the UPC system represent a...

Radioactivity and Environment

International Nuclear Information System (INIS)

Sanchez Leon, J.G.

1993-01-01

Radioactivity is one of the most studied natural phenomena. Most of irradiation suffered by the human being is produced by natural sources. The second source in order of importance is nuclear medicine. The average level of radiation received by the man is 2.4 mSv/year and this value can be modified naturally in 20-30%. The author provides a review on radioactivity sources like natural (cosmic rays, extraterrestrial radiation, internal earth radiation, radon) and artificial (Nuclear explosions, professional exposure, nuclear medicine, nuclear power plants and accidents)

An Assessment Of Traditional Uighur Medicine In Current Xinjiang ...

African Journals Online (AJOL)

Results: Data showed that, among the registered and studied traditional Uighur medicine, the main therapeutic areas of traditional Uighur medicine focused on skin disease, urogenital disease, rheumatism and digestive system disease. The representative traditional Uighur patent medicine included the following: ...

Nanotechnology and patents in agriculture, food technology, nutrition and medicine - advantages and risks: worldwide patented nano- and absorber particles in food nutrition and agriculture.

Science.gov (United States)

Benckiser, Gero

2012-12-01

The keywords nanotechnology, super absorber, agriculture, nutrition, and food technology exhibited 28,149 positive matches under more than 68 million patents worldwide. A closer look at the first 500 nanotechnology, agriculture, nutrition and biotechnology related patents, published during 2011-2012, unveiled that 64% are parts of machines and control devices while about 36% comprise metal oxides, fertilizers, pesticides and drugs, which are compounds and often applied in combination with inorganic or organic super absorbing polymeric structures. The latter compounds are in the focus of this special issue.

Teaching Chemistry Students How To Use Patent Databases and Glean Patent Information

Science.gov (United States)

MacMillan, Margy; Shaw, Lawton

2008-07-01

Patent literature is an important source of chemical information that is often neglected by chemical educators. This paper describes an effort to teach chemistry students how to use patent databases to search for information on applied chemical technology related to the manufacture of industrial and specialty chemicals. Students in a second-year-level organic chemistry class were shown how to search patent literature as part of a group research paper assignment that involved determining the feasibility of starting an industrial chemical operation to manufacture a given industrial chemical. Students who were assigned high value or specialty chemicals were most likely to cite patent literature in their final papers. Students who were assigned plastics or bulk commodity chemicals were less likely to cite patents. It is suggested that students made choices about the usefulness of patent literature and that patents were most useful when current patents existed and provided the patent owner a competitive advantage. For plastics or commodity chemicals, manufacturing technologies tend to be mature and are well described by more accessible information sources. Suggestions are made for effective introduction of patent literature instruction into upper-level chemistry courses.

“To patent or not to patent? the case of Novartis’ cancer drug Glivec in India”

Science.gov (United States)

2014-01-01

Background Glivec (imatinib mesylate), produced by the pharmaceutical company Novartis, is prescribed in the case of Chronic Myeloid Leukemia, one of the most common blood cancers in eastern countries. After more than a decade of legal battles surrounding its patentability, the Supreme Court of India gave its final decision on April 1st of 2013, rejecting the appeal of the Swiss giant drug manufacturer. In 2006, the Indian Patent Office first refused Glivec’s patent under Section 3(d) of the Indian Patent Act arguing that it was only a modified version of an existing drug, Imatinib, and therefore that the drug was not innovative. Novartis replied filing legal challenges against the Indian government but the final verdict in April of 2013 ends the battle. Indeed, the Supreme Court stated that even if the bioavailability of the drug was improved, it did not demonstrate enhanced efficacy and that Glivec was not patentable. Methods The research primarily focused on journal, newspaper and magazine articles relevant to the time frame of the lawsuit (from 1994 to 2013) as well as news searches through Google, Factiva, ProQuest, PubMed, and YouTube where press articles from court verdicts were obtained by using the following keywords: “India”, “Novartis”, “Glivec”, “Patent”, “Novartis Case”, and “Supreme Court of India”. The data sources were interpreted and analyzed according to the authors’ own prior knowledge and understanding of the exigencies of the TRIPS Agreement. Results This case illuminates how India is interpreting international law to fit domestic public health needs. Conclusions The Novartis case arguably sets an important precedent for the global pharmaceutical industry and ideally will help improve access to lifesaving medicines in the developing world by demanding that patient health needs supersede commercial interests. The Supreme Court of India’s decision may affect the interpretation of the article of the TRIPS Agreement

A guide of patent map

International Nuclear Information System (INIS)

1999-12-01

This book introduces application and characteristic of patent information, types of patent information data and research of patent information, arrangement of patent information and patent map, analysis of patent information, necessity, writing period arrangement way of patent map, cases of patent map on selection of task of research and development, system of research and development and application, examples of PM such as MAP by year, application, technique, Inventor, and claim point map and computerization like data arrangement of PM patent, collection of analysis range and item analysis of patent, cases and written reports on patent analysis.

Discrimination in the patent system: evidence from standard-essential patents

NARCIS (Netherlands)

de Rassenfosse, G.; Raiteri, E.; Bekkers, R.N.A.

2017-01-01

This paper tests for traces of discrimination against foreigners in the patent prosecution process. It focuses on the case of China and looks specifically at patent applications declared as essential to a technological standard, so called standard-essential patents. The identification strategy

Analysis of the systems for management of radioactive wastes from nuclear medicine clinics of the city of Recife, Pernambuco, Brazil

International Nuclear Information System (INIS)

Lira, Renata Farias de; Lopes, Ferdinand de Jesus; Passos, Robson Silva; Silva, Valeria Cosma Bento da; Belo, Igor Burgo; Santos, Marcus Aurelio Pereira dos

2009-01-01

In nuclear medicine compounds marked with radionuclides, called radiopharmaceuticals, for obtention diagnostic information and for diseases treatment. The physicochemical characteristics of the radiopharmaceuticals determine his fixation at target-organ, and the physical characteristics determine the compound application in diagnostic or therapy. The handling of radiopharmaceuticals generates solid, liquid and gas wastes. The presence of these wastes implies in a adequate management according to regulation standards established by the Brazilian Nuclear Energy Commission (CNEN). The objective of safe management of radioactive wastes is to protect the human being and the preservation of the environment, limiting possible radiological impacts for the future generation, and comprehend a set of technical and administrative activities involved in the collection, segregation, handling, conditioning, transportation, storage, control and elimination, or the final deposition. This work intends to verify if the radioactive waste management systems from the nuclear medicine clinics at the city of Recife are conformal with te normative regulations issued by the CNEN. The initial obtained results are used to elaboration of conformal verification spreadsheet and its application in six nuclear medicine clinics at Recife

Airborne radioactive effluents: releases and processing

International Nuclear Information System (INIS)

Grissom, M.C.

1982-10-01

This bibliography contains 870 citations on airborne radioactive waste included in the Department of Energy's Energy Data Base from January 1981 through August 1982. These citations are to research reports, journal articles, books, patents, theses, and conference papers from worldwide sources. Five indexes, each preceded by a brief description, are provided: Corporate Author, Personal Author, Subject, Contract Number, and Report Number

High-level radioactive wastes. Supplement 1

International Nuclear Information System (INIS)

McLaren, L.H.

1984-09-01

This bibliography contains information on high-level radioactive wastes included in the Department of Energy's Energy Data Base from August 1982 through December 1983. These citations are to research reports, journal articles, books, patents, theses, and conference papers from worldwide sources. Five indexes, each preceded by a brief description, are provided: Corporate Author, Personal Author, Subject, Contract Number, and Report Number. 1452 citations

Present status of radioactive wastes from nuclear medicine in the hospitals of Guangdong province and the preliminary exploration to some relevant problems

International Nuclear Information System (INIS)

Kong Lingfeng

1999-01-01

In Guangdong province of China nuclear medicine is quite developed. There are about 50 hospitals (not including the hospitals only with radioimmunoassay) in the medical units of Guangdong province which have their own nuclear medical departments. More than 40 ECTs are owned by the hospitals and more than 10 radioisotopes, such as 131 I, 125 I, 99 Mo- 99m Tc, 90 Sr, 32 P, 153 Sm etc., are mainly used. The thesis, based on the author's work in checking the use of radiopharmaceuticals in the hospitals of Guangdong province, investigates and summarizes the actual situations of the use of radiopharmaceuticals and the discharge and treatment of radioactive wastes in nuclear medical departments of the hospitals in Guangdong province. According to the actual problems in administration and disposal of the radioactive wastes in the hospitals, it makes a preliminary exploration and puts forward some countermeasures and suggestions on how to supervise and administer the discharge of radioactive wastes in the hospitals, and how to further solve them, in order to prevent and reduce the radioactive contamination and damage to the environment and the public caused by the development of nuclear medicine

Products with Natural Components to Heal Dermal Burns: A Patent Review.

Science.gov (United States)

de Melo Costa, Aida Carla Santana; Pereira Ramos, Karen Perez; Serafini, Mairim Russo; de Carvalho, Fernanda Oliveira; Teixeira, Luciana Garcez Barretto; Garcao, Diogo Costa; Shanmugam, Saravanan; de Souza Araujo, Adriano Antunes; Nunes, Paula Santos

2015-01-01

Burns are a global public health problem, and non-fatal burn injuries are a leading cause of morbidity. The scale of the problem has led researchers to seek to develop new prod- ucts (both synthetic and natural) for use in the treatment of burn lesions. The aim of this study was to examine all patents in databases between 2010 and 2015 related to natural prod- ucts for the treatment of burn-related wounds that targeted tissue repair and healing. The search term "burn" and the code A61K36/00 (plant and other natural derivatives used in medicinal prepara- tions) from the international classification of patents were used to identify treatments. The search was performed in the WIPO, ESPACENET and USPTO databases. The highest number of patent ap- plications was found in the WIPO data base (617), followed by ESPACENET(23) and USPTO(6). The USA and China were the countries with the most patent applications, and 2008 was the year that had the highest number of applications. Patent applications written in Spanish, English and Portuguese and that were published between 2010 and 2015 were se- lected. 559 patent applications in other languages, and 63 that did not result in the creation of new products between 2010 and 2015 were excluded and the remaining 13 patents application were selected for full reading of the text. Through this study we were able to identify and summarize the new active natural compounds that can be used in the treatment of burns, both in terms of tissue recovery and analgesia.

Economic Justification of Patents and Exceptions to Patentability

DEFF Research Database (Denmark)

Nordberg, Ana

2012-01-01

The present article is the conclusion of a review of economic justifications for patent rights conducted with the objective of determining whether such arguments are per se capable of sustaining the existence of a different patentability regime for inventions of methods for treatment and diagnostic...... methods (art.53 (c) European Patent Convention). It starts by exploring the normative background and summarily describes the different types of claims allowed under the current legal framework and their differences. The following sections will describe and apply the main economic arguments sustaining...... patent rights inventions of methods for treatment and diagnostic methods. These reasoning will be later confronted with contra-arguments. This piece will finalize with the formulation of conclusions extracted from the previous debate, inter-alia that economic reasoning does not per se sustain...

Impact on access to medicines from TRIPS-Plus: a case study of Thai-US FTA.

Science.gov (United States)

Kessomboon, Nusaraporn; Limpananont, Jiraporn; Kulsomboon, Vidhaya; Maleewong, Usawadee; Eksaengsri, Achara; Paothong, Prinya

2010-05-01

This study assessed the impact of the Thai-US Free Trade Agreement (FTA) on access to medicines in Thailand. We first interpreted the text of the sixth round of Thai-US negotiations in 2006 on intellectual property rights (IPR). The impact was estimated using a macroeconomic model of the impact of changes in IPR. The estimated impact is based on a comparison between the current IPR situation and the proposed changes to IPR. The FTA text involves the period of patent extension from the Trade-Related Aspects of Intellectual Property Rights Agreement (TRIPS Agreement). The provisions involve the period of patent extension, which have to do with compensation for delays in patent registration and/or drug registration, data exclusivity that would result in a delay in generic drug entry, and the enforcing role of the Thai Food and Drug Administration of patent linkages. As a worst case scenario for this single provision, a 10 year patent extension would be given to compensate for delays in patent registration and/or drug registration. The impact on access to medicine, in the year 2027, would be: 1) A 32% increase in the medicine price index, 2) spending on medicines would increase to approximately USD 11,191 million, (USD1 = THB 33.9 on September 2, 2009), and 3) the domestic industry could loss USD 3.3 million. These results suggest there would be a severe restriction on the access to medicines under the TRIPS-Plus proposal. IPR protection of pharmaceuticals per the TRIPS-Plus proposal should be excluded from FTA negotiations.

Patents for Soldiers

Science.gov (United States)

2016-06-10

PATENTS FOR SOLDIERS A thesis presented to the Faculty of the U.S. Army Command and General Staff College in partial fulfillment...COVERED (From - To) AUG 2015 – JUNE 2016 4. TITLE AND SUBTITLE Patents for Soldiers 5a. CONTRACT NUMBER 5b. GRANT NUMBER 5c. PROGRAM...protection of an innovative idea; that is, a patent . A Soldier’s pursuit of patents provides the Army with tangible and intangible benefits. There are on

Solidification Technologies for Radioactive and Chemical Liquid Waste Treatment - Final CRADA Report

International Nuclear Information System (INIS)

Castiglioni, Andrew J.; Gelis, Artem V.

2016-01-01

This project, organized under DOE/NNSA's Global Initiatives for Proliferation Prevention program, joined Russian and DOE scientists in developing more effective solidification and storage technologies for liquid radioactive waste. Several patent applications were filed by the Russian scientists (Russia only) and in 2012, the technology developed was approved by Russia's Federal State Unitary Enterprise RADON for application throughout Russia in cleaning up and disposing of radioactive waste.

The therapeutic potential of truffle fungi: a patent survey

Directory of Open Access Journals (Sweden)

Małgorzata Gajos

2014-12-01

Full Text Available The purpose of this article is to research and retrieve patent information regarding the therapeutic use of truffles. Truffles have a unique value as a foodstuff and impact positively on human health and well-being. They are applied in such industries as the pharmaceutical industry and the cosmetic industry. Patent documentation available in the Espacenet network and the Patentscope service were analyzed by key word and patent specifications were examined to describe state of the art and to identify scientific research trends in therapeutic applications of truffles. Medicinal properties of truffles such as the anticancer or cardiovascular effect, a reduction in blood lipids, immunological resistance and increased energy were identified. Other therapeutic benefits include sedative action, prevention of hormonal imbalances in women, pre-menopause symptom relief, senile urethritis and prostate disorders, sleep disorders and increased absorption of calcium from milk. Truffles can also be used to alleviate symptoms of milk intolerance such as diarrhoea or bloating, to ease rheumatic pains and to treat and prevent further development or recurrence of senile cataract.

Management of waste from the use of radioactive material in medicine, industry, agriculture, research and education. Safety guide

International Nuclear Information System (INIS)

2009-01-01

Radioactive waste is generated in a broad range of activities involving the use of radioactive material in medicine, industry, agriculture, research and education. The amounts of waste generated from these activities are often limited in volume and activity. However, they have to be managed as radioactive waste. While the principles and safety requirements are the same for managing any amount of radioactive waste, a number of issues have to be considered specifically in organizations conducting activities in which only small amounts of waste are generated. This is the case in particular in respect of spent and disused sealed radioactive sources. For activities involving the generation and management of small amounts of radioactive waste, the types of facilities concerned and the arrangements for waste management vary considerably. Furthermore, the types of radioactive waste differ from facility to facility. The safe management of small amounts of radioactive waste should therefore be given specific consideration. The nature of the radioactive waste generated in the various activities under consideration also varies greatly. It may be in the form of discrete sealed or unsealed radiation sources or process materials or consumable materials. Waste arises as a result of many activities, including: diagnostic, therapeutic and research applications in medicine. Process control and measurement in industry. And numerous uses of radioactive material in agriculture, geological exploration, construction and other fields. The radioactive waste under consideration can be in solid, liquid or gaseous form. Solid waste can include: spent or disused sealed sources. Contaminated equipment, glassware, gloves and paper. And animal carcasses, excreta and other biological waste. Liquid waste can include: aqueous and organic solutions resulting from research and production processes. Excreta. Liquids arising from the decontamination of laboratory equipment or facilities. And liquids from

Management of waste from the use of radioactive material in medicine, industry, agriculture, research and education. Safety guide

International Nuclear Information System (INIS)

2006-01-01

Radioactive waste is generated in a broad range of activities involving the use of radioactive material in medicine, industry, agriculture, research and education. The amounts of waste generated from these activities are often limited in volume and activity. However, they have to be managed as radioactive waste. While the principles and safety requirements are the same for managing any amount of radioactive waste, a number of issues have to be considered specifically in organizations conducting activities in which only small amounts of waste are generated. This is the case in particular in respect of spent and disused sealed radioactive sources. For activities involving the generation and management of small amounts of radioactive waste, the types of facilities concerned and the arrangements for waste management vary considerably. Furthermore, the types of radioactive waste differ from facility to facility. The safe management of small amounts of radioactive waste should therefore be given specific consideration. The nature of the radioactive waste generated in the various activities under consideration also varies greatly. It may be in the form of discrete sealed or unsealed radiation sources or process materials or consumable materials. Waste arises as a result of many activities, including: diagnostic, therapeutic and research applications in medicine. Process control and measurement in industry. And numerous uses of radioactive material in agriculture, geological exploration, construction and other fields. The radioactive waste under consideration can be in solid, liquid or gaseous form. Solid waste can include: spent or disused sealed sources. Contaminated equipment, glassware, gloves and paper. And animal carcasses, excreta and other biological waste. Liquid waste can include: aqueous and organic solutions resulting from research and production processes. Excreta. Liquids arising from the decontamination of laboratory equipment or facilities. And liquids from

Compulsory patent licensing and local drug manufacturing capacity in Africa

Science.gov (United States)

2014-01-01

Abstract Africa has the highest disease burden in the world and continues to depend on pharmaceutical imports to meet public health needs. As Asian manufacturers of generic medicines begin to operate under a more protectionist intellectual property regime, their ability to manufacture medicines at prices that are affordable to poorer countries is becoming more circumscribed. The Doha Declaration on the TRIPS Agreement and Public Health gives member states of the World Trade Organization (WTO) the right to adopt legislation permitting the use of patented material without authorization by the patent holder, a provision known as “compulsory licensing”. For African countries to take full advantage of compulsory licensing they must develop substantial local manufacturing capacity. Because building manufacturing capacity in each African country is daunting and almost illusory, an African free trade area should be developed to serve as a platform not only for the free movement of goods made pursuant to compulsory licences, but also for an economic or financial collaboration towards the development of strong pharmaceutical manufacturing capacity in the continent. Most countries in Africa are in the United Nations list of least developed countries, and this allows them, under WTO law, to refuse to grant patents for pharmaceuticals until 2021. Thus, there is a compelling need for African countries to collaborate to build strong pharmaceutical manufacturing capacity in the continent now, while the current flexibilities in international intellectual property law offer considerable benefits. PMID:24700981

GenMed 010: a one day workshop on generic medicines

Directory of Open Access Journals (Sweden)

Shankar PR

2011-03-01

Full Text Available This report outlines the content of a one-day workshop onGeneric Medicines that was held at KIST Medical College,Lalitpur, Nepal on 13th December 2010, which was attendedby 32 delegates from different institutions in Nepal, includingpharmacists, pharmacologists and medical doctors. Rightmedicine, right patient, right dose, right frequency andduration, right information and right monitoring areconditions to be fulfilled for the rational use of medicine(RUM. The World Health Organization (WHO defines genericmedicine as ‘a pharmaceutical product, usually intended to beinterchangeable with the innovator product, marketed afterthe expiry of patent or other exclusivity rights’. Economicfactors, supportive legislation and regulation, public andprofessional acceptance and quality assurance are keyenabling factors promoting use of generics. Increased patentprotection for medicines and removing process patents is akey feature of new trade agreements and newer medicines fordiseases like HIV/AIDS, tuberculosis and infectious diseasesare likely to be more expensive. The Medicine andTherapeutics Committee (MTC can play a key role inpromoting generic medicine use in institutions.Nepal being among the Least Developed Countries (LDCsneed not provide patent protection for medicines until 31stDecember 2015. Only a few ‘true’ generics are available inNepal and there is huge cost variation in the price of differentbranded generics. Clinicians have concerns about the qualityof medicines in general, substitution of poor quality brands bypharmacists and about therapeutic substitution. Genericshave to meet the same regulatory requirements and bebioequivalent to reference preparations assuring their quality.

High-level radioactive wastes. Supplement 1

Energy Technology Data Exchange (ETDEWEB)

McLaren, L.H. (ed.)

1984-09-01

This bibliography contains information on high-level radioactive wastes included in the Department of Energy's Energy Data Base from August 1982 through December 1983. These citations are to research reports, journal articles, books, patents, theses, and conference papers from worldwide sources. Five indexes, each preceded by a brief description, are provided: Corporate Author, Personal Author, Subject, Contract Number, and Report Number. 1452 citations.

Well logging radioactive detector assembly

International Nuclear Information System (INIS)

Osburn, T.D.

1992-01-01

This patent describes a well logging instrument of the type having a radioactive logging sub having a sealed chamber and have a radioactive source for emitting radioactive energy into the well formation, the instrument having a radioactive energy detector for detecting gamma rays resulting from the emission of the radioactive energy into the well formation, and means for pressing the sub against the well of the well, an improved Dewar flask for the detector. It comprises: an inner housing formed of titanium and containing the detector; an outer housing formed of titanium, having a cylindrical side wall surrounding the inner housing and separated by a clearance which is evacuated, the outer housing being located within the sealed chamber in the sub of the instrument; a window section formed in the side wall of the outer housing adjacent the detector and on a side of the side wall closest to the wall of the well when the sub is pressed against the wall of the well; and wherein the inner housing has a cylindrical side wall that is of lesser wall thickness than the wall thickness of the side wall of the outer housing other than in the window section

Patent landscape of neglected tropical diseases: an analysis of worldwide patent families.

Science.gov (United States)

Akinsolu, Folahanmi Tomiwa; de Paiva, Vitor Nobre; Souza, Samuel Santos; Varga, Orsolya

2017-11-14

"Neglected Tropical Diseases" (NTDs) affect millions of people in Africa, Asia and South America. The two primary ways of strategic interventions are "preventive chemotherapy and transmission control" (PCT), and "innovative and intensified disease management" (IDM). In the last 5 years, phenomenal progress has been achieved. However, it is crucial to intensify research effort into NTDs, because of the emerging drug resistance. According to the World Health Organization (WHO), the term NTDs covers 17 diseases, namely buruli ulcer, Chagas disease, dengue, dracunculiasis, echinococcosis, trematodiasis, human African trypanosomiasis, leishmaniasis, leprosy, lymphatic filariasis, onchocerciasis, rabies, schistosomiasis, soil-transmitted helminthes, taeniasis, trachoma, and yaws. The aim of this study is to map out research and development (R&D) landscape through patent analysis of these identified NTDs. To achieve this, analysis and evaluation have been conducted on patenting trends, current legal status of patent families, priority countries by earliest priority years and their assignee types, technological fields of patent families over time, and original and current patent assignees. Patent families were extracted from Patseer, an international database of patents from over 100 patent issuing authorities worldwide. Evaluation of the patents was carried out using the combination of different search terms related to each identified NTD. In this paper, a total number of 12,350 patent families were analyzed. The main countries with sources of inventions were identified to be the United States (US) and China. The main technological fields covered by NTDs patent landscape are pharmaceuticals, biotechnology, organic fine chemistry, analysis of biological materials, basic materials chemistry, and medical technology. Governmental institutions and universities are the primary original assignees. Among the NTDs, leishmaniasis, dengue, and rabies received the highest number of

Truth and falsity of patent

International Nuclear Information System (INIS)

Park, Gum Jin

2006-10-01

This book describes the process of the effect to build the business of patent strongly in difficult situation. The titles of this contents are finally, lawsuit if formed, the task of patent application introduction of tasks of patent negotiation, negotiation with Fujitsu, Mitsubishi, Oki and NEC, amalgamation between LG semiconductor and Hyundai Electronic Industry, life in incorporated company, current condition of application for a patent, the method to process strategy patent, how to make strong patent and effective negotiation strategy for a patent and strategy of patent application.

Travel in the depth of radioactivity

International Nuclear Information System (INIS)

1996-09-01

This educational booklet gives a general presentation of radioactivity: origin of natural radioactivity, characteristics of atoms and isotopes, the radioactivity phenomenon, its decay and measurement units, the radiations and their use in medicine, industry, agriculture and food industry, biology etc.. (J.S.)

Comprehension and application of patent information

International Nuclear Information System (INIS)

Lee, Sang Nam

2004-05-01

This book gives descriptions of conception of patent information such as the meaning, characteristic, function, investigation and map of patent information, pro-patent period and patent strategy of the business. It also deals with comprehension of patent information like publication of nations, patent document, patent procedure in Korea, patent procedure in Japan, the U.S, and Europe, article and function of patent document, patent information survey such as writing of search keyword, procedure of the survey and search site of other countries, patent analysis and patent map.

Data anonymization patent landscape

Directory of Open Access Journals (Sweden)

Mirjana Pejić Bach

2017-01-01

Full Text Available The omnipresent, unstoppable increase in digital data has led to a greater understanding of the importance of data privacy. Different approaches are used to implement data privacy. The goal of this paper is to develop a data anonymization patent landscape, by determining the following: (i the trend in data anonymization patenting, (ii the type of technical content protected in data anonymization, (iii the organizations and countries most active in patenting data anonymization know-how; and (iv the topics emerging most often in patent titles. Patents from the PatSeer database relating to data anonymization from 2001 to 2015 were analyzed. We used the longitudinal approach in combination with text mining techniques to develop a data anonymization patent landscape. The results indicated the following. The number of single patent families is growing with a high increase after 2010, thus indicating a positive trend in the area of patenting data anonymization solutions. The majority of patenting activities relate to the G Physics section. Organizations from the USA and Japan assigned the majority of patents related to data anonymization. The results of text mining indicate that the most often used word in titles of data anonymization patents are “anonym*, “method”, “data” and “system”. Several additional words that indicated the most frequent topics related to data anonymization were: “equipment”, “software”, “protection”, “identification”, or “encryption”, and specific topics such as “community”, “medical”, or “service”.

37 CFR 1.710 - Patents subject to extension of the patent term.

Science.gov (United States)

2010-07-01

... of Patent Term Extension of Patent Term Due to Regulatory Review § 1.710 Patents subject to extension... primarily manufactured using recombinant DNA, recombinant RNA, hybridoma technology, or other processes...

Patent border wars: defining the boundary between scientific discoveries and patentable inventions.

Science.gov (United States)

Holman, Christopher M

2007-12-01

Drawing an appropriate boundary between unpatentable natural phenomena and patentable inventions is crucial in preventing the patent laws from unduly restricting access to fundamental scientific discoveries. Some would argue that, particularly in the U.S., patents are being issued that purport to claim a novel product or process but that, in effect, encompass any practical application of a fundamental biological principle. Examples include gene patents, which Congress is considering banning, and patents relating to biological correlations and pathways, such as the patents at issue in the headline-grabbing LabCorp v. Metabolite and Ariad v. Eli Lilly litigations. In view of the mounting concern, it seems likely that Congress and/or the courts will address the issue, and perhaps substantially shift the boundary.

Patenting Nanomedicine in Europe:

DEFF Research Database (Denmark)

Nordberg, Ana

Patenting Nanomedicine in Europe: Applying the ‘medical methods exception’ to emerging technologies is based on the authors PhD dissertation, defended in March 2014, at the University of Copenhagen. The book debates restrictions on the patentability of medical methods in European Patent Law....... The main question addressed is whether it is viable and advisable the reinterpretation, reformulation or replacement of Article 53 (c) EPC – a provision restricting the patenting of medical methods. The subject is approached by reference to emerging technologies, and using nanomedicine innovation...... as example and point of departure. Nanotechnology inventions blur the lines between patentable subject matter and what may fall under the exception from patentability. It is a good example of how in recent years, emerging technologies have been challenging the patent system and exposing the need for re...

Patent Keyword Extraction Algorithm Based on Distributed Representation for Patent Classification

Directory of Open Access Journals (Sweden)

Jie Hu

2018-02-01

Full Text Available Many text mining tasks such as text retrieval, text summarization, and text comparisons depend on the extraction of representative keywords from the main text. Most existing keyword extraction algorithms are based on discrete bag-of-words type of word representation of the text. In this paper, we propose a patent keyword extraction algorithm (PKEA based on the distributed Skip-gram model for patent classification. We also develop a set of quantitative performance measures for keyword extraction evaluation based on information gain and cross-validation, based on Support Vector Machine (SVM classification, which are valuable when human-annotated keywords are not available. We used a standard benchmark dataset and a homemade patent dataset to evaluate the performance of PKEA. Our patent dataset includes 2500 patents from five distinct technological fields related to autonomous cars (GPS systems, lidar systems, object recognition systems, radar systems, and vehicle control systems. We compared our method with Frequency, Term Frequency-Inverse Document Frequency (TF-IDF, TextRank and Rapid Automatic Keyword Extraction (RAKE. The experimental results show that our proposed algorithm provides a promising way to extract keywords from patent texts for patent classification.

Used, Blocking and Sleeping Patents

DEFF Research Database (Denmark)

Torrisi, Salvatore; Gambardella, Alfonso; Giuri, Paola

2016-01-01

This paper employs data from a large-scale survey (InnoS&T) of inventors in Europe, the USA, and Japan who were listed in patent applications filed at the European Patent Office with priority years between 2003 and 2005. We provide evidence regarding the reasons for patenting and the ways in which...... patents are being utilized. A substantial share of patents is neither used internally nor for market transactions, which confirms the importance of strategic patenting and inefficiency in the management of intellectual property. We investigate different types of unused patents—unused blocking patents...... and sleeping patents. We also examine the association between used and unused patents and their characteristics such as family size, scope, generality and overlapping claims, technology area, type of applicant, and the competitive environment from where these patents originate. We discuss our results...

COMMUNITY MEDICINE & PRIMARY HEALTH CARE

African Journals Online (AJOL)

ajiboro

Management Sciences for Health (MSH) defined ... Poor supply chains, weak stock ... pharmacies and patent medicine stores for their ACT supply. ..... Global Health Observatory (GHO); program. ... logistics of supply and distribution is yet to be.

Radioactive waste management: a series of bibliographies. Radioactive waste inventories and projections. Supplement 1

International Nuclear Information System (INIS)

McLaren, L.H.

1986-01-01

This bibliography contains information on radioactive waste inventories and projections included in the Department of Energy's Energy Data Base from October 1982 through December 1984. The arrangement is by report number for reports, followed by nonreports in reverse chronological order. These citations are to research reports, journal articles, books, patents, theses, and conference papers from worldwide sources. Five indexes, each preceded by a brief description, are provided: Corporate Author, Personal Author, Subject, Contract Number, and Report Number. 31 abstracts

Invention note and patent note

International Nuclear Information System (INIS)

Chang, Sung Su

1997-09-01

This book deals with origin of invention and term related patent and invention, making idea, brain storming, 10 laws of invention skill, attitude of inventors, invention order, making good inventions, patent system, preparation of application, procedure and method of patent, management of patent, patent and trademark office, patent lawyer, copyright, new intellectual property right, industrial property right, trademark, invasion of industrial property right, patent, Judgment, preparation of items, application of industrial property right and effect of inventor and related people.

How Important are Noncorporate Patents?

DEFF Research Database (Denmark)

Schneider, Cédric

2011-01-01

This article analyses the innovative performances of noncorporate inventors using patent citations data from the European Patent Office. The results show that inventions patented outside an established corporate framework are on average less ‘important’ than corporate patents, but with large...... variations across technology classes. Patents applied for by independent inventors, start-ups and corporate firms are of comparable ‘quality’ in emerging technologies. The results also highlight that in these fields noncorporate patents are more ‘radical’ than corporate patents....

Pre-empted Patents, Infringed Patents and Firms’ Participation in Markets for Technology

DEFF Research Database (Denmark)

Grimpe, Christoph; Hussinger, Katrin

2014-01-01

In recent years, firms have increasingly contributed to and been confronted with a patent landscape characterized by numerous but marginal inventions, overlapping claims and patent fences. As a result, firms risk their patent applications to be pre-empted or to be infringed upon by rivals. While...... patents on firms’ engagement in in- and cross-licensing. Based on a sample of more than 1100 German manufacturing firms our results show that firms engage in in-licensing as a reaction to pre-empted patents and in cross-licensing if their protected IP was infringed upon. However, these effects vary...

Radioactive waste management

International Nuclear Information System (INIS)

2003-01-01

Almost all IAEA Member States use radioactive sources in medicine, industry, agriculture and scientific research, and countries remain responsible for the safe handling and storage of all radioactively contaminated waste that result from such activities. In some cases, waste must be specially treated or conditioned before storage and/or disposal. The Department of Technical Co-operation is sponsoring a programme with the support of the Nuclear Energy Department aimed at establishing appropriate technologies and procedures for managing radioactive wastes. (IAEA)

Interventional Closure of a Patent Ductus Arteriosus Using an Amplatz Canine Duct Occluder in an Alpaca Cria.

Science.gov (United States)

Chapel, E C; Lozier, J; Lakritz, J; Schober, K E

2017-07-01

A 6-month old female alpaca cria presented to The Ohio State University for evaluation of a cardiac murmur. Echocardiography revealed a left-to-right shunting patent ductus arteriosus, a restrictive left-to-right shunting perimembranous ventricular septal defect, and secondary moderate left atrial and ventricular dilation. Aortic root angiography demonstrated a type IIA patent ductus arteriosus (PDA). Interventional closure of the PDA was successfully performed, without complication, using an Amplatz canine duct occluder. This case report describes the materials and methods used for interventional closure of a PDA in an alpaca cria. Copyright © 2017 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.

Patent protection strategies

Directory of Open Access Journals (Sweden)

Himanshu Gupta

2010-01-01

Full Text Available It is widely recognized that the pharmaceutical industry faces serious financial challenges. Large numbers of blockbuster drugs are losing patent protection and going generic. The pipeline of new drugs is too sparse to fill the gap and generate a platform for future growth. Moreover, many of the new products are biologics with much narrower target patient populations and comparatively higher prices relative to traditional pharmaceuticals. So now the time has come for pharmaceutical scientists to have a better understanding of patent fundamentals. This need is illustrated by analyses of key scientific and legal issues that arose during recent patent infringement cases involving Prozac, Prilosec, and Buspar. Facing this scenario, the pharmaceutical industry has moved to accelerate drug development process and to adopt at the same time different strategies to extend the life time of the patent monopoly to provide the economic incentives and utilizing it for drug discovery and development. This review covers the need of patent protection and various strategies to extend the patent.

Managing the patent thicket and maximizing patent lifetime in vaccine technology.

Science.gov (United States)

Mertes, Maria M M; Stötter, Gerd

2010-10-01

Patents are exclusive rights for a limited period of time that are granted to provide an incentive for innovation and in exchange for the public disclosure of an invention. Patenting in the medical field, especially in the field of human vaccine technologies, is full of pitfalls, because the products that finally access the market are often covered by a multitude of exclusive IP rights. This commentary gives an overview on obstacles in vaccine patenting and how to overcome them, and intends to provide a patenting guideline for researchers.

Patent Races and Market Value

DEFF Research Database (Denmark)

Czarnitzki, Dirk; Hussinger, Katrin; Leten, Bart

Patent races are models of strategic interactions between firms competing to develop an invention. The winning firm secures a patent, protecting the invention from imitation. This paper tests the assumption made about the reward structure in patent races, both in discrete and complex industries. We...... identify patent race winners using detailed information from the patent examination reports at the European Patent Office (EPO). Estimates of a market value equation featuring large, R&D-intensive U.S., European and Japanese firms, show that if firms win patent races, their market value increases...... significantly. We further show that the gain in market value is significantly larger for patent race winners in discrete industries than for firms in complex industries....

US patent interferences vs. international first-to-file patent systems, and current GATT problems

International Nuclear Information System (INIS)

Parkhurst, R.W.; Serbinowski, P.A.

1991-01-01

Simultaneous superconductivity research activities by different entities have resulted in numerous US patent applications, some of which may claim identical inventions and thus likely will be involved in interference proceedings in the US Patent and Trademark Office to determine which inventors are entitled to priority of invention and the resulting US patent. The determination in an interference proceeding of what inventors were the first-to-invent a patentable invention is contrasted with the patent systems in the rest of the world where the first inventor to file his patent application automatically gains priority. This issue and other aspects of US patent law are the subjects of criticism of US patent law and practice in the current Uruguay round of talks on the General Agreement on Trade and Tariffs (GATT). Interesting aspects of each of these subjects will be discussed

Radioactive waste inventories and projections

International Nuclear Information System (INIS)

McLaren, L.H.

1982-11-01

This bibliography contains information on radioactive waste inventories and projections included in the Department of Energy's Energy Data Base from January 1981 through September 1982. The arrangement is by report number for reports, followed by nonreports in reverse chronological order. These citations are to research reports, journal articles, books, patents, theses, and conference papers from worldwide sources. Five indexes, each preceded by a brief description, are provided: Corporate Author, Personal Author, Subject, Contract Number, and Report Number. (25 abstracts)

A study of western pharmaceuticals contained within samples of Chinese herbal/patent medicines collected from New York City's Chinatown.

Science.gov (United States)

Miller, Gretchen M; Stripp, Richard

2007-09-01

In America, recent growth in the popularity of Chinese herbal/patent medicines (CHM/CPM) has generated concerns as to the safety of these and other herbal remedies. Lack of strict federal regulations has lead to the possibility of improper labeling and even adulteration of these products with western drugs or other chemical contaminants. Our laboratory has conducted an analytical study to determine the presence of undeclared pharmaceuticals and therapeutic substances within CHM/CPM sold in New York City's Chinatown. Ninety representative samples randomly purchased in the form of pills, tablets, creams and teas were screened by appropriate analytical techniques including TLC, GC/MS and HPLC. Five samples contained nine different western pharmaceuticals. Two of these samples contained undeclared or mislabeled substances. One sample contained two pharmaceuticals contraindicated in people for whom the product was intended. Drugs identified include promethazine, chlormethiazole, chlorpheniramine, diclofenac, chlordiazepoxide, hydrochlorothiazide, triamterene, diphenhydramine and sildenafil citrate (Viagra).

Device for sampling liquid radioactive materials

International Nuclear Information System (INIS)

Vlasak, L.

1987-01-01

Remote sampling of radioactive materials in the process of radioactive waste treatment is claimed by the Czechoslovak Patent Document 238599. The existing difficulties are eliminated consisting in a complex remote control of sampling featuring the control of sliding and rotary movements of the sampling device. The new device consists of a vertical pipe with an opening provided with a cover. A bend is provided above the opening level housing flow distributors. A sampling tray is pivoted in the cover. In sampling, the tray is tilted in the vertical pipe space while it tilts back when filled. The sample flows into a vessel below the tray. Only rotary movement is thus sufficient for controlling the tray. (Z.M.)

Strategic management and utilization of patents

International Nuclear Information System (INIS)

Kim, Gyeong Go; Yun, Gwon Jun

1993-11-01

This book deals with why does management of patents need?, system of management of patents with function and site of management of patents and system and composition, what does management of patents department do?, task like technical development, management regulation, patent information, management of patents in small business with technical development of small business, how does business manage the patents in real, introduction of management of patents in the U.S, Europe, Japan, and Korea, and management of patents as strategic management.

Spreadsheet Patents

DEFF Research Database (Denmark)

Borum, Holger Stadel; Kirkbro, Malthe Ettrup; Sestoft, Peter

2018-01-01

This technical report gives a list of US patents and patent applications related to spreadsheet implementation technology. It is intended as a companion to the monograph Spreadsheet Implementation Technology (Peter Sestoft, MIT Press 2014), and substantially extends and updates an appendix from...

First test of WTO mechanism for procuring generic medicines under compulsory licence, via Canada's Access to Medicines Regime.

Science.gov (United States)

Elliott, Richard

2007-12-01

In July 2007, Rwanda became the first nation to initiate use of a procedure under the rules of the World Trade Organization (WTO) that is supposed to let developing countries import lower-cost, generic medicines produced in other countries under compulsory licences. And two months later, based on Rwanda's initiative, Canada's Commissioner of Patents issued the first compulsory licence under this system to permit the production of a patented AIDS drug to that country.

Discrimination against foreigners in the patent system : evidence from standard-essential patents

NARCIS (Netherlands)

de Rassenfosse, G.; Raiteri, E.; Bekkers, R.N.A.

This paper tests for traces of discrimination against foreign firms in the patent prosecution process. It focuses on the case of China and looks specifically at patent applications declared as essential to a technological standard. The choice of standard-essential patents (SEPs) is particularly

US Photovoltaic Patents, 1988--1990

Energy Technology Data Exchange (ETDEWEB)

1991-12-01

This document contains US patents on terrestrial photovoltaic (PV) power applications, including systems, components, and materials, as well as manufacturing and support functions. The patent entries in this document were issued from 1988 through 1990. The entries were located by searching USPA, the data base of the US Patent Office. The final search retrieved all patents under the class ``Batteries, Thermoelectric and Photoelectric`` and the subclasses ``Photoelectric,`` ``Testing,`` and ``Applications.`` The search also located patents that contained the words ``photovoltaic(s)`` or ``solar cell(s)`` and their derivatives. A manual search of the patents in the Solar Energy Research Institute (SERI) patent file augmented the data base search. After the initial list was compiled, most of the patents on the following subjects were excluded: space photovoltaic technology, use of the photovoltaic effect for detectors and subjects only peripherally concerned with photovoltaics. Some patents on these three subjects were included when it appeared that those inventions might be of use in terrestrial PV power technologies.

Derivative Technology of DNA Barcoding (Nucleotide Signature and SNP Double Peak Methods) Detects Adulterants and Substitution in Chinese Patent Medicines.

Science.gov (United States)

Gao, Zitong; Liu, Yang; Wang, Xiaoyue; Song, Jingyuan; Chen, Shilin; Ragupathy, Subramanyam; Han, Jianping; Newmaster, Steven G

2017-07-19

Lonicerae japonicae Flos has been used to produce hundred kinds of Chinese patent medicines (CPMs) in China. Economically motivated adulterants have been documented, leading to market instability and a decline in consumer confidence. ITS2 has been used to identify raw medicinal materials, but it's not suitable for the identification of botanical extracts and complex CPMs. Therefore, a short barcode for the identification of processed CPMs would be profitable. A 34 bp nucleotide signature (5' CTAGCGGTGGTCGTACGATAGCCAATGCATGAGT 3') was developed derived from ITS2 region of Eucommiae Folium based on unique motifs. Mixtures of powdered Lonicerae japonicae Flos and Lonicerae Flos resulted in double peaks at the expected SNP (Single Nucleotide Polymorphisms) positions, of which the height of the peaks were roughly indicative of the species' ratio in the mixed powder. Subsequently we tested 20 extracts and 47 CPMs labelled as containing some species of Lonicera. The results revealed only 17% of the extracts and 22% of the CPMs were authentic, others exist substitution or adulterant; 7% were shown to contain both of two adulterants Eucommiae Folium and Lonicerae Flos. The methods developed in this study will widely broaden the application of DNA barcode in quality assurance of natural health products.

Patent Searching for Librarians and Inventors.

Science.gov (United States)

Wherry, Timothy Lee

Information on patents is provided for librarians and laypersons requiring an understanding of the system and the processes involved. Chapter 1 discusses successful patents; terms and concepts; patent types; copyright; trademark; requirements; patent examiners; patent pending; expiration; patentee and assignee; and reissued patents. Chapter 2…

DOE Patents Available for Licensing

International Nuclear Information System (INIS)

Stuber, C.

1981-01-01

DOE Patents Available for Licensing (DOE PAL) provides abstracting and indexing coverage of the DOE patent literature, including patent applications, that concerns any apsect of energy production, conservation, and utilization. The citations are arranged by subject category. DOE is prepared to grant exclusive or nonexclusive, revocable licenses under DOE-owned US patents and patent applications in accordance with the provisions of 10CFR781

Prospects and trends in the development of terahertz technologies: patent landscape

Directory of Open Access Journals (Sweden)

D. А. Usanov

2017-01-01

Full Text Available The article is dedicated to the analysis of areas where terahertz radiation is applicable with the hwlp of a patent papers review, as well as to obtaining knowledge about the invention activity changes in this area over the past 35 years.Orbit patent databases’ capabilities were used to complete this analysis. Data search was conducted by keywords “terahertz” or “THz.” The searches were neither limited by submission dates, by priorities, nor by the country. A comprehensive analysis will allow to determine a more than 7389 patent-analog families’ aplications submitted in the period between 1980 and 2017 years. Statistical processing of obtained documents has been completed with the assistance of program software, indicated in the database. It was revealed that terahertz technologies have significant prospects to be applied in various areas; a fact, that is confirmed by an identified range of fields, where electromagnetic radiation of terahertz spectrum is applicable and is constantly growing. The dynamics of patenting is characterized by annual stable positive growth in the number of applications for inventions in the researched area. The highest number of inventions was identified in the field of instrumentation technologies, optics, telecommunications, semiconductor technologies, and medicine. Additionally, there was analyzed the state of patenting over the course of last five years. Examples of inventions were given. There were identified leading countries and companies in the researched area.

Pharmaceutical patents and access to essential medicines in sub ...

African Journals Online (AJOL)

The World Trade Organisation (WTO) agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) has reawakened old arguments over the impact of the intellectual property (IP) system on public access to essential medicines. As used here, essential medicines are those needed in symptom management, ...

Research method of nuclear patent information

International Nuclear Information System (INIS)

Mo Dan; Gao An'na; Sun Chenglin; Wang Lei; You Xinfeng

2010-01-01

When faced with a huge amount of nuclear patent information, the key to effective research include: (1) Choose convenient way to search, quick access to nuclear technology related patents; (2) To overcome the language barrier, analysis the technical content of patent information; (3) Organize the publication date of retrieved patent documents, analysis the status and trends of nuclear technology development; (4) Research the patented technology of main applicants; (5) Always pay attention to the legal status of patent information, free use the invalid patents, at the same time avoid the patent infringement. Summary, patent information is important to obtain the latest technical information source, and the research work of patent information is a comprehensive understanding and mastery way for advanced nuclear technology. (authors)

US Photovoltaic Patents, 1988--1990

Energy Technology Data Exchange (ETDEWEB)

1991-12-01

This document contains US patents on terrestrial photovoltaic (PV) power applications, including systems, components, and materials, as well as manufacturing and support functions. The patent entries in this document were issued from 1988 through 1990. The entries were located by searching USPA, the data base of the US Patent Office. The final search retrieved all patents under the class Batteries, Thermoelectric and Photoelectric'' and the subclasses Photoelectric,'' Testing,'' and Applications.'' The search also located patents that contained the words photovoltaic(s)'' or solar cell(s)'' and their derivatives. A manual search of the patents in the Solar Energy Research Institute (SERI) patent file augmented the data base search. After the initial list was compiled, most of the patents on the following subjects were excluded: space photovoltaic technology, use of the photovoltaic effect for detectors and subjects only peripherally concerned with photovoltaics. Some patents on these three subjects were included when it appeared that those inventions might be of use in terrestrial PV power technologies.

Technology Clusters Exploration for Patent Portfolio through Patent Abstract Analysis

Directory of Open Access Journals (Sweden)

Gabjo Kim

2016-12-01

Full Text Available This study explores technology clusters through patent analysis. The aim of exploring technology clusters is to grasp competitors’ levels of sustainable research and development (R&D and establish a sustainable strategy for entering an industry. To achieve this, we first grouped the patent documents with similar technologies by applying affinity propagation (AP clustering, which is effective while grouping large amounts of data. Next, in order to define the technology clusters, we adopted the term frequency-inverse document frequency (TF-IDF weight, which lists the terms in order of importance. We collected the patent data of Korean electric car companies from the United States Patent and Trademark Office (USPTO to verify our proposed methodology. As a result, our proposed methodology presents more detailed information on the Korean electric car industry than previous studies.

Cross-Border Patent Disputes: Unified Patent Court or International Commercial Arbitration?

Directory of Open Access Journals (Sweden)

Ana Alba Betancourt

2016-04-01

Full Text Available Currently, the enforcement of a patent that is registered in several countries involves the risk of getting different and conflicting decisions from the national courts. In 2013, 25 European countries entered in an agreement that aims to homogenise the patent system by creating the European patent with unitary effect and a Unified Patent Court (UPC. This article focuses on the UPC, which aims to have a single court proceeding for cross-border patent conflicts. Does the UPC system represent an advantage compared to the current litigation system? The paper argues that it does and explores what it considers to be the two main advantages of a UPC over the current system of cross-border litigation of patents: the ability to drag several conflicts to a single procedure and the neutrality of the decision makers. These advantages are consequently compared to the characteristics of arbitration. Then, an explanation is provided with regards to how the UPC system is going to work in terms of jurisdiction, preliminary injunctions, the choice of law and enforcement of decisions, comparing those same procedural aspects to arbitration. The article finds that arbitration involves many of the same advantages (as compared to the UPC and that the procedural issues studied in both means are, so too, similar. Therefore, arbitration represents a viable alternative to the UPC when it comes to reducing the risks in solving cross-border patent conflicts.

The Coordination of Independently-Owned Vacuum Tube Patents in the Alleged Early Radio Patent Thicket

DEFF Research Database (Denmark)

Howells, John; Ron D, Katznelson

-examines the legal trajectories and entrepreneurial exploitation of these patents with a focus on vacuum tube technology where Fleming’s diode patent ‘overlapped’ with earlier prior art and, dependent on court decisions, with later commercial implementations of De Forest’s triode patents. We show, by means...... of the relevant historical record, patent claims, litigation records and other relevant law, how the ‘overlapping’ patent rights were resolved by the courts and by the immunity of suppliers to the Government from patent infringement liability. We trace the cross-licensing agreements between the different radio...

Recent Patents in Agricultural Biotechnology; Focus on Health.

Science.gov (United States)

Makhzoum, Abdullah; Venkataraman, Srividhya; Tremouillaux-Guiller, Jocelyne; Hefferon, Kathleen

2016-01-01

Agricultural biotechnology, including the generation of genetically modified food crops, has been the subject of much controversy over the last few years. Initially serving the basic needs of farmers, Ag Biotech has more recently gained much appeal for its opportunities with respect to both the nutritional and pharmaceutical sciences. The following review describes a number of recently approved patents that could have direct implications for the field of medicine. Topics range from the development of pharmaceuticals in plants using hairy roots or virus expression vectors, to the role of epigenetics for improving the nutritional value of food crops. Many of these patents were developed by smaller companies or publically funded research institutes, disproving the perception that intellectual property in Ag Biotech is restricted to only large multinational corporations. The review concludes with a discussion of the future of these technologies in the face of the current negative political climate. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Application of radioactive substances in research in nuclear medicine: current trends and radiation exposure to the study subjects

International Nuclear Information System (INIS)

Minkov, V.; Schwarz, E.R.; Bauer, B.; Nosske, D.; Erzberger, A.; Brix, G.

2001-01-01

Aim: Analysis of the application of radioactive substances in research in the field of nuclear medicine in human beings and of the resulting radiation exposure to study subjects. Methods: Assessment of applications for approval submitted in accordance with Paragraph 41 of the Radiation Protection Ordinance, evaluated by the Federal office for Radiation Protection together with the Federal Institute for Pharmaceuticals and Medical Products, within the period from 1997 to 1999. Results: The focus of the studies on the diagnostic application of radioactive substances in medicine evaluated has, since 1998, shifted from oncological to neurological and psychological aspects, while, at the same time, the number of PET studies increased constantly The proportion of healthy study subjects included in the diagnostic studies increased from 7 to 22%. The number of therapeutic applications of radioactive substances has, since 1997, undergone a three-fold increase, and in the process of this, the focus of attention lay within the area of radioimmuno-therapy and endovascular brachytherapy. The effective dose was, among up to 49% of the investigated healthy study subjects higher than 5 mSv, and among up to 6% of these subjects was at levels of over 20 mSv. Up to 22% of the patients received, within the scope of diagnostic studies, an effective dose of between 20 and 50 mSv. An exceeding of the 50 mSv limit occurred among up to 3% of the patients. Conclusions: In spite of the increasing numbers of PET applications, conventional nuclear medicine has maintained its importance in the field of medical research. Further developments in the areas of radiochemistry and molecular biology led to an increase in the importance of radio-immuno therapy. The evaluation of new radiopharmaceuticals and the extension of basic biomedical research, resulted in an increase in the proportion of healthy study subjects included in the studies. The radiation exposure among subjects resulting directly from

Radioactivity and environment

Energy Technology Data Exchange (ETDEWEB)

Trivedi, R N [Fertilizer Association of India, New Delhi

1977-12-01

Power generation from radioisotopes is one of the major applications of nuclear energy for peaceful purposes and is in practice in over twenty countries including India. Other well-known applications of radioactive substances are in medicine, industry, scientific and industrial research programs, and nuclear weapons. The only serious disadvantage with the radioisotopes and their waste products is the constant release of radiation energy which contaminates the environment and endangers the life. An attempt has been made to identify the major sources of radioactivity in the environment and assess its potential impact on the environment. Recent developments in safety measures for prevention of contamination and control of radioactivity and in radioactive wastes management are also discussed.

Minimization of radioactive material deposition in water-cooled nuclear reactors

International Nuclear Information System (INIS)

Ruiz, C.P.; Blaies, D.M.

1988-01-01

This patent describes the method for inhibiting the deposition of radioactive cobalt in a water-bearing vessel of a water-cooled nuclear reactor which comprises adding zinc ion to water entering the water-bearing vessel. The improvement contains a substantially lower proportion of the /sup 64/Zn isotope than naturally occurring zinc

Reducing Risks from Sealed Radioactive Sources in Medicine

International Nuclear Information System (INIS)

2014-01-01

Sealed radioactive sources are commonly used in a variety of medical applications for both diagnosis and therapy. The sources used in medical applications usually have high levels of radioactivity and, therefore, have the potential to cause serious and life threatening injuries if used improperly or maliciously, or risky if they become lost or are stolen

Optimal patent policies: A survey

DEFF Research Database (Denmark)

Poulsen, Odile

2002-01-01

This paper surveys some of the patent literature, in particular, it focuses on optimal patent policies. We compare two situations. The first where the government only has a single policy tool to design the optimal patent policy, namely the optimal patent length. In the second situation......, the government uses two policy tools, the optimal breadth and length. We show that theoretical models give very different answers to what is the optimal patent policy. In particular, we show that the optimal patent policy depends among othet things on the price elasticity of demand, the intersectoral elasticity...... of research outputs as well as the degree of compettition in the R&D sector. The actual law on intellectual property, which advocates a unique patent length of 20 years is in general not supported by theoretical models....

Alienation from the Objectives of the Patent System: How to Remedy the Situation of Biotechnology Patent.

Science.gov (United States)

Jiang, Li

2018-03-12

Some fundamental biotechnologies hold unprecedented potential to eradicate many incurable diseases. However, in absence of regulations, the power of patent makes the future use of some important biotechnology in few institution's hands. The excessive patents restrict researcher access to the fundamental technologies. It generates concerns and complaints of deteriorating the public health and social welfare. Furthermore, intellectual curiosities, funding, respect among colleagues etc., rather than patents, are the real motivations driving a major ground-breaking discoveries in biotechnology. These phenomena reveal that some biotechnology patents are alienated from the purpose of patent system. Therefore, it is necessary to take some approaches to stop over-patenting these fundamental biotechnology inventions. This article proposes a model regulatory framework for controlling biotechnology patent alienating from the purpose of patent system.

Bauhinia forficata in the treatment of diabetes mellitus: a patent review.

Science.gov (United States)

de Souza, Bárbara Verônica Cardoso; Moreira Araújo, Regilda Saraiva Dos Reis; Silva, Oskar Almeida; Faustino, Lucas Costa; Gonçalves, Maria Fabrícia Beserra; Dos Santos, Mirian Lima; Souza, Grasielly Rocha; Rocha, Lindalva Moura; Cardoso, Mônica Larissa Sousa; Nunes, Lívio César Cunha

2018-02-01

Diabetes Mellitus has been considered an epidemic by the World Health Organization, with a high risk of morbidity and mortality. The treatment of this pathology consists in glycemic control, which can be done by oral hypoglycemic agents, insulin therapy, dietary guidance, regular physical activity, and psychosocial support. In addition, other adjuvant treatments are employed, such as phytotherapic, and one of the most used plants is Bauhinia forficata. Areas covered: In the current review, patents using Bauhinia forficata for the Diabetes Mellitus treatment have been analyzed. There were 03 patents in WIPO, 01 in Espacenet, 01 in USPTO, and 02 in INPI. Expert opinion: Patents on the adjuvant treatment of Diabetes Mellitus by Bauhinia forficata are discussed. Although there are some phytotherapy products containing this medicinal plant which has hypoglycemic effect here is still a need for the development of more products based on natural resources, for the treatment of this pathology, without side effects and with other benefits, to assist in the glycemia control in diabetic patients, and to improve their quality of life.

Research and Development Strategy in Biological Technologies: A Patent Data Analysis of Japanese Manufacturing Firms

Directory of Open Access Journals (Sweden)

Hidemichi Fujii

2016-04-01

Full Text Available Biological technology allows us to invent new medical approaches, create effective food production methods and reserves and develop new materials for industrial production. There is a diversity of biological technology types, and different technologies have different priorities for invention. This study examines the factors that are important for the invention of biology-related technologies in Japan using patent application data and a decomposition analysis framework. As the results show, patent applications related to biochemistry and biotechnology increased until 1995 because of the expanded scale of R&D activities and the high priority assigned to biological technology. However, the number of patent applications stagnated after 1995, because the importance of biochemistry, especially waste-gas treatment technologies, decreased. Additionally, patent applications for medicines and disease-related technologies increased rapidly from 1971 to 1995. The primary determinant of rapid growth is an increase in research priority, especially among firms in the chemical industry whose technologies are related to supplemental foods and foods with health-promoting benefits. Finally, patent applications involving foodstuff- and agriculture-related technologies increased from 1971 to 1995 due to increased R&D and the increased priority of biological technology.

Can patents prohibit research? On the social epistemology of patenting and licensing in science.

Science.gov (United States)

Biddle, Justin B

2014-03-01

A topic of growing importance within philosophy of science is the epistemic implications of the organization of research. This paper identifies a promising approach to social epistemology--nonideal systems design--and uses it to examine one important aspect of the organization of research, namely the system of patenting and licensing and its role in structuring the production and dissemination of knowledge. The primary justification of patenting in science and technology is consequentialist in nature. Patenting should incentivize research and thereby promote the development of knowledge, which in turn facilitates social progress. Some have disputed this argument, maintaining that patenting actually inhibits knowledge production. In this paper, I make a stronger argument; in some areas of research in the US--in particular, research on GM seeds--patents and patent licenses can be, and are in fact being, used to prohibit some research. I discuss three potential solutions to this problem: voluntary agreements, eliminating patents, and a research exemption. I argue against eliminating patents, and I show that while voluntary agreements and a research exemption could be helpful, they do not sufficiently address the problems of access that are discussed here. More extensive changes in the organization of research are necessary.

77 FR 4509 - Patent Public Advisory Committee Public Hearings on the Proposed Patent Fee Schedule

Science.gov (United States)

2012-01-30

... patent fees. The publication of that Notice will open a comment window through which the public may...-P-2012-0002] Patent Public Advisory Committee Public Hearings on the Proposed Patent Fee Schedule... Trademark Office (USPTO) may set or adjust by rule any patent or trademark fee established, authorized, or...

Patenting Human Genes in Europe

DEFF Research Database (Denmark)

Minssen, Timo

2017-01-01

In accordance with the concept of the book and the assigned scope of the contribution, this chapter describes the European law with respect to the patent-eligibility of isolated DNA sequences. This chapter will further include a brief comparison with recent developments from the US and Australia....... It will, however, not focus on the important debates regarding the patent-eligibility of other biological material, diagnostic methods patents (as data aggregators) or abstract ideas which will be addressed by other contributions. Moreover, the analysis will merely concentrate on patent-eligibility. Other...... patentability requirement will only be briefly touched upon in the discussion part. The paper starts out in section 1.5.2 by discussing the patent-eligibility of isolated human DNA sequences on the European national level and under the Biotechnology Directive. Then the patent-eligibility of isolated human DNA...

US photovoltaic patents: 1991--1993

Energy Technology Data Exchange (ETDEWEB)

Pohle, L

1995-03-01

This document contains US patents on terrestrial photovoltaic (PV) power applications, including systems, components, and materials as well as manufacturing and support functions. The patent entries in this document were issued from 1991 to 1993. The entries were located by searching USPA, the database of the US Patent Office. The final search retrieved all patents under the class ``Batteries, Thermoelectric and Photoelectric`` and the subclasses ``Photoelectric,`` ``Testing,`` and ``Applications.`` The search also located patents that contained the words ``photovoltaic(s)`` or ``solar cell(s)`` and their derivatives. After the initial list was compiled, most of the patents on the following subjects were excluded: space photovoltaic technology, use of the photovoltaic effect for detectors, and subjects only peripherally concerned with photovoltaic. Some patents on these three subjects were included when ft appeared that those inventions might be of use in terrestrial PV power technologies.

Study on the Application of Chinese Patent Drug and Chinese Formula of Rabdosia Rubescens

Science.gov (United States)

Peng, Mengfan; Liu, Baosong; Mao, Mingsan

2018-01-01

Rabdosia rubescens contais many active ingredients such as terpenoids, flavonoids, polysaccharides and organic acids. Modern research has proved that Rabdosia rubescens has the effect of heat-clearing and detoxicating, antibacterial and anticancer, promoting blood circulation to arrest pain and anti-tumor. It is used in the treatment of sore throat, rheumatoid arthritis and various kinds of cancer. The clinical application of Rabdosia rubescens is restricted in the fat-soluble components, and the solubility of water solubility is ignored. The application of prescriptions, Chinese patent drug and food therapy of Rabdosia rubescens are less and fragmented. This paper inquires relevant literature, the application of Rabdosia rubescens in prescription, Chinese patent medicine and food therapy was reviewed, in order to make Rabdosiae rubescens play a greater role in the relevant area. On the basis of make the best use of everything, to promote the innovation and development of Chinese medicine and services to the people in our country.

Summary of the Law relating to Atomic Energy and Radioactive Subtances as at March 1979

International Nuclear Information System (INIS)

Sim, D.F.; Ritchie, K.J.S.

1979-01-01

This Note contains summaries of new laws and regulations on atomic energy and radioactive substances and amendments made to previous ones in the United Kingdom as at March 1979, including international regulations and agreements. New materials referred to includes the Nuclear Installations (Excepted Matter) Regulations 1978, the Medicines (Radioactive Substances) Order 1978, the Medicines (Committee on Radiation from Radioactive Medicinal Products) Order 1978 and the Medicines (Administration of Radioactive Substances) Regulations 1978. The Note also reproduces other amendments in nuclear legislation, already referred to in a previous Note dated March 1978. (NEA) [fr

Performance of Patenting Firms

DEFF Research Database (Denmark)

Madsen, Erik Strøjer; Smith, Valdemar; Nielsen, Anders Østergaard

2000-01-01

Most countries focus on industries with high technology and the governments grant subsidies to innovating firms. However, there has been remarkable few studies of the performance of innovative firms or industries. This study examines the performance of patent active firms compared to the non-patenting...... firms within the manufacturing sector in Denmark. Performance is measured both by growth in employment as well as in the return on equity and profit share in turnover. The results suggest that differences in performance of patenting and non-patenting firms are very small, which questions the political...

Natural radioactivity in industry, medicine, dentistry, hobbies, and camping

International Nuclear Information System (INIS)

Robertson, M.

1996-01-01

A recent enquiry asked about the potential hazards of radioactivity in gas lamp mantles. This has prompted a quick review of uses, for other reasons, of materials which are incidentally radioactive. Thorium and uranium are the two highest atomic number elements which occur naturally in commercial quantities. They are both naturally radioactive. Both have been used for a variety of purposes utilising their chemical and physical, rather than radioactive properties. They have been incorporated in specialised industrial items and in some materials encountered in everyday life. While the properties of uranium and thorium make these materials useful for a variety of purposes, the fact that they are also incidentally radioactive materials means that any potential radiological hazards should also be taken into accoutnt. The use of these materials for medical and dental purposes has been discontiunued for these reasons. The only readily availabe consumer product which uses these materials on any scale is the thoriated gas lamp mantle. The radiological consequences of this use are small. (author). 2 refs

Foreign patent documentation and information research

International Nuclear Information System (INIS)

Wang Tongsheng; Wu Xianfeng; Liu Jia; Cao Jifen; Song Tianbao; Feng Beiyuan; Zhang Baozhu

2014-01-01

Patent documentations are important scientific and technical documentations, which gather legal information, technical information and economic information together. According to WIPO forecasts, making full use of patent documentation can save 40% of research funding and 60% of the study period. Foreign patent documentations are the world's most valuable patent documentations, and many original technologies that have significant influence are first disclosed in foreign patent documentation. Studying and making use of foreign patent documentations can improve our starting point of scientific and technological innovation, and reduce the research investment. This paper analyzes foreign patent documentation and, combining with the actual development of nuclear technology in our country, makes specific recommendations for patent documentation research. (authors)

Development of sealed radioactive sources immobilized in epoxy resin for verification of detectors used in nuclear medicine

Energy Technology Data Exchange (ETDEWEB)

Tiezzi, Rodrigo; Rostelato, Maria Elisa C.M.; Nagatomi, Helio R.; Zeituni, Calos A.; Benega, Marcos A.G.; Souza, Daiane B. de; Costa, Osvaldo L. da; Souza, Carla D.; Rodrigues, Bruna T.; Souza, Anderson S. de; Peleias Junior, Fernando S.; Santos, Rafael Melo dos; Melo, Emerson Ronaldo de, E-mail: rktiezzi@gmail.com [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil); Karan Junior, Dib [Universidade de Sao Paulo (USP), Sao Paulo, SP (Brazil)

2015-07-01

The radioactive sealed sources are used in verification ionization chamber detectors, which measure the activity of radioisotopes used in several areas, such as in nuclear medicine. The measurement of the activity of radioisotopes must be made with accuracy, because it is administered to a patient. To ensure the proper functioning of the ionization chamber detectors, standardized tests are set by the International Atomic Energy Agency (IAEA) and the National Nuclear Energy Commission using sealed radioactive sources of Barium-133, Cesium-137 and Cobalt-57. The tests assess the accuracy, precision, reproducibility and linearity of response of the equipment. The focus of this work was the study and the development of these radioactive sources with standard Barium-133, Cesium-137 and Cobalt-57,using a polymer, in case commercial epoxy resin of diglycidyl ether of bisphenol A (DGEBA) and a curing agent based on modified polyamine diethylenetriamine (DETA), to immobilize the radioactive material. The polymeric matrix has the main function of fix and immobilize the radioactive contents not allowing them to leak within the technical limits required by the standards of radiological protection in the category of characteristics of a sealed source and additionally have the ability to retain the emanation of any gases that may be formed during the manufacture process and the useful life of this artifact. The manufacturing process of a sealed source standard consists of the potting ,into bottle standardized geometry, in fixed volume of a quantity of a polymeric matrix within which is added and dispersed homogeneously to need and exact amount in activity of the radioactive materials standards. Accordingly, a study was conducted for the choice of epoxy resin, analyzing its characteristics and properties. Studies and tests were performed, examining the maximum solubility of the resin in water (acidic solution, simulating the conditions of radioactive solution), loss of mechanical

Dynamics of radioactive waste generation

International Nuclear Information System (INIS)

Dogaru, Daniela; Virtopeanu, Cornelia; Ivan, Alexandrina

2008-01-01

In Romania there are in operation three facilities licensed for collection, treatment and storage of radioactive waste resulted from industry, research, medicine, and agriculture, named institutional radioactive waste. The repository, which is of near surface type, is designed for disposing institutional radioactive waste. The institutional radioactive wastes generated are allowed to be disposed into repository according to the waste acceptance criteria, defined for the disposal facility. The radioactive wastes which are not allowed for disposal are stored on the site of each facility which is special authorised for this. The paper describes the dynamics of generation of institutional waste in Romania, both for radioactive waste which are allowed to be disposed into repository and for radioactive waste which are not allowed to be disposed of. (authors)

Patents, Inducement Prizes, and Contestant Strategy

DEFF Research Database (Denmark)

Davis, Jerome; Davis, Lee N.

2006-01-01

Debate over the merits of patents versus inducement prizes has tended to ignore the signaling roles of patents, and totally ignores the impact of patent signaling on prize contests. This paper asks: How does patent signaling affect the strategic choices of firms considering entering prize contests......? First, we consider contests that do not allow patenting, then contests that do. If patenting is not allowed, we argue, patent-holders, both internal and external to the contest, can adversely impact prize contests by claiming prize winner violation of their patents, and suing for damages. The likelihood...... of such challenges being made can deter entry, particularly in contests requiring large sunk costs. Furthermore, the firm's decisionmaking process will discriminate against entering prize contests and favor R&D projects with patentable outcomes. Together, these problems may circumscribe any future wider role...

Increasing the Discovery and Use of Non-Patent Literature (NPL): Scientific Publications in Patent Examination

OpenAIRE

F. Loizides; B. Diallo; A. Pollard; A. Mavri

2017-01-01

In this work we present findings on non-patent literature use, and specifically scientific publications such as academic articles. We interview patent examiners and observe their prior art searching in order to provide insights into the perceived usage of non-patent literature and produce high level requirements for advancing non-patent literature search tools.

Shengmai Injection, a Traditional Chinese Patent Medicine, for Intradialytic Hypotension: A Systematic Review and Meta-Analysis

Directory of Open Access Journals (Sweden)

Chao-yang Chen

2013-01-01

Full Text Available Intradialytic hypotension (IDH is a global public health problem. A rising number of IDH sufferers resort to Chinese patent medicine, Shengmai Injection (SMI in China. The objectives of present study are to assess the effectiveness and safety of SMI as an adjunct therapy for IDH. A systematic search of 6 medical databases was performed up to December 2011. Randomized trials involving SMI adjuvant therapy versus conventional therapy were identified. RevMan 5.0 was used for data analysis. Ten randomized clinical trials with 437 participants were identified. Methodological quality was considered inadequate in all trials. Compared with conventional therapy, SMI adjunct therapy showed significant effects in improving the clinic effective rate (P<0.01, decreasing the incidence of IDH episode (P<0.01, decreasing the frequency of nursing interventions (P<0.01, and increasing diastolic blood pressure (P<0.01. There was no statistical significance in the improvement of mean arterial pressure (P=0.22 and systolic blood pressure (P=0.08 between two groups. Four studies had mentioned adverse events, but no serious adverse effects were reported in any of the included trials. In conclusion, SMI adjunct therapy appears to be potentially effective in treatment of IDH and is generally safe. However, further rigorous designed trials are needed.

Shengmai injection, a traditional chinese patent medicine, for intradialytic hypotension: a systematic review and meta-analysis.

Science.gov (United States)

Chen, Chao-Yang; Lu, Ling-Yan; Chen, Peng; Ji, Kang-Ting; Lin, Jia-Feng; Yang, Peng-Lin; Tang, Ji-Fei; Wang, Yan

2013-01-01

Intradialytic hypotension (IDH) is a global public health problem. A rising number of IDH sufferers resort to Chinese patent medicine, Shengmai Injection (SMI) in China. The objectives of present study are to assess the effectiveness and safety of SMI as an adjunct therapy for IDH. A systematic search of 6 medical databases was performed up to December 2011. Randomized trials involving SMI adjuvant therapy versus conventional therapy were identified. RevMan 5.0 was used for data analysis. Ten randomized clinical trials with 437 participants were identified. Methodological quality was considered inadequate in all trials. Compared with conventional therapy, SMI adjunct therapy showed significant effects in improving the clinic effective rate (P < 0.01), decreasing the incidence of IDH episode (P < 0.01), decreasing the frequency of nursing interventions (P < 0.01), and increasing diastolic blood pressure (P < 0.01). There was no statistical significance in the improvement of mean arterial pressure (P = 0.22) and systolic blood pressure (P = 0.08) between two groups. Four studies had mentioned adverse events, but no serious adverse effects were reported in any of the included trials. In conclusion, SMI adjunct therapy appears to be potentially effective in treatment of IDH and is generally safe. However, further rigorous designed trials are needed.

Patenting Nanomedicine in Europe

DEFF Research Database (Denmark)

Nordberg, Ana

This work addresses the question of determining whether reinterpretation, reformulation or replacement of article 53 (c) of the European Patent Convention is viable and advisable. It does so by reference to novel or resurfacing interpretative concerns connected with emerging technologies exemplif......This work addresses the question of determining whether reinterpretation, reformulation or replacement of article 53 (c) of the European Patent Convention is viable and advisable. It does so by reference to novel or resurfacing interpretative concerns connected with emerging technologies...... exemplified by nanomedicine, while considering known interpretative issues and traditional objections to this provision. The debate concerning the patentability of ‘medical methods’ is multi-layered and complex. The ‘medical methods exception’ is a public policy mechanism, intended to introduce flexibility...... in the patent system in order to allow for the protection of core ethical values of society. Nanotechnology inventions blur the lines between patentable subject matter and what may fall under the exception from patentability. It is a good example of how in recent years, emerging technologies have been...

Constructing an Intelligent Patent Network Analysis Method

Directory of Open Access Journals (Sweden)

Chao-Chan Wu

2012-11-01

Full Text Available Patent network analysis, an advanced method of patent analysis, is a useful tool for technology management. This method visually displays all the relationships among the patents and enables the analysts to intuitively comprehend the overview of a set of patents in the field of the technology being studied. Although patent network analysis possesses relative advantages different from traditional methods of patent analysis, it is subject to several crucial limitations. To overcome the drawbacks of the current method, this study proposes a novel patent analysis method, called the intelligent patent network analysis method, to make a visual network with great precision. Based on artificial intelligence techniques, the proposed method provides an automated procedure for searching patent documents, extracting patent keywords, and determining the weight of each patent keyword in order to generate a sophisticated visualization of the patent network. This study proposes a detailed procedure for generating an intelligent patent network that is helpful for improving the efficiency and quality of patent analysis. Furthermore, patents in the field of Carbon Nanotube Backlight Unit (CNT-BLU were analyzed to verify the utility of the proposed method.

Environmentally conscious patent histories

Science.gov (United States)

Crouch, Dennis D.; Crouch, Henry L.

2004-02-01

There is a need for investigators, legislators, and business leaders to understand the magnitude of innovation and discovery in the field of environmentally conscious technologies (ECTs). Knowledge of the "big picture" is important to providing a national and global account of actual environmental stewardship over the last twenty-five years. A recitation of the Environmental Protection Agency (EPA) supported Acts which have been enacted into law reveals one facet of the multifaceted dynamic of environmental consciousness. The popular discussion and debate, as well as partisan lobbying, which created the political forces leading to environmentally conscious legislation is another facet. A third facet is the corporate response to the threats and opportunities predicted by CEO"s and others through environmental scanning. This paper examines changes in environmentally conscious inventive effort by comparing data from United States Patents issued from 1976 through 2003. Patents are useful tool for measuring technological innovation because they are publicly available records of innovative activity. Although not all inventions result in patent applications, the monopoly rights granted on the invention give the inventor a strong incentive to obtain patents on any viable product or process. Among the results, we found a significant increase in patents relating to environmentally conscious products and processes during the period in question. Specifically, a dramatic increase in patent activity was seen for the decade of the 1990"s. Surprisingly, the patenting rate from 2000 to 2003 seems to have stabilized. Additionally public discussion of ECTs appears to have a positive impact on patent filings.

Labor Mobility and Patenting Activity

DEFF Research Database (Denmark)

Kaiser, Ulrich; Kongsted, Hans Christian; Rønde, Thomas

We measure the quantitative importance of labor mobility as a vehicle for the transmission of knowledge and skills across firms. For this purpose we create a unique data set that matches all applications of Danish firms at the European Patent Office to linked employer-employee register data...... for the years 1999-2002. The Danish workforce is split into "R&D workers", who hold a bachelor's or a master's degree in a technical field, and "non{R&D workers". We find that mobile R&D workers ("R&D joiners"') contribute more to patenting activity than immobile R&D workers. Furthermore, R&D workers who have...... previously been employed by a patenting firm ("patent exposed workers") have a larger effect on patenting activity than R&D workers without this experience. Patent exposed R&D joiners constitute the most productive group of workers: for firms that patented prior to 1999, one additional worker of this type...

Are biosimilars patentable?

Science.gov (United States)

Rolfe, Damian; Parker, Jayson; Morgan, Max

2016-08-01

This paper explores whether, and under what circumstances, a biosimilar approved in the United States under the Biologics Price Competition and Innovation Act (hereafter 'BPCIA') can be patented. The possibility that a biosimilar product could have meaningful patent protection arises from specific requirements for biosimilarity under the BPCIA, which account for the fact that manufacturing processes of biologics are inherently imprecise. The requirements for biosimilar approval may provide sufficient leeway to a biosimilar applicant to patent structural or formulation differences that provide non-clinical but business-relevant advantages over the reference molecule, such as improved shelf-life or ease of manufacture, without compromising clinical biosimilarity. Examination of the BPCIA and related Acts, Food and Drug Administration (FDA) guidance papers, case law, patent database searching, and relevant scholarly articles. Legislative and regulatory requirements for the approval of a biosimilar under the BPCIA are focused on clinical results and allow a degree of leeway for differences to exist between a biosimilar's structure and non-clinical components and those of the biosimilar's reference molecule. This leeway can be exploited to provide the biosimilar with potentially patentable business-relevant advantages over its reference product while maintaining clinical biosimilarity to the reference product.

Radioactively labelled substances for in vivo and in vitro tests from the time of their production up to their use in nuclear medicine

International Nuclear Information System (INIS)

Riccato, M.T.

1976-01-01

Most important production steps and control tests applied to radionuclides and radioactive labelled compounds used in nuclear medicine are described. Radiopharmaceutical products are subdivided in products for therapy and for in vivo and in vitro diagnostics tests. (orig./HP) [de

Radioactive Study of Malagasy medicinal plants and essential oil by gamma spectrometry

International Nuclear Information System (INIS)

RAMAROSON, V.

1997-01-01

Medicinal plants and essential oil derived from environmental samples such as plants, flowers, bushes or wild trees. Then, it is normal that naturally occuring radionuclides from Thorium and Uranium series on the one hand, K-40, a primordial radionuclide and common for all the samples on the other hand have been identified in such samples. Their activity are very low as it was expected to be, and Pb-210, one of the most radiotoxic among all natural radionuclides was not detected. Particularly, for essential oil, only the light radionuclide K-40 remains in the obtained oil, it is estimated that heavy metals such as Pb-212, identified in plants could not follow the vapour phase during the distillation process. However, detected counts per second of K-40 decrease from plants to oil which are then non-radioactive [fr

Social support in the practices of informal providers: The case of patent and proprietary medicine vendors in Nigeria.

Science.gov (United States)

Sieverding, Maia; Liu, Jenny; Beyeler, Naomi

2015-10-01

The social and institutional environments in which informal healthcare providers operate shape their health and business practices, particularly in contexts where regulatory enforcement is weak. In this study, we adopt a social capital perspective to understanding the social networks on which proprietary and patent medicine vendors (PPMVs) in Nigeria rely for support in the operation of their shops. Data are drawn from 70 in-depth interviews with PPMVs in three states, including interviews with local leaders of the PPMV professional association. We find that PPMVs primarily relied on more senior colleagues and formal healthcare professionals for informational support, including information about new medicines and advice on how to treat specific cases of illness. For instrumental support, including finance, start-up assistance, and intervention with regulatory agencies, PPMVs relied on extended family, the PPMVs with whom they apprenticed, and the leaders of their professional association. PPMVs' networks also provided continual reinforcement of what constitutes good PPMV practice through admonishments to follow scope of practice limitations. These informal reminders, as well as monitoring activities conducted by the professional association, served to reinforce PPMVs' concern with avoiding negative customer health outcomes, which were perceived to be detrimental to their business reputations. That PPMVs' networks both encouraged practices to reduce the likelihood of poor health outcomes, and provided advice regarding customers' health conditions, highlights the potential impact of informal providers' access to different forms of social capital on their delivery of health services, as well as their success as microenterprises. Copyright © 2015 Elsevier Ltd. All rights reserved.

Decoding gene patents in Australia.

Science.gov (United States)

Denley, Adam; Cherry, James

2014-10-03

Patents directed to naturally occurring genetic material, such as DNA, RNA, chromosomes, and genes, in an isolated or purified form have been granted in Australia for many years. This review provides scientists with a summary of the gene patent debate from an Australian perspective and specifically reviews how the various levels of the legal system as they apply to patents-the Australian Patent Office, Australian courts, and Australian government-have dealt with the issue of whether genetic material is proper subject matter for a patent. Copyright © 2015 Cold Spring Harbor Laboratory Press; all rights reserved.

The Seductive-Plausibility of Patent Hold-Up Myths — A Flawed Historiography of Patents

DEFF Research Database (Denmark)

Howells, John; Katznelson, Ron D

In previous work we have shown that a flawed historiography of patents continues to be the basis for patent policy advocacy. We set out objective standards of evidence that allegations of development block due to assertion of patents must meet. We show the extent of the errors in the historical...... record in the aircraft, automobile, radio and incandescent lamp technologies. We then evaluate how they measure against the objective standards. We find many simple errors and that an absence of indicia of development block characterise scholarship alleging that assertion of patents blocked development...... of multiple case studies subjected to such standards justifies the rebuttable presumption that “pioneer patents have never blocked development”....

Accidents during transport of radioactive material

International Nuclear Information System (INIS)

Agarwal, S.P.

2008-01-01

Radioactive materials are a part of modern technology and life. They are used in medicine, industry, agriculture, research and electrical power generation. Tens of millions of packages containing radioactive materials are consigned for transport each year throughout the world. In India, about 80000 packages containing radioactive material are transported every year. The amount of radioactive material in these packages varies from negligible amounts used in consumer products to very large amounts in shipment of irradiator sources and spent nuclear fuel

Nuclear medicine

International Nuclear Information System (INIS)

Anon.

1993-01-01

The area of nuclear medicine, the development of artificially produced radioactive isotopes for medical applications, is relatively recent. Among the subjects covered in a lengthy discussion are the following: history of development; impact of nuclear medicine; understanding the most effective use of radioisotopes; most significant uses of nuclear medicine radioimmunoassays; description of equipment designed for use in the field of nuclear medicine (counters, scanning system, display systems, gamma camera); description of radioisotopes used and their purposes; quality control. Numerous historical photographs are included. 52 refs

Patenting and the gender gap: should women be encouraged to patent more?

Science.gov (United States)

de Melo-Martín, Inmaculada

2013-06-01

The commercialization of academic science has come to be understood as economically desirable for institutions, individual researchers, and the public. Not surprisingly, commercial activity, particularly that which results from patenting, appears to be producing changes in the standards used to evaluate scientists' performance and contributions. In this context, concerns about a gender gap in patenting activity have arisen and some have argued for the need to encourage women to seek more patents. They believe that because academic advancement is mainly dependent on productivity (Stuart and Ding in American Journal of Sociology 112:97-144, 2006; Azoulay et al. in Journal of Economic Behavior & Organization 63:599-623, 2007), differences in research output have the power to negatively impact women's careers. Moreover, in the case of patenting activity, they claim that the gender gap also has the potential to negatively affect society. This is so because scientific and technological advancement and innovation play a crucial role in contemporary societies. Thus, women's more limited involvement in the commercialization of science and technology can also be detrimental to innovation itself. Nevertheless, calls to encourage women to patent on grounds that such activity is likely to play a significant role in the betterment of both women's careers and society seem to be based on two problematic assumptions: (1) that the methods to determine women's productivity in patenting activities are an appropriate way to measure their research efforts and the impact of their work, and (2) that patenting, particularly in academia, benefits society. The purpose of this paper is to call into question these two assumptions.

Patent pools: Intellectual property rights and competition.

NARCIS (Netherlands)

Rodriguez, V.F.

2010-01-01

Patent pools do not correct all problems associated with patent thickets. In this respect, patent pools might not stop the outsider problem from striking pools. Moreover, patent pools can be expensive to negotiate, can exclude patent holders with smaller numbers of patents or enable a group of major

[Analysis of difficult problems on European Union laws and regulations of traditional herbal medicinal products].

Science.gov (United States)

Qu, Li-Ping; Zhang, Xiao-Qun; Xiong, Yan; Wang, Yi-Tao; Zou, Wen-Jun

2017-10-01

Registration of Chinese patent medicine in European Union (EU) is of great significance to the internationalization of traditional Chinese medicine as EU market acts as an important position in the global botanical market. In retrospect, the domestic studies on EU regulations of traditional herbal medicinal products have been conducted for more than 10 years, but there is still some cognitive bias and lack of research. In this paper, a review of the relevant research progress and the main misunderstanding problems about Directive 2004/24/EC, like the centralized and decentralized supervision system of traditional herbal medicinal products in the EU, marketing authorization procedures for traditional herbal medicinal products, Community Herbal Monograph and List Entries, would be systematically analyzed, so as to provide reference for the registration of Chinese patent medicine in EU. Copyright© by the Chinese Pharmaceutical Association.

Does the market share of generic medicines influence the price level?: a European analysis.

Science.gov (United States)

Dylst, Pieter; Simoens, Steven

2011-10-01

After the expiry of patents for originator medicines, generic medicines can enter the market, and price competition may occur. This process generates savings to the healthcare payer and to patients, but knowledge about the factors affecting price competition in the pharmaceutical market following patent expiry is still limited. This study aimed to investigate the relationship between the market share of generic medicines and the change of the medicine price level in European off-patent markets. Data on medicine volumes and values for 35 active substances were purchased from IMS Health. Ex-manufacturer prices were used, and the analysis was limited to medicines in immediate-release, oral, solid dosage forms. Countries included were Austria, Belgium, Denmark, Germany, France, Italy, the Netherlands, Spain, Sweden and the UK, which constitute a mix of countries with low and high generic medicines market shares. Data were available from June 2002 until March 2007. Market volume has risen in both high and low generic market share countries (+29.27% and +27.40%, respectively), but the cause of the rise is different for the two markets. In low generic market share countries, the rise was caused by the increased use of generic medicines, while in high market share countries, the rise was driven by the increased use of generic medicines and a shift of use from originator to generic medicines. Market value was substantially decreased in high generic market share countries (-26.6%), while the decrease in low generic market share countries was limited (-0.06%). In high generic market share countries, medicine prices dropped by -43.18% versus -21.56% in low market share countries. The extent to which price competition from generic medicines leads to price reductions appears to vary according to the market share of generic medicines. High generic market share countries have seen a larger decrease in medicine prices than low market share countries.

[Anaphylactic shock due to patent blue: four case report and review of literature].

Science.gov (United States)

Lucas, N; Interne, S Benay; Laine, P; Nicolie, B; Fondrinier, E

2010-04-01

Description of four cases of anaphylactic shock with blue dye injection (bleu patenté V Guerbet 2.5%) during sentinel node biopsy for breast cancer. Women with breast carcinoma and combined approach with radioactive tracer and blue patent injection. Four cases were observed, which means an incidence of 0.57%. We report one case of grade II anaphylactic reaction and three cases of grade III requiring active reanimation and adrenaline perfusion. One patient developed a pulmonary embolism during the postoperative period, but no death was observed. We find an incidence of 1.06% of allergy but only 0.25% of anaphylactic shock (grade III). These rare but serious cases must weigh up the benefits and risks of using blue dye. We suggest using blue dye injection only in case of radioisotope detection failure. Of course, this approach must be evaluated. (c) 2009 Elsevier Masson SAS. All rights reserved.

Interactive overlay maps for US Patent (USPTO) data based on International Patent Classifications (IPC)

NARCIS (Netherlands)

Leydesdorff, L.; Kushnir, D.; Rafols, I.

2014-01-01

We report on the development of an interface to the US Patent and Trademark Office (USPTO) that allows for the mapping of patent portfolios as overlays to basemaps constructed from citation relations among all patents contained in this database during the period 1976-2011. Both the interface and the

Patents - Superconductor materials, processes and devices

International Nuclear Information System (INIS)

Test, A.

1987-01-01

A patent is a grant by a country to an inventor or his assignee of the right to exclude others for a limited period of time from making, using or selling the patented invention within its territory. It is reported that basic patents have been filed by IBM and the University of Houston to protect a broad range of warm superconducting materials or compounds. It is believed that other researchers are seeking patents to protect related or improved materials, processes and apparatus. Because of the importance of this field and to speed up the patent process, the United States Patent Office is giving, upon request, special expedited status to these patent applications. A survey of Japanese companies shows that more than 1500 patents have been applied for in Japan relating to superconducting materials, compositions, apparatus using superconductors and improvements. It appears that the goal of the Japanese companies is to obtain a patent position in Japan so that they can trade with companies wishing to do business in Japan for rights in other parts of the world

Can this kind of idea be a patent?

Energy Technology Data Exchange (ETDEWEB)

Yu, Jae Bok

2004-08-15

This book mentions patent such as application, what is patents, patent law, procedure and patent attorney, which includes business idea is patent. Is internet domain name or name-brand? We can make a big money with others idea, the difference among patent, trademark, utility model rights and registration of design, priority system, new weapon in digital period, patent is a knife and a shield, the cost from application to registration, what is hunting of patent information, writing document for patent, patent examination and patent lawyer.

Can this kind of idea be a patent?

International Nuclear Information System (INIS)

Yu, Jae Bok

2004-08-01

This book mentions patent such as application, what is patents, patent law, procedure and patent attorney, which includes business idea is patent. Is internet domain name or name-brand? We can make a big money with others idea, the difference among patent, trademark, utility model rights and registration of design, priority system, new weapon in digital period, patent is a knife and a shield, the cost from application to registration, what is hunting of patent information, writing document for patent, patent examination and patent lawyer.

78 FR 31885 - Patent Term Extension

Science.gov (United States)

2013-05-28

... DEPARTMENT OF COMMERCE Patent and Trademark Office Patent Term Extension ACTION: Proposed collection; comment request. SUMMARY: The United States Patent and Trademark Office (USPTO), as part of its... States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. Federal Rulemaking Portal...

78 FR 7759 - Patent Cooperation Treaty

Science.gov (United States)

2013-02-04

... DEPARTMENT OF COMMERCE Patent and Trademark Office Patent Cooperation Treaty ACTION: Proposed collection; comment request. SUMMARY: The United States Patent and Trademark Office (USPTO), as part of its... States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. Federal Rulemaking Portal...

75 FR 20561 - Patent Term Extension

Science.gov (United States)

2010-04-20

... DEPARTMENT OF COMMERCE Patent and Trademark Office Patent Term Extension ACTION: Proposed collection; comment request. SUMMARY: The United States Patent and Trademark Office (USPTO), as part of its... Officer, Office of the Chief Information Officer, United States Patent and Trademark Office, P.O. Box 1450...

[The apprentice education system of Chinese medicinal industry in modern Kunming].

Science.gov (United States)

Yang, Zhuqing

2015-07-01

In the late Qing Dynasty, following the appearance of the Chinese medicinal materials industry trade association of Kunming, the "master agreement" as a professional regulation, also implemented, marking the beginning of the contractualization and institutionalization of apprentice education in Yunnan. The contents and implementation of the "master agreement" was organized by the Chinese medicinal materials industry trade association of Kunming and its craft union. The apprentice education in Kunming traditional Chinese medicinal industry has the following characteristics: expanding the source of talent; adepting at agricultural production of the accorded apprentice; conforming to the conditions of human manipulation of Chinese traditional medicine; being in line with the characteristics and rules of Chinese medicine skills taught by oral narration and tacit understanding; unity of the medical and pharmaceutical professionals; and non-governmental organization. Apprentice training had trained a number of medical talents, and promoted the transformation of manual workshop to industrialization in Kunming. Apprentice education had catalyzed the establishment of specialized shops selling patent medicines exclusively to separated from those running both crude drugs and patent medicines, to form a set of effective teaching system, thus exerting profound influence on later generations.

Low-level radioactive biomedical wastes

International Nuclear Information System (INIS)

Casarett, G.W.

A summary of the management and hazards of low-level radioactive biomedical wastes is presented. The volume, disposal methods, current problems, regulatory agencies, and possible solutions to disposal problems are discussed. The benefits derived from using radioactivity in medicine are briefly described. Potential health risks are discussed. The radioactivity in most of the radioactive biomedical waste is a small fraction of that contained naturally in the human body or in the natural environment. Benefit-risk-cost considerations are presented. The cost of managing these wastes is getting so high that a new perspective for comparison of radioactivity (facts, risks, costs, benefits and trade-offs) and alternate approaches to minimize the risk and cost and maximize the benefits is suggested

Patentability of methods of human enhancement

DEFF Research Database (Denmark)

Nordberg, Ana

2015-01-01

This article explores how to apply patentability rules to human enhancement, particularly focusing on Article 53(c) of the European Patent Convention (EPC). The global size and value of the cosmetic and wellness market and industry allow for the prediction of considerable market potential for hum...... future evolution and the corresponding public policy choices. This article seeks to provide prospective patentees with guidance and awareness concerning the patentability of methods for human enhancement.......This article explores how to apply patentability rules to human enhancement, particularly focusing on Article 53(c) of the European Patent Convention (EPC). The global size and value of the cosmetic and wellness market and industry allow for the prediction of considerable market potential for human...... enhancement. Patents will be instrumental for companies to protect investment in innovation and tap into this potentially valuable market. The European patent system contains, in Article 53(c) EPC, an exception from patentability for methods for treatment and diagnostic methods. Such rule was created...

Published patent applications and patents from the promoted R + D area

International Nuclear Information System (INIS)

Jaeckel, G.; Zierl, I.

1977-09-01

The Ministry for Research and Technology of the Federal Republic of Germany has sponsored technological R + D for industrial innovations since 1969. The following compilation includes the published patent applications and patents from all projects which were sponsored up to and including 1973. (orig.) [de

Radioactive waste management solutions

International Nuclear Information System (INIS)

Siemann, Michael

2015-01-01

One of the more frequent questions that arise when discussing nuclear energy's potential contribution to mitigating climate change concerns that of how to manage radioactive waste. Radioactive waste is produced through nuclear power generation, but also - although to a significantly lesser extent - in a variety of other sectors including medicine, agriculture, research, industry and education. The amount, type and physical form of radioactive waste varies considerably. Some forms of radioactive waste, for example, need only be stored for a relatively short period while their radioactivity naturally decays to safe levels. Others remain radioactive for hundreds or even hundreds of thousands of years. Public concerns surrounding radioactive waste are largely related to long-lived high-level radioactive waste. Countries around the world with existing nuclear programmes are developing longer-term plans for final disposal of such waste, with an international consensus developing that the geological disposal of high-level waste (HLW) is the most technically feasible and safe solution. This article provides a brief overview of the different forms of radioactive waste, examines storage and disposal solutions, and briefly explores fuel recycling and stakeholder involvement in radioactive waste management decision making

TERM OF THE PATENT. PREMISES FOR THE CREATION OF THE SUPPLEMENTARY PROTECTION CERTIFICATE

Directory of Open Access Journals (Sweden)

BUCURA IONESCU

2013-05-01

Full Text Available The legal nature of the rights derived from the patent was object of numerous theories and discussions in literature. Their main features represent recognized characteristics for the property right, nevertheless the limitation in time, in space and the ubiquity make the difference. Especially for new medicinal or plant protection products, due to the limitation in time, the period of effective protection under the patent is insufficient to cover the investment put into the research. There exists a risk of research centres situated in the Member States relocating to countries that offer greater protection. The uniform solution at Community level was created in form of regulations, as the most appropriate legal instrument to prevent the heterogeneous development of national patent laws affecting the free movement of products in the internal market. The duration of the protection granted by the patent may be extended to additional 5 years, by a supplementary protection certificate, granted, under same conditions provided by the regulation, by each Member State. The Community regulations created a legal form of a new national sui generis right, belonging both to the intellectual property right, namely patent right, and the administrative right of the marketing authorization. The main objective of the paper consists in informing the Romanian specialists in the field about the latest evolutions in intellectual property rights, especially in protection of the inventions, as a consequence of Romania’s accession to the European Community.

Children's (Pediatric) Nuclear Medicine

Medline Plus

Full Text Available ... Tell your doctor about your child’s recent illnesses, medical conditions, medications and allergies. Depending on the type ... Nuclear Medicine? Nuclear medicine is a branch of medical imaging that uses small amounts of radioactive material ...

The History of Patenting Genetic Material.

Science.gov (United States)

Sherkow, Jacob S; Greely, Henry T

2015-01-01

The US Supreme Court's recent decision in Association for Molecular Pathology v. Myriad Genetics, Inc. declared, for the first time, that isolated human genes cannot be patented. Many have wondered how genes were ever the subjects of patents. The answer lies in a nuanced understanding of both legal and scientific history. Since the early twentieth century, "products of nature" were not eligible to be patented unless they were "isolated and purified" from their surrounding environment. As molecular biology advanced, and the capability to isolate genes both physically and by sequence came to fruition, researchers (and patent offices) began to apply patent-law logic to genes themselves. These patents, along with other biological patents, generated substantial social and political criticism. Myriad Genetics, a company with patents on BRCA1 and BRCA2, two genes critical to assessing early-onset breast and ovarian cancer risk, and with a particularly controversial business approach, became the antagonist in an ultimately successful campaign to overturn gene patents in court. Despite Myriad's defeat, some questions concerning the rights to monopolize genetic information remain. The history leading to that defeat may be relevant to these future issues.

A systematic review of the role of proprietary and patent medicine vendors in healthcare provision in Nigeria.

Directory of Open Access Journals (Sweden)

Naomi Beyeler

Full Text Available Interventions to reduce the burden of disease and mortality in sub-Saharan Africa increasingly recognize the important role that drug retailers play in delivering basic healthcare services. In Nigeria, owner-operated drug retail outlets, known as patent and proprietary medicine vendors (PPMVs, are a main source of medicines for acute conditions, but their practices are not well understood. Greater understanding of the role of PPMVs and the quality of care they provide is needed in order to inform ongoing national health initiatives that aim to incorporate PPMVs as a delivery mechanism.This paper reviews and synthesizes the existing published and grey literature on the characteristics, knowledge and practices of PPMVs in Nigeria. We searched published and grey literature using a number of electronic databases, supplemented with website searches of relevant international agencies. We included all studies providing outcome data on PPMVs in Nigeria, including non-experimental studies, and assessed the rigor of each study using the WHO-Johns Hopkins Rigor scale. We used narrative synthesis to evaluate the findings.We identified 50 articles for inclusion. These studies provided data on a wide range of PPMV outcomes: training; health knowledge; health practices, including drug stocking and dispensing, client interaction, and referral; compliance with regulatory guidelines; and the effects of interventions targeting PPMVs. In general, PPMVs have low health knowledge and poor health treatment practices. However, the literature focuses largely on services for adult malaria, and little is known about other health areas or services for children.This review highlights several concerns with the quality of the private drug retail sector in Nigeria, as well as gaps in the existing evidence base. Future research should adopt a more holistic view of the services provided by PPMV shops, and evaluate intervention strategies that may improve the services provided in

37 CFR 1.215 - Patent application publication.

Science.gov (United States)

2010-07-01

... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Patent application publication. 1.215 Section 1.215 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES National Processing Provisions Publication...

Analysis of US patents on spacer grids

International Nuclear Information System (INIS)

Kim, Hyung Kyu; Song, Kee Nam; Yoon, Kyung Ho; Kang, Hong Seok; Kim, Hyung Kyu; Jeon, Tae Hyun; Oh, Dong Seok; In, Wang Ki; Bang, Jae Keun; Oh, Seung Eun; Seo, Jeong Min; Lee, Jin Seok; Park, Seong Keun

1997-06-01

The total of 137 US patents on spacer grids patented from 1968 through 1993 are analyzed and summarized. Database is constituted with designing the appropriate fields by which each patent can be identified. The fields consist of patent number, inventor, assignee, date of patent, title and major foci of the patent. The major foci are again classified by detailed subjects such as the fretting failure and fuel rod support-related, the strength-related, the fabrication-related as for mechanical subjects, while the cooling performance-related and the pressure drop-related as for thermal-hydraulic one. The 92% of the patents analyzed were issued form nuclear companies of USA, France and Germany. Among the patents dealing with mechanical subjects, the fretting failure and fuel rod support-related is more than the pressure drop-related among the patents of thermal-hydraulic subjects. The number of patents issued from Japan ranks just after Germany i.e., the 4th country. It is thought that much concern as well as investment should be increased in this field, the patent of nuclear components. (author). 2 tabs., 5 figs

Analysis of US patents on spacer grids

Energy Technology Data Exchange (ETDEWEB)

Kim, Hyung Kyu; Song, Kee Nam; Yoon, Kyung Ho; Kang, Hong Seok; Kim, Hyung Kyu; Jeon, Tae Hyun; Oh, Dong Seok; In, Wang Ki; Bang, Jae Keun [Korea Atomic Energy Research Institute, Taejon (Korea, Republic of); Oh, Seung Eun; Seo, Jeong Min; Lee, Jin Seok; Park, Seong Keun [Korea Nuclear Fuel Company, Taejon (Korea, Republic of)

1997-06-01

The total of 137 US patents on spacer grids patented from 1968 through 1993 are analyzed and summarized. Database is constituted with designing the appropriate fields by which each patent can be identified. The fields consist of patent number, inventor, assignee, date of patent, title and major foci of the patent. The major foci are again classified by detailed subjects such as the fretting failure and fuel rod support-related, the strength-related, the fabrication-related as for mechanical subjects, while the cooling performance-related and the pressure drop-related as for thermal-hydraulic one. The 92% of the patents analyzed were issued form nuclear companies of USA, France and Germany. Among the patents dealing with mechanical subjects, the fretting failure and fuel rod support-related is more than the pressure drop-related among the patents of thermal-hydraulic subjects. The number of patents issued from Japan ranks just after Germany i.e., the 4th country. It is thought that much concern as well as investment should be increased in this field, the patent of nuclear components. (author). 2 tabs., 5 figs.

Analysis of Patent Databases Using VxInsight

Energy Technology Data Exchange (ETDEWEB)

BOYACK,KEVIN W.; WYLIE,BRIAN N.; DAVIDSON,GEORGE S.; JOHNSON,DAVID K.

2000-12-12

We present the application of a new knowledge visualization tool, VxInsight, to the mapping and analysis of patent databases. Patent data are mined and placed in a database, relationships between the patents are identified, primarily using the citation and classification structures, then the patents are clustered using a proprietary force-directed placement algorithm. Related patents cluster together to produce a 3-D landscape view of the tens of thousands of patents. The user can navigate the landscape by zooming into or out of regions of interest. Querying the underlying database places a colored marker on each patent matching the query. Automatically generated labels, showing landscape content, update continually upon zooming. Optionally, citation links between patents may be shown on the landscape. The combination of these features enables powerful analyses of patent databases.

Children's (Pediatric) Nuclear Medicine

Medline Plus

Full Text Available ... Nuclear Medicine? Nuclear medicine is a branch of medical imaging that uses small amounts of radioactive material to ... a radiologist or other physician. To locate a medical imaging or radiation oncology provider in your community, you ...

The diffusion of patented oil and gas technology with environmental uses: A forward patent citation analysis

International Nuclear Information System (INIS)

Duch-Brown, Néstor; Costa-Campi, María Teresa

2015-01-01

Relevant advances in the mitigation of environmental impact could be obtained by the appropriate diffusion of existing environmental technologies. In this paper, we look at the diffusion of knowledge related to environmental technologies developed within the oil and gas industry. To assess knowledge spillovers from oil and gas inventions as a measure of technology diffusion, we rely on forward patent citations methodology. Results show that there is a strong likelihood that the citing patent will be eventually linked to environmental technologies if the original oil and gas invention has already environmental uses. Moreover, both intra and intersectoral spillovers produce a “turnabout” effect, meaning that citing patents show the opposite quality level of the cited patent. Our results support the idea that more sector-specific environmental policies, with an emphasis on diffusion, would significantly improve the use of environmental technologies developed within the oil and gas industry. -- Highlights: •Knowledge spillovers from oil and gas inventions are of an intrasectoral nature. •Environmental uses in original patents diffuse to patents with environmental uses. •The “turnabout” effect converts low quality patents into high quality citing patents. •Diffusion of oil and gas inventions need more ad hoc instruments

The Academic Advantage: Gender Disparities in Patenting

Science.gov (United States)

Sugimoto, Cassidy R.; Ni, Chaoqun; West, Jevin D.; Larivière, Vincent

2015-01-01

We analyzed gender disparities in patenting by country, technological area, and type of assignee using the 4.6 million utility patents issued between 1976 and 2013 by the United States Patent and Trade Office (USPTO). Our analyses of fractionalized inventorships demonstrate that women’s rate of patenting has increased from 2.7% of total patenting activity to 10.8% over the nearly 40-year period. Our results show that, in every technological area, female patenting is proportionally more likely to occur in academic institutions than in corporate or government environments. However, women’s patents have a lower technological impact than that of men, and that gap is wider in the case of academic patents. We also provide evidence that patents to which women—and in particular academic women—contributed are associated with a higher number of International Patent Classification (IPC) codes and co-inventors than men. The policy implications of these disparities and academic setting advantages are discussed. PMID:26017626

The academic advantage: gender disparities in patenting.

Science.gov (United States)

Sugimoto, Cassidy R; Ni, Chaoqun; West, Jevin D; Larivière, Vincent

2015-01-01

We analyzed gender disparities in patenting by country, technological area, and type of assignee using the 4.6 million utility patents issued between 1976 and 2013 by the United States Patent and Trade Office (USPTO). Our analyses of fractionalized inventorships demonstrate that women's rate of patenting has increased from 2.7% of total patenting activity to 10.8% over the nearly 40-year period. Our results show that, in every technological area, female patenting is proportionally more likely to occur in academic institutions than in corporate or government environments. However, women's patents have a lower technological impact than that of men, and that gap is wider in the case of academic patents. We also provide evidence that patents to which women--and in particular academic women--contributed are associated with a higher number of International Patent Classification (IPC) codes and co-inventors than men. The policy implications of these disparities and academic setting advantages are discussed.

The academic advantage: gender disparities in patenting.

Directory of Open Access Journals (Sweden)

Cassidy R Sugimoto

Full Text Available We analyzed gender disparities in patenting by country, technological area, and type of assignee using the 4.6 million utility patents issued between 1976 and 2013 by the United States Patent and Trade Office (USPTO. Our analyses of fractionalized inventorships demonstrate that women's rate of patenting has increased from 2.7% of total patenting activity to 10.8% over the nearly 40-year period. Our results show that, in every technological area, female patenting is proportionally more likely to occur in academic institutions than in corporate or government environments. However, women's patents have a lower technological impact than that of men, and that gap is wider in the case of academic patents. We also provide evidence that patents to which women--and in particular academic women--contributed are associated with a higher number of International Patent Classification (IPC codes and co-inventors than men. The policy implications of these disparities and academic setting advantages are discussed.

Safe transport of radioactive material

International Nuclear Information System (INIS)

1994-01-01

Delivering radioactive material to where it is needed is a vital service to industry and medicine. Millions of packages are shipped all over the world by all modes of transport. The shipments pass through public places and must meet stringent safety requirements. This video explains how radioactive material is safely transported and describes the rules that carriers and handlers must follow

The fallacy of Software Patents

CERN Multimedia

CERN. Geneva

2015-01-01

Software patents are usually used as argument for innovation but do they really promote innovation? Who really benefits from software patents? This talk attempts to show the problems with software patents and how they can actually harm innovation having little value for software users and our society in general.

37 CFR 1.41 - Applicant for patent.

Science.gov (United States)

2010-07-01

... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Applicant for patent. 1.41 Section 1.41 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES National Processing Provisions Who May Apply for A...

37 CFR 1.314 - Issuance of patent.

Science.gov (United States)

2010-07-01

... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Issuance of patent. 1.314 Section 1.314 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES National Processing Provisions Allowance and Issue of...

37 CFR 1.315 - Delivery of patent.

Science.gov (United States)

2010-07-01

... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Delivery of patent. 1.315 Section 1.315 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES National Processing Provisions Allowance and Issue of...

14 CFR 1260.28 - Patent rights.

Science.gov (United States)

2010-01-01

... 14 Aeronautics and Space 5 2010-01-01 2010-01-01 false Patent rights. 1260.28 Section 1260.28... Provisions § 1260.28 Patent rights. Patent Rights May 2006 As stated at § 1260.136, this award is subject to... “Patent Rights (Small Business Firms and Nonprofit Organizations)” and the following: (a) Where the term...

Using Patent Classification to Discover Chemical Information in a Free Patent Database: Challenges and Opportunities

Science.gov (United States)

Ha¨rtinger, Stefan; Clarke, Nigel

2016-01-01

Developing skills for searching the patent literature is an essential element of chemical information literacy programs at the university level. The present article creates awareness of patents as a rich source of chemical information. Patent classification is introduced as a key-component in comprehensive search strategies. The free Espacenet…

A proposal for measuring the degree of public health-sensitivity of patent legislation in the context of the WTO TRIPS Agreement.

Science.gov (United States)

Chaves, Gabriela Costa; Oliveira, Maria Auxiliadora

2007-01-01

This study aims to propose a framework for measuring the degree of public health-sensitivity of patent legislation reformed after the World Trade Organization's TRIPS (Trade-Related Aspects of Intellectual Property Rights) Agreement entered into force. The methodology for establishing and testing the proposed framework involved three main steps:(1) a literature review on TRIPS flexibilities related to the protection of public health and provisions considered "TRIPS-plus"; (2) content validation through consensus techniques (an adaptation of Delphi method); and (3) an analysis of patent legislation from nineteen Latin American and Caribbean countries. The results show that the framework detected relevant differences in countries' patent legislation, allowing for country comparisons. The framework's potential usefulness in monitoring patent legislation changes arises from its clear parameters for measuring patent legislation's degree of health sensitivity. Nevertheless, it can be improved by including indicators related to government and organized society initiatives that minimize free-trade agreements' negative effects on access to medicines.

Effect of firm variables on patent price

Directory of Open Access Journals (Sweden)

Shyam Sreekumaran Nair

2012-03-01

Full Text Available In this study, using singleton patent auction price data from Ocean Tomo, LLC, we analyse the effect of firm variables on patent price. Patents owned by small firms attract higher price than patents owned by large firms, if they engage in multi-country filings. The patents owned by small firms get cited more than the patents owned by large firms. The patents owned by individual inventors attract a higher price than the patents owned by organisations when multi-country filings are not included. We believe that the lack of resources is preventing individual inventors from engaging in multi-country filings and maximising the revenue from their invention. A larger representative data should be used to replicate the results before generalising it.

The Academic Advantage: Gender Disparities in Patenting

OpenAIRE

Sugimoto, Cassidy R.; Ni, Chaoqun; West, Jevin D.; Larivi?re, Vincent

2015-01-01

We analyzed gender disparities in patenting by country, technological area, and type of assignee using the 4.6 million utility patents issued between 1976 and 2013 by the United States Patent and Trade Office (USPTO). Our analyses of fractionalized inventorships demonstrate that women's rate of patenting has increased from 2.7% of total patenting activity to 10.8% over the nearly 40-year period. Our results show that, in every technological area, female patenting is proportionally more likely...

Patent data mining method and apparatus

Science.gov (United States)

Boyack, Kevin W.; Grafe, V. Gerald; Johnson, David K.; Wylie, Brian N.

2002-01-01

A method of data mining represents related patents in a multidimensional space. Distance between patents in the multidimensional space corresponds to the extent of relationship between the patents. The relationship between pairings of patents can be expressed based on weighted combinations of several predicates. The user can select portions of the space to perceive. The user also can interact with and control the communication of the space, focusing attention on aspects of the space of most interest. The multidimensional spatial representation allows more ready comprehension of the structure of the relationships among the patents.

Radioactivity and Environment. Radioactividad y Medio Ambiente

Energy Technology Data Exchange (ETDEWEB)

Sanchez Leon, J.G. (Jefe de Seguridad Nuclear de la Fabrica de Juzbado. Empresa Nacional de Uranio. (Spain))

1993-01-01

Radioactivity is one of the most studied natural phenomena. Most of irradiation suffered by the human being is produced by natural sources. The second source in order of importance is nuclear medicine. The average level of radiation received by the man is 2.4 mSv/year and this value can be modified naturally in 20-30%. The author provides a review on radioactivity sources like natural (cosmic rays, extraterrestrial radiation, internal earth radiation, radon) and artificial (Nuclear explosions, professional exposure, nuclear medicine, nuclear power plants and accidents).

A new class of medicament: radioactivity isotopes (1962)

International Nuclear Information System (INIS)

Cohen, Y.

1962-01-01

Very many radioelement are used in medicine, either for diagnosis or as therapeutics. The development of medicine has entailed an increase in the number of application of radioactive isotopes. Firstly used in the form of simple inorganic molecules for diagnosis or as anticancer therapeutics, radioelements are now used for labelling organic molecules, allowing functional specific studies of any kind of nature. Their production is made difficult by their radio-active properties. Their pharmaceutical properties, determined by tests and controls, depend either from radiochemistry and from medicine. The author reminds, in this report, the methods for the preparation and analysis, and set out the medical application. (author) [fr

43 CFR 402.10 - Patent.

Science.gov (United States)

2010-10-01

... 43 Public Lands: Interior 1 2010-10-01 2010-10-01 false Patent. 402.10 Section 402.10 Public Lands... LANDS IN FEDERAL RECLAMATION PROJECTS Public Lands § 402.10 Patent. When a purchaser has complied fully... and patent and shall state the statutory authority for such liens. The receipt shall be submitted to...

Study of radioactive aerosols emissions and establishment of a model in a nuclear medicine environment during the use of a technetium generator

International Nuclear Information System (INIS)

Bombardier, Pierre

2012-01-01

This work deals with the control of radioactive aerosols emissions inside the nuclear medicine facilities. These emissions occur during pulmonary scintigraphy examinations using aerosols marked with 99m Tc. Using a test chamber, we have developed a method permitting to quantify these emissions around the aerosol generator. A method dedicated to emissions measurement coming from the patient during the pulmonary ventilation is also described. The results obtained on one patient are exposed in this thesis. We characterized and modelled the ventilation of a complete nuclear medicine department with a CFD (Computational Fluid Dynamics) software. This permitted us to study the dissemination of the radioactive aerosol and to compare it with measures of ambient air activity. The numerical model of this department was then employed to test containment solutions and to help defining the best location for air contaminations sensors. An original method combining staff position information and the simulation of the dissemination for the aerosol released has been used to confirm the exposure levels for several professional groups and enhance the workplace studies. (author)

Handbook of radioactivity measurements procedures. Second edition

International Nuclear Information System (INIS)

Anon.

1985-01-01

This report is concerned with the measurement of radioactivity in general, but specifically it deals with radioactive materials that have become available in the last three decades, from nuclear reactors and particle accelerators, for applications in medicine, scientific research, and industry. It is also concerned with low-level radioactivity measurements for the monitoring of radioactivity in environmental media, such as air and water, in connection with the control of radioactive effluents associated with the production of nuclear power or the use of radionuclides. Included in appendices are nuclear decay data for selected radionuclides and statistics of radioactive decay. An extensive bibliography is also included

Security in transport, storage and disposal of radioactive materials, providing to the department of nuclear medicine in hospitals Rafael Angel Calderon Guardia, San Juan de Dios and Mexico

International Nuclear Information System (INIS)

Elizondo Valle, Alejandro; Jimenez Mendez, Christian; Leiton Araya, Christopher; Villalobos Rodriguez, Geovanny; Leal Vega, Olga Maritza; Lopez Gatjens, Santiago

2010-01-01

The security is analysed for the transport and storage of radioactive sources and the management of radioactive waste product of practices and interventions in nuclear medicine services in hospitals Calderon Guardia, San Juan de Dios and Mexico. The objective is to assess the compliance with current regulations, the effectiveness and efficiency of the same. The security and compliance with current regulations were considered related to the transport of radioactive sources by the two private companies that provide this service, from the Juan Santamaria airport customs to three hospitals evaluated. Compliance with national and international rules on storage of radioactive sources and waste materials were analyzed. For this has been studied Costa Rican law and the recommendations of international organizations related to the subject matter, in the three nuclear medicine services valued. The national and international background related to radiological accidents occurred with radioactive sources during transport, storage and waste were revised, where highlights that in most cases, these accidents occurred for breach of the regulations established. Studies in Costa Rica on radioactive waste management were analysed, and the current status of nuclear medicine services in terms of radiation safety, which helped with the investigation. The compliance and regulations were analyzed by the result of observation and interviews during development, to finally make a series of findings and provide recommendations that are considered relevant. Various variants and indicators that are defined in the theoretical framework were used; also, the strategy of methodology is described. The purpose of the work has been to provide a scientific nature, and that methodology met the objectives, offering an approach from different angles and the actors involved, and a critical and objective analysis strictly in order to contribute to public health. The research is a valuable tool that provides

37 CFR 1.705 - Patent term adjustment determination.

Science.gov (United States)

2010-07-01

... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Patent term adjustment determination. 1.705 Section 1.705 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES Adjustment and Extension of Patent Term...

Radioactive waste processing and disposal: a bibliography. Part 1. Abstracts; Part 2. Indexes

International Nuclear Information System (INIS)

McLaren, L.H.

1985-03-01

This compilation contains 4567 citations to foreign and domestic research reports, journal articles, patents, conference proceedings, and books dealing with radioactive waste management. These citations were added to the DOE Energy Data Base from January 1983 through December 1983. Five indexes are included: Corporate Author, Personal Author, Subject, Contract Number, and Report Number

Patenting of university and non-university public research organisations in Germany: evidence from patent applications for medical research results.

Directory of Open Access Journals (Sweden)

Peter Tinnemann

Full Text Available BACKGROUND: Patents are one of the most important forms of intellectual property. They grant a time-limited exclusivity on the use of an invention allowing the recuperation of research costs. The use of patents is fiercely debated for medical innovation and especially controversial for publicly funded research, where the patent holder is an institution accountable to public interest. Despite this controversy, for the situation in Germany almost no empirical information exists. The purpose of this study is to examine the amount, types and trends of patent applications for health products submitted by German public research organisations. METHODS/PRINCIPAL FINDINGS: We conducted a systematic search for patent documents using the publicly accessible database search interface of the German Patent and Trademark Office. We defined keywords and search criteria and developed search patterns for the database request. We retrieved documents with application date between 1988 and 2006 and processed the collected data stepwise to compile the most relevant documents in patent families for further analysis. We developed a rationale and present individual steps of a systematic method to request and process patent data from a publicly accessible database. We retrieved and processed 10194 patent documents. Out of these, we identified 1772 relevant patent families, applied for by 193 different universities and non-university public research organisations. 827 (47% of these patent families contained granted patents. The number of patent applications submitted by universities and university-affiliated institutions more than tripled since the introduction of legal reforms in 2002, constituting almost half of all patent applications and accounting for most of the post-reform increase. Patenting of most non-university public research organisations remained stable. CONCLUSIONS: We search, process and analyse patent applications from publicly accessible databases

Entrepreneurial patent management in pharmaceutical startups.

Science.gov (United States)

Holgersson, Marcus; Phan, Tai; Hedner, Thomas

2016-07-01

Startups fill an increasingly important role as innovators in the pharmaceutical industry, and patenting is typically central to their success. This article aims to explore patent management in pharmaceutical startups. The results show that startups need to deal with several challenges related to patenting and an 'entrepreneurial' approach to patent management is called for. Resource constraints, venture capital provision, exits and other conditions and events must be readily considered in the patent management process to build a successful pharmaceutical venture, something that could benefit the pharmaceutical industry as a whole. Copyright © 2016 Elsevier Ltd. All rights reserved.

Development of sealed radioactive sources immobilized in epoxy resin for verification of detectors used in nuclear medicine

International Nuclear Information System (INIS)

Tiezzi, Rodrigo

2016-01-01

The radioactive sealed sources are used in verification ionization chamber detectors, which measure the activity of radioisotopes used in several areas, such as in nuclear medicine. The measurement of the activity of radioisotopes must be made with accuracy, because it is administered to a patient. To ensure the proper functioning of the ionization chamber detectors, standardized tests are set by the International Atomic Energy Agency (IAEA) and the National Nuclear Energy Commission using sealed radioactive sources of Barium-133, Cesium-137 and Cobalt-57. The tests assess the accuracy, precision, reproducibility and linearity of response of the equipment. The focus of this work was the study and the development of these radioactive sources with standard Barium-133 and Cesium-137,using a polymer, in case commercial epoxy resin of diglycidyl ether of bisphenol A (DGEBA) and a curing agent based on modified polyamine diethylenetriamine (DETA), to immobilize the radioactive material. The polymeric matrix has the main function of fix and immobilize the radioactive contents not allowing them to leak within the technical limits required by the standards of radiological protection in the category of characteristics of a sealed source and additionally have the ability to retain the emanation of any gases that may be formed during the manufacture process and the useful life of this artifact. The manufacturing process of a sealed source standard consists of the potting ,into bottle standardized geometry, in fixed volume of a quantity of a polymeric matrix within which is added and dispersed homogeneously to need and exact amount in activity of the radioactive materials standards. Accordingly, a study was conducted for the choice of epoxy resin, analyzing its characteristics and properties. Studies and tests were performed, examining the maximum miscibility of the resin with the water (acidic solution, simulating the conditions of radioactive solution), loss of mechanical and

Nuclear medicine

International Nuclear Information System (INIS)

Kand, Purushottam

2012-01-01

Nuclear medicine is a specialized area of radiology that uses very small amounts of radioactive materials to examine organ function and structure. Nuclear medicine is older than CT, ultrasound and MRI. It was first used in patients over 60-70 years ago. Today it is an established medical specialty and offers procedures that are essential in many medical specialities like nephrology, pediatrics, cardiology, psychiatry, endocrinology and oncology. Nuclear medicine refers to medicine (a pharmaceutical) that is attached to a small quantity of radioactive material (a radioisotope). This combination is called a radiopharmaceutical. There are many radiopharmaceuticals like DTPA, DMSA, HIDA, MIBI and MDP available to study different parts of the body like kidneys, heart and bones etc. Nuclear medicine uses radiation coming from inside a patient's body where as conventional radiology exposes patients to radiation from outside the body. Thus nuclear imaging study is a physiological imaging, whereas diagnostic radiology is anatomical imaging. It combines many different disciplines like chemistry, physics mathematics, computer technology, and medicine. It helps in diagnosis and to treat abnormalities very early in the progression of a disease. The information provides a quick and accurate diagnosis of wide range of conditions and diseases in a person of any age. These tests are painless and most scans expose patients to only minimal and safe amounts of radiation. The amount of radiation received from a nuclear medicine procedure is comparable to, or often many times less than, that of a diagnostic X-ray. Nuclear medicine provides an effective means of examining whether some tissues/organs are functioning properly. Therapy using nuclear medicine in an effective, safe and relatively inexpensive way of controlling and in some cases eliminating, conditions such as overactive thyroid, thyroid cancer and arthritis. Nuclear medicine imaging is unique because it provides doctors with

Automated Patent Categorization and Guided Patent Search using IPC as Inspired by MeSH and PubMed.

Science.gov (United States)

Eisinger, Daniel; Tsatsaronis, George; Bundschus, Markus; Wieneke, Ulrich; Schroeder, Michael

2013-04-15

Document search on PubMed, the pre-eminent database for biomedical literature, relies on the annotation of its documents with relevant terms from the Medical Subject Headings ontology (MeSH) for improving recall through query expansion. Patent documents are another important information source, though they are considerably less accessible. One option to expand patent search beyond pure keywords is the inclusion of classification information: Since every patent is assigned at least one class code, it should be possible for these assignments to be automatically used in a similar way as the MeSH annotations in PubMed. In order to develop a system for this task, it is necessary to have a good understanding of the properties of both classification systems. This report describes our comparative analysis of MeSH and the main patent classification system, the International Patent Classification (IPC). We investigate the hierarchical structures as well as the properties of the terms/classes respectively, and we compare the assignment of IPC codes to patents with the annotation of PubMed documents with MeSH terms.Our analysis shows a strong structural similarity of the hierarchies, but significant differences of terms and annotations. The low number of IPC class assignments and the lack of occurrences of class labels in patent texts imply that current patent search is severely limited. To overcome these limits, we evaluate a method for the automated assignment of additional classes to patent documents, and we propose a system for guided patent search based on the use of class co-occurrence information and external resources.

Solid radioactive waste: evaluation of residual activity in nuclear medicine services

International Nuclear Information System (INIS)

Alabarse, Frederico G.; Xavier, Ana M.; Magalhaes, Maisa H.; Guerrero, Jesus S.P.

2009-01-01

An experimental programme to estimate, with a better degree of accuracy, the activity that remains adsorbed in flasks and syringes used in Nuclear Medicine Services for the administration of radionuclides to patients submitted to diagnostic or therapy is been conducted under the coordination of the Radioactive Waste Division of the Brazilian Nuclear Energy Commission, CNEN. The adopted recommendation in Brazil to allow an expedite solid waste management in nuclear medicine facilities, up to the present, is to consider that 2% of the initial activity remains adsorbed in the solid waste, which easily allows the calculation of the storage time to achieve regulatory clearance levels by decay. This research evaluates 17 different kinds of radiopharmaceuticals and three radioisotopes: 99m Tc, 67 Ga and 201 Tl. Results obtained by means of a weighting method to estimate the residual mass in flasks show that the ratio of the mass of the liquid that remains in the solid waste to the mass of the empty flask is constant. This suggests that the residual activity depends on the initial activity concentration of radiopharmaceutical contained in each flask, as assumed by the regulatory body. Additionally, results obtained by determining the remaining activity in flasks, shortly after the injection of its radionuclide contents in patients, indicate that an average value for the residual activity of the order of 10% of the initial activity contained in the flasks or syringes should be adopted to determine the decay storage time before the release of solid waste in the urban conventional land fill disposal system. The 'rule of thumb' of 10 half-lives for storage before clearance is also discussed in the present work. (author)

Radiation management for infectious waste from nuclear medicine studies

International Nuclear Information System (INIS)

Kondo, Yuji; Takeuchi, Yasuyuki; Masumoto, Kazuya

2003-01-01

An industrial waste management service has refused to collect medical waste from our hospital owing to radioactive contamination found in the waste in July 2000. An investigation revealed that the ''three-way stopcock'' and handling diapers used for radioisotope examination were the radioactive contaminants. We therefore reconsidered the system of medical waste maintenance especially for radioactive materials. Since February 2001, we have resumed radiation maintenance by following the manual for the handling diapers of patients administered radiopharmaceuticals issued by five organizations associated with Japan Radiological Society (JRS), Japanese Society of Radiological Technology (JSRT), the Japanese Society of Nuclear Medicine (JSNM), the Japanese Society of Nuclear Medicine Technology (JSNMT), and Japan Association on Radiological Protection in Medicine (JARPM). A major change was to check the radioactive waste at the individual departments and at a centralized check system. This eliminated the problem of dumping radioactive material into medical waste as well as resolving the concerns of the industrial waste management service. (author)

Radiation protection rules for handling of sealed radioactive sources in medicine

International Nuclear Information System (INIS)

1985-02-01

The rules presented here relate to the use of sealed radioactive sources in medical therapy, with the radioactive sources being temporarily or permanently incorporated into body cavities or body tissues, or fixed to the body surface. They also relate to radioactive sources with dimensions below 5 mm (as e.g. seeds). (orig./HP) [de

Patent Law for Computer Scientists

Science.gov (United States)

Closa, Daniel; Gardiner, Alex; Giemsa, Falk; Machek, Jörg

More than five centuries ago the first patent statute was passed by the Venetian senate. It already had most of the features of modern patent law, recognizing the public interest in innovation and granting exclusive right in exchange for a full disclosure. Some 350 years later the industrial revolution led to globalisation. The wish to protect intellectual property on a more international level evolved and supranational treaties were negotiated. Patent laws are still different in many countries, however, and inventors are sometimes at a loss to understand which basic requirements should be satisfied if an invention is to be granted a patent. This is particularly true for inventions implemented on a computer. While roughly a third of all applications (and granted patents) relate, in one way or another, to a computer, applications where the innovation mainly resides in software or in a business method are treated differently by the major patent offices. The procedures at the USPTO, JPO and EPO and, in particular, the differences in the treatment of applications centring on software are briefly explained. In later sections of this book, a wealth of examples will be presented. The methodology behind the treatment of these examples is explained.

Management of Radioactive Spills in Nuclear Medicine; Teaching and Assessing with Objectively Structured Assessment of Technical Skills

International Nuclear Information System (INIS)

Hussain, Riffat Parveen

2015-01-01

Routine work in nuclear medicine requires the careful elution of radioactivity and its subsequent, storage and handling. Though all effort is maintained to prevent any “spill” of this radioactivity, accidents are bound to happen. The response to this spill is a methodically worked out a plan that is written and adopted as a “standard operating procedure.” This protocol is taught to all involved in the area of working as a mock drill/apprenticeship model. No formal evaluation of learning is in place except for the mock drills. The objectively structured assessment of technical skills (OSATS) is a variation on the Objective Structured Clinical Examination, which is a form of workplace based assessment. The OSATS is cited in the Accreditation Council of Graduate Medical Education evaluation toolbox on the website as the most desirable evaluation tool for the patient care topics. It is the objective of this paper is to introduce the “OSATS” for teaching, and assessment of the learning, of the protocol for the management of radioactive spill. As a review of the literature on the subject failed to reveal any such teaching protocol/material/document for this important technical skill, we hope that it may act as a landmark for the development of teaching and assessment of other technical skills also

Nuclear medicine environmental discharge measurement. Final report

International Nuclear Information System (INIS)

Gesell, T.F.; Prichard, H.M.; Davis, E.M.; Pirtle, O.L.; DiPietro, W.

1975-06-01

The discharge of most man-made radioactive materials to the environment is controlled by Federal, State or local regulatory agencies. Exceptions to this control include the radioactive wastes eliminated by individuals who have undergone diagnostic or therapeutic nuclear medicine procedures. The purpose of this study is to estimate the amount of radioactivity released to the environment via the nuclear medicine pathway for a single sewage drainage basin and to measure the amounts discharged to the environment. The report is organized into a review of previous studies, scope of work, facility data, environmental measurements and estimates of population exposure

The administration of radioactive substances

International Nuclear Information System (INIS)

Bourdillon, P.J.; Godfrey, B.E.; O'Brien, R.

1983-01-01

A brief history is given of the evolution of a system to approve the licensing of doctors and dentists to use radioactive medicinal products in man. Currently, the Administration of Radioactive Substances Advisory Committee (ARSAC) is appointed by UK Health Ministers to advise them on the granting, renewal, suspension, revocation and variation of certificates. The type of information requested on the application form for a certificate is outlined. (UK)

Radioactivity: ''small users, big problems''

International Nuclear Information System (INIS)

McDonnell, C.

1993-01-01

In the United Kingdom there are at least one thousand small users of radioactivity in industry, in medicine, in higher education establishments and even schools. These users of small amounts of radioactivity, covering a wide variety of forms and applications, have difficulty in disposing of their wastes. Disposal provisions for users outside the nuclear industry, the practical problems they encounter and the future developments likely are discussed. (UK)

[Systematic review on methodology of randomized controlled trials of post-marketing Chinese patent drugs for treatment of type 2 diabetes].

Science.gov (United States)

Ma, Li-xin; Wang, Yu-yi; Li, Xin-xue; Liu, Jian-ping

2012-03-01

Randomized controlled trial (RCT) is considered as the gold standard for the efficacy assessment of medicines. With the increasing number of Chinese patent drugs for treatment of type 2 diabetes, the methodology of post-marketing RCTs evaluating the efficacy and specific effect has become more important. To investigate post-marketing Chinese patent drugs for treatment of type 2 diabetes, as well as the methodological quality of post-marketing RCTs. Literature was searched from the books of Newly Compiled Traditional Chinese Patent Medicine and Chinese Pharmacopeia, the websites of the State Food and Drug Administration and the Ministry of Human Resources and Social Security of the People's Republic of China, China National Knowledge Infrastructure Database, Chongqing VIP Chinese Science and Technology Periodical Database, Chinese Biomedical Database (SinoMed) and Wanfang Data. The time period for searching ran from the commencement of each database to August 2011. RCTs of post-marketing Chinese patent drugs for treatment of type 2 diabetes with intervention course no less than 3 months. Two authors independently evaluated the research quality of the RCTs by the checklist of risk bias assessment and the data collection forms based on the CONSORT Statement. Independent double data-extraction was performed. The authors identified a total of 149 Chinese patent drugs for treatment of type 2 diabetes. According to different indicative syndromes, the Chinese patent drugs can be divided into the following types, namely, yin deficiency and interior heat (n=48, 32%), dual deficiency of qi and yin (n=58, 39%) and dual deficiency of qi and yin combined with blood stasis (n=22, 15%). A total of 41 RCTs meeting the inclusion criteria were included. Neither multicenter RCTs nor endpoint outcome reports were found. Risk bias analysis showed that 81% of the included studies reported randomization for grouping without sequence generation, 98% of these studies did not report

Method of removing radioactive waste from oil

International Nuclear Information System (INIS)

Belanger, R.L.

1986-01-01

This patent describes a method of removing particulates, radioactive contaminants, and moisture from oil, which consists of: straining out the particulates by passing the oil through a coarse filter screen to a receiving vessel; forming an upper stratum of oil and a lower stratum of sludge, consisting of mud, oil, particulates, and moisture, by heating the upper two-thirds of the receiving vessel; skimming off the stratum of oil from the receiving vessel; transferring the sludge from the receiving vessel to a container; transferring additional separated oil to the receiving vessel; conveying the oil skimmed from the receiving vessel to a mixing vessel; adding an effective amount of Calcium Hypochlorite crystals containing 65% free Chlorine to the mixing vessel to initiate salt formation with the radioactive contaminants; mixing the contents of the mixing vessel for at least ten minutes; transferring the mixture from the mixing vessel to a circulating heater; outputting the mixture from the circulating heater to a second mixing vessel; removing moisture from the oil; and filtering from the oil, the solid radioactive contaminant-salts and residual particulate matter

76 FR 72000 - Patent, Trademark & Copyright Acts

Science.gov (United States)

2011-11-21

... DEPARTMENT OF THE INTERIOR Geological Survey Patent, Trademark & Copyright Acts AGENCY: U.S... Consultants, 1255 Roberts Boulevard NW., Suite 200, Kennesaw, GA 30144, on U.S. Patent Application Serial No. 12/133,666, and a divisional patent application to be filed shortly at the Patent and Trademark...

78 FR 51177 - Notice of Intent To Grant Partially Exclusive Patent License; ICAP Patent Brokerage, LLC

Science.gov (United States)

2013-08-20

... DEPARTMENT OF DEFENSE Department of the Navy Notice of Intent To Grant Partially Exclusive Patent License; ICAP Patent Brokerage, LLC AGENCY: Department of the Navy, DoD. ACTION: Notice. SUMMARY: The Department of the Navy hereby gives notice of its intent to grant to ICAP Patent Brokerage, LLC, a revocable...

78 FR 72872 - Notice of Intent To Grant Partially Exclusive Patent License; ICAP Patent Brokerage, LLC

Science.gov (United States)

2013-12-04

... DEPARTMENT OF DEFENSE Department of the Navy Notice of Intent To Grant Partially Exclusive Patent License; ICAP Patent Brokerage, LLC AGENCY: Department of the Navy, DoD. ACTION: Notice. SUMMARY: The Department of the Navy hereby gives notice of its intent to grant to ICAP Patent Brokerage, LLC, a revocable...

48 CFR 970.2703 - Patent rights.

Science.gov (United States)

2010-10-01

... 48 Federal Acquisition Regulations System 5 2010-10-01 2010-10-01 false Patent rights. 970.2703 Section 970.2703 Federal Acquisition Regulations System DEPARTMENT OF ENERGY AGENCY SUPPLEMENTARY REGULATIONS DOE MANAGEMENT AND OPERATING CONTRACTS Patents, Data, and Copyrights 970.2703 Patent rights. ...

Beyond Invention: Patent as Knowledge Law

OpenAIRE

Madison, Michael

2017-01-01

The decision of the Supreme Court of the United States in Bilski v. Kappos, concerning the legal standard for determining patentable subject matter under the American Patent Act, is used as a starting point for a brief review of historical, philosophical, and cultural influences on subject matter questions in both patent and copyright law. The article suggests that patent and copyright law jurisprudence was constructed initially by the Court with explicit attention to the relationship between...

48 CFR 970.2702-3 - Patent indemnity.

Science.gov (United States)

2010-10-01

... 48 Federal Acquisition Regulations System 5 2010-10-01 2010-10-01 false Patent indemnity. 970.2702... SUPPLEMENTARY REGULATIONS DOE MANAGEMENT AND OPERATING CONTRACTS Patents, Data, and Copyrights 970.2702-3 Patent indemnity. (a) Contracting officers must use the clause at 970.5227-6, Patent Indemnity—Subcontracts to...

The ethics of patenting human embryonic stem cells.

Science.gov (United States)

Chapman, Audrey R

2009-09-01

Just as human embryonic stem cell research has generated controversy about the uses of human embryos for research and therapeutic applications, human embryonic stem cell patents raise fundamental ethical issues. The United States Patent and Trademark Office has granted foundational patents, including a composition of matter (or product) patent to the Wisconsin Alumni Research Foundation (WARF), the University of Wisconsin-Madison's intellectual property office. In contrast, the European Patent Office rejected the same WARF patent application for ethical reasons. This article assesses the appropriateness of these patents placing the discussion in the context of the deontological and consequentialist ethical issues related to human embryonic stem cell patenting. It advocates for a patent system that explicitly takes ethical factors into account and explores options for new types of intellectual property arrangements consistent with ethical concerns.

Developing a Systematic Patent Search Training Program

Science.gov (United States)

Zhang, Li

2009-01-01

This study aims to develop a systematic patent training program using patent analysis and citation analysis techniques applied to patents held by the University of Saskatchewan. The results indicate that the target audience will be researchers in life sciences, and aggregated patent database searching and advanced search techniques should be…

Method for reduction in volume and encapsulation of water-containing weakly radioactive waste

International Nuclear Information System (INIS)

Fox, D.W.; Miller, G.P.; Weech, M.E.

1982-01-01

Solutions and slurries of waste material in water are dehydrated and enclosed in a polymerizate for final storage. The water is removed as an azeotropic mixture and the dehydrated waste residue is then enclosed in an organic polymerizate. The method and system disclosed in this patent claim are particularly suitable for safe removal of radioactive waste. (orig.) [de

48 CFR 31.205-30 - Patent costs.

Science.gov (United States)

2010-10-01

... 48 Federal Acquisition Regulations System 1 2010-10-01 2010-10-01 false Patent costs. 31.205-30....205-30 Patent costs. (a) The following patent costs are allowable to the extent that they are incurred... patent application where title or royalty-free license is to be conveyed to the Government. (b) General...

A Moral Economy of Patents: Case of Finnish Research Universities' Patent Policies

Science.gov (United States)

Kauppinen, Ilkka

2014-01-01

The primary objective of this paper is to demonstrate the usefulness of the concept of moral economy for higher education studies through a study of Finnish research universities' patent policies. Patent policies not only stimulate the commercialization of research, they also set norms for behavior and aim to clarify how to distribute rights and…

48 CFR 35.012 - Patent rights.

Science.gov (United States)

2010-10-01

... 48 Federal Acquisition Regulations System 1 2010-10-01 2010-10-01 false Patent rights. 35.012 Section 35.012 Federal Acquisition Regulations System FEDERAL ACQUISITION REGULATION SPECIAL CATEGORIES OF CONTRACTING RESEARCH AND DEVELOPMENT CONTRACTING 35.012 Patent rights. For a discussion of patent rights, see...

Prizes for innovation of new medicines and vaccines.

Science.gov (United States)

Love, James; Hubbard, Tim

2009-01-01

This article argues that prizes can help stimulate medical innovation, control costs and ensure greater access to new medicines and vaccines. The authors explore four increasingly ambitious prize options to reward medical innovation, each addressing flaws in the current patent system. The first option promotes innovation through a large prize fund linked to the impact on health outcomes; the second option rewards the sharing of knowledge, data, and technology with open source dividends; the third option awards prizes for interim benchmarks and discrete technical problems; and the final option removes the exclusive right to use patented inventions in upstream research in favor of prizes. The authors conclude that a system of prizes to reward drug development would break the link between R&D incentives and product prices, and that such a reform is needed to improve innovation and access to new medicines and vaccines.

Confidential patent application with an example of preparation

Directory of Open Access Journals (Sweden)

Obrad T. Čabarkapa

2013-12-01

Full Text Available In order that the invention solving a technical problem receives a patent protection, it is necessary to file a patent application. For the protection of confidential inventions which are important for defense and national security, a confidential patent application[1] must be filed. A confidential patent application is an important and complex document, the parts of which are,  in principle, exposed in an established order. For the preparation of patent applications, it is necessary to engage experts with higher education, primarily in the technical field the invention relates to. The contents of the patent application is a basis for examining whether the application meets the requirements for patentability and whether the right to patent protection is achieved. Besides theoretical discussions on patent application, the paper gives a short version of an example of an application regarding a protected confidential invention. Introduction The basic condition for the exercise of patent protection is filing a patent application, the test procedure and, eventually, depending on the test results - the recognition or rejection of the patent. The paper gives a description of all parts of the patent application on an example of a confidential invention already patented. The content of the confidential patent application The confidential patent application for confidential invention protection consists of the following parts: The application for a patent; description of the invention; the claims (indication of what is new and what is required to be protected by patenting; abstract (short summary of the invention  and a draft of the invention (to which the description and the claims are referred. The application for a patent The application for patent is filed on Form P-1 and a request for the petty patent on Form MP-1. The data entered in the file is, for example: the applicant; the lawyer; the name of the invention in Serbian and English; the inventor

A Database of EPO-Patenting Firms in Denmark

DEFF Research Database (Denmark)

Nielsen, Anders Østergaard

1998-01-01

The first section gives a brief introduction of the basic stages to be observed by the patent applicant from idea to the patent is granted. Section two presents three examples of how patents are registered in the online patent database INPADOC. Section three accounts for the initial analysis...... of the existing patent stock issued to firms with domicile in Denmark. Sections four and five report the basic characteristics of the EPO-patent sample and the procedures for linking the patent statistics to accounting data at the firm level, and finally they present the basic properties of the resulting database...

Digital pathology: A systematic evaluation of the patent landscape.

Science.gov (United States)

Cucoranu, Ioan C; Parwani, Anil V; Vepa, Suryanarayana; Weinstein, Ronald S; Pantanowitz, Liron

2014-01-01

Digital pathology is a relatively new field. Inventors of technology in this field typically file for patents to protect their intellectual property. An understanding of the patent landscape is crucial for companies wishing to secure patent protection and market dominance for their products. To our knowledge, there has been no prior systematic review of patents related to digital pathology. Therefore, the aim of this study was to systematically identify and evaluate United States patents and patent applications related to digital pathology. Issued patents and patent applications related to digital pathology published in the United States Patent and Trademark Office (USPTO) database (www.uspto.gov) (through January 2014) were searched using the Google Patents search engine (Google Inc., Mountain View, California, USA). Keywords and phrases related to digital pathology, whole-slide imaging (WSI), image analysis, and telepathology were used to query the USPTO database. Data were downloaded and analyzed using the Papers application (Mekentosj BV, Aalsmeer, Netherlands). A total of 588 United States patents that pertain to digital pathology were identified. In addition, 228 patent applications were identified, including 155 that were pending, 65 abandoned, and eight rejected. Of the 588 patents granted, 348 (59.18%) were specific to pathology, while 240 (40.82%) included more general patents also usable outside of pathology. There were 70 (21.12%) patents specific to pathology and 57 (23.75%) more general patents that had expired. Over 120 unique entities (individual inventors, academic institutions, and private companies) applied for pathology specific patents. Patents dealt largely with telepathology and image analysis. WSI related patents addressed image acquisition (scanning and focus), quality (z-stacks), management (storage, retrieval, and transmission of WSI files), and viewing (graphical user interface (GUI), workflow, slide navigation and remote control). An

Digital pathology: A systematic evaluation of the patent landscape

Directory of Open Access Journals (Sweden)

Ioan C. Cucoranu

2014-01-01

Full Text Available Introduction: Digital pathology is a relatively new field. Inventors of technology in this field typically file for patents to protect their intellectual property. An understanding of the patent landscape is crucial for companies wishing to secure patent protection and market dominance for their products. To our knowledge, there has been no prior systematic review of patents related to digital pathology. Therefore, the aim of this study was to systematically identify and evaluate United States patents and patent applications related to digital pathology. Materials and Methods: Issued patents and patent applications related to digital pathology published in the United States Patent and Trademark Office (USPTO database (www.uspto.gov (through January 2014 were searched using the Google Patents search engine (Google Inc., Mountain View, California, USA. Keywords and phrases related to digital pathology, whole-slide imaging (WSI, image analysis, and telepathology were used to query the USPTO database. Data were downloaded and analyzed using the Papers application (Mekentosj BV, Aalsmeer, Netherlands. Results: A total of 588 United States patents that pertain to digital pathology were identified. In addition, 228 patent applications were identified, including 155 that were pending, 65 abandoned, and eight rejected. Of the 588 patents granted, 348 (59.18% were specific to pathology, while 240 (40.82% included more general patents also usable outside of pathology. There were 70 (21.12% patents specific to pathology and 57 (23.75% more general patents that had expired. Over 120 unique entities (individual inventors, academic institutions, and private companies applied for pathology specific patents. Patents dealt largely with telepathology and image analysis. WSI related patents addressed image acquisition (scanning and focus, quality (z-stacks, management (storage, retrieval, and transmission of WSI files, and viewing (graphical user interface (GUI

[The Glivec® case: the first example of a global debate on the drug patent system].

Science.gov (United States)

Moital, Inês; Bosch, Fèlix; Farré, Magí; Maddaleno, Mariano; Baños, Josep-E

2014-01-01

To describe the sequence of events involving the Glivec® case in India and to analyze the opinions generated in distinct settings. We performed a systematic search for articles concerning the imatinib (Glivec®) patent in India. We selected those sources that described the events, decisions of the authorities involved, and press and scientific opinions. Dates and arguments presented by the involved parties were clearly identified. Of 886 documents initially obtained, we selected 40 documents published between 2003 and 2013. Most of them were press news and commentaries. The process lasted 7 years, starting in 2006 when the Indian Patent Office rejected the patent application filed by Novartis. It ended in 2013 when the Indian Supreme Court upheld this decision. It was argued that the Indian Patent Law would facilitate access to medicines in the Third World and the final decision has received support by the general population. Although the court's final decision has been supported by several institutions, an objective analysis should also take into account the arguments of the pharmaceutical companies and other entities. The Glivec® case gave rise to an intense debate on the appropriateness of international standards on patents, their applicability and how they should be adopted in each country. This case, as well as other cases, should serve to stimulate reflection on the international patent system and to achieve scenarios in which the health of the poorest populations is protected but also balanced against intellectual property protection and innovation. Copyright © 2014 SESPAS. Published by Elsevier Espana. All rights reserved.

Patents and Innovation: Friends or Foes?

OpenAIRE

Lévêque, François

2007-01-01

Over 2 million patents are currently in force in the EU and in the USA. Do they testify innovation is blockaded for they restrict freedom in research or do they give evidence innovation is flourishing for patent law provides incentives to invent new products and processes? In other terms do patents freeze or spur innovation? The question arises for massive anecdotal evidence shows the patent system may have turned on its head, e.g., USPTO and EPO examiners spend less than 30 hours pe...

Herbal drug patenting in India: IP potential.

Science.gov (United States)

Sahoo, Niharika; Manchikanti, Padmavati; Dey, Satya Hari

2011-09-01

Herbal drugs are gaining worldwide prominence due to their distinct advantages. Developing countries have started exploring the ethnopharmacological approach of drug discovery and have begun to file patents on herbal drugs. The expansion of R&D in Indian herbal research organizations and presence of manufacturing units at non-Indian sites is an indication of the capability to develop new products and processes. The present study attempts to identify innovations in the Indian herbal drug sector by analyzing the patenting trends in India, US and EU. Based on key word and IPC based search at the IPO, USPTO, Esp@cenet and WIPO databases, patent applications and grant in herbal drugs by Indian applicants/assignees was collected for the last ten years (from 1st January 2001 to 31st October 2010). From this collection patents related to human therapeutic use only were selected. Analysis was performed to identify filing trends, major applicants/assignees, disease area and major plant species used for various treatments. There is a gradual increase in patent filing through the years. In India, individual inventors have maximum applications and grants. CSIR, among research organizations and Hindustan Unilever, Avesthagen, Piramal Life Science, Sahajanand Biotech and Indus Biotech among the companies have the maximum granted patents in India, US and EU respectively. Diabetes, cancer and inflammatory disorders are the major areas for patenting in India and abroad. Recent patents are on new herbal formulations for treatment of AIDS, hepatitis, skin disorders and gastrointestinal disorders. A majority of the herbal patents applications and grants in India are with individual inventors. Claim analysis indicates that these patents include novel multi-herb compositions with synergistic action. Indian research organizations are more active than companies in filing for patents. CSIR has maximum numbers of applications not only in India but also in the US and EU. Patents by research

The problem and solution of enterprise patent application

International Nuclear Information System (INIS)

Li Dabo; Yang Xiaoqing

2010-01-01

Recently, the situation of Chinese patent application is pleasant, but there are still some hiding disquiets. For the most enterprises, the passion of current patent application may not be derived from the internal motility but mainly derived by the government policy. Because of the shortage of related knowledge on patent, there are still some problems for our enterprises, such as blurring the scope of patent application and failing the organization of the documents of patent application which causing the patent cannot be applied timely. In some cases, the patent cannot obtain the effective protection even if it has been applied and obtained the authorization successfully. For such problems, we should enhance the cooperation between enterprises and agency organizations and build a patent engineer group which should participate in the whole R and D process and can prepare the documents of the patent application effectively and timely. What's more, we should inhibit the phenomena of infringement of patent rights and use 'existing technique' effectively by the methods of document retrieval. (authors)

Nuclear medicine

International Nuclear Information System (INIS)

Sibille, L.; Nalda, E.; Collombier, L.; Kotzki, P.O.; Boudousq, V.

2011-01-01

Nuclear medicine is a medical specialty using the properties of radioactivity. Radioactive markers associated with vectors are used as a tracer or radiopharmaceutical for diagnostic purposes and/or therapy. Since its birth more than half a century ago, it has become essential in the care of many patients, particularly in oncology. After some definitions, this paper presents the main nuclear techniques - imaging for diagnostic, radiopharmaceuticals as therapeutic agents, intra-operative detection, technique of radioimmunoassay - and the future of this field. (authors)

Affordability and availability of off-patent drugs in the United States—the case for importing from abroad: observational study

Science.gov (United States)

Gupta, Ravi; Bollyky, Thomas J; Cohen, Matthew; Ross, Joseph S

2018-01-01

Abstract Objectives To evaluate whether off-patent prescription drugs at risk of sudden price increases or shortages in the United States are available from independent manufacturers approved in other well regulated settings around the world. Design Observational study. Setting Off-patent drugs in the USA and approved by the Food and Drug Administration, up to 10 April 2017. Study cohort Novel tablet or capsule prescription drugs approved by the FDA since 1939 that were no longer protected by patents or other market exclusivity and had up to three generic versions. Main outcome measures Number of additional manufacturers that had obtained approval from any of seven non-US regulators with similar standards (European Medicines Agency (European Union), HealthCanada (Canada), Therapeutic Goods Association (Australia), Medsafe (New Zealand), Swissmedic (Switzerland), Medicines Control Council (South Africa), and the Israel Health Ministry). Association with drug characteristics including US orphan drug designation for drugs treating rare diseases, World Health Organization essential medicine designation, treatment area, drug product complexity (that is, with attributes that could complicate establishing bioequivalence or manufacturing), and total Medicaid spending in 2015. Results Of 170 eligible study drugs, more than half (109, 64%) had at least one manufacturer approved by a non-US regulator and 32 (19%) had four or more. Among 44 (26%) drugs with no FDA approved generic versions, 21 (48%) were available from at least one manufacturer approved by one of the seven non-US regulators, and two (5%) by four or more manufacturers. Across all drugs and regulators (including the FDA), 66 (39%) drugs were available from four or more total manufacturers. Of 109 drugs with at least one non-US regulator approved manufacturer, 12 (11%) were approved for patients with rare diseases and 29 (27%) were WHO designated essential medicines; only 12 (11%) were complex products that might

Decoding Gene Patents in Australia

OpenAIRE

Denley, Adam; Cherry, James

2015-01-01

Patents directed to naturally occurring genetic material, such as DNA, RNA, chromosomes, and genes, in an isolated or purified form have been granted in Australia for many years. This review provides scientists with a summary of the gene patent debate from an Australian perspective and specifically reviews how the various levels of the legal system as they apply to patents—the Australian Patent Office, Australian courts, and Australian government—have dealt with the issue of whether genetic m...

Radiation and medicine: introduction

International Nuclear Information System (INIS)

Lentle, B.; Singh, H.

1984-01-01

A brief historical review is given of the development of the various nuclear medicine techniques which have been evolved since the discovery of X-rays and radioactivity. The role of various disciplines, such as radiobiology, radiation chemistry, radiation physics and computers in the application of radiation in medicine is discussed. (U.K.)

75 FR 34749 - Determination of Regulatory Review Period for Purposes of Patent Extension; BYSTOLIC; U.S. Patent...

Science.gov (United States)

2010-06-18

... and FDA-2008-E-0267] Determination of Regulatory Review Period for Purposes of Patent Extension; BYSTOLIC; U.S. Patent Nos. 5,759,580 and 6,545,040 AGENCY: Food and Drug Administration, HHS. ACTION... determination because of the submission of applications to the Director of Patents and Trademarks, Department of...

Introductory physics of nuclear medicine

International Nuclear Information System (INIS)

Chandra, R.

1976-01-01

This presentation is primarily addressed to resident physicians in nuclear medicine, as well as residents in radiology, pathology, and internal medicine. Topics covered include: basic review; nuclides and radioactive processes; radioactivity-law of decay, half-life, and statistics; production of radionuclides; radiopharmaceuticals; interaction of high-energy radiation with matter; radiation dosimetry; detection of high-energy radiation; in-vitro radiation detection; in-vivo radiation detection using external detectors; detectability or final contrast in a scan; resolution and sensitivity of a scanner; special techniques and instruments; therapeutic uses of radionuclides; biological effects of radiation; and safe handling of radionuclides

Scientific Prediction and Prophetic Patenting in Drug Discovery.

Science.gov (United States)

Curry, Stephen H; Schneiderman, Anne M

2015-01-01

Pharmaceutical patenting involves writing claims based on both discoveries already made, and on prophesy of future developments in an ongoing project. This is necessitated by the very different timelines involved in the drug discovery and product development process on the one hand, and successful patenting on the other. If patents are sought too early there is a risk that patent examiners will disallow claims because of lack of enablement. If patenting is delayed, claims are at risk of being denied on the basis of existence of prior art, because the body of relevant known science will have developed significantly while the project was being pursued. This review examines the role of prophetic patenting in relation to the essential predictability of many aspects of drug discovery science, promoting the concepts of discipline-related and project-related prediction. This is especially directed towards patenting activities supporting commercialization of academia-based discoveries, where long project timelines occur, and where experience, and resources to pay for patenting, are limited. The need for improved collaborative understanding among project scientists, technology transfer professionals in, for example, universities, patent attorneys, and patent examiners is emphasized.

Patents associated with high-cost drugs in Australia.

Directory of Open Access Journals (Sweden)

Andrew F Christie

Full Text Available Australia, like most countries, faces high and rapidly-rising drug costs. There are longstanding concerns about pharmaceutical companies inappropriately extending their monopoly position by "evergreening" blockbuster drugs, through misuse of the patent system. There is, however, very little empirical information about this behaviour. We fill the gap by analysing all of the patents associated with 15 of the costliest drugs in Australia over the last 20 years. Specifically, we search the patent register to identify all the granted patents that cover the active pharmaceutical ingredient of the high-cost drugs. Then, we classify the patents by type, and identify their owners. We find a mean of 49 patents associated with each drug. Three-quarters of these patents are owned by companies other than the drug's originator. Surprisingly, the majority of all patents are owned by companies that do not have a record of developing top-selling drugs. Our findings show that a multitude of players seek monopoly control over innovations to blockbuster drugs. Consequently, attempts to control drug costs by mitigating misuse of the patent system are likely to miss the mark if they focus only on the patenting activities of originators.

Patents associated with high-cost drugs in Australia.

Science.gov (United States)

Christie, Andrew F; Dent, Chris; McIntyre, Peter; Wilson, Lachlan; Studdert, David M

2013-01-01

Australia, like most countries, faces high and rapidly-rising drug costs. There are longstanding concerns about pharmaceutical companies inappropriately extending their monopoly position by "evergreening" blockbuster drugs, through misuse of the patent system. There is, however, very little empirical information about this behaviour. We fill the gap by analysing all of the patents associated with 15 of the costliest drugs in Australia over the last 20 years. Specifically, we search the patent register to identify all the granted patents that cover the active pharmaceutical ingredient of the high-cost drugs. Then, we classify the patents by type, and identify their owners. We find a mean of 49 patents associated with each drug. Three-quarters of these patents are owned by companies other than the drug's originator. Surprisingly, the majority of all patents are owned by companies that do not have a record of developing top-selling drugs. Our findings show that a multitude of players seek monopoly control over innovations to blockbuster drugs. Consequently, attempts to control drug costs by mitigating misuse of the patent system are likely to miss the mark if they focus only on the patenting activities of originators.

Patent portfolio management: literature review and a proposed model.

Science.gov (United States)

Conegundes De Jesus, Camila Kiyomi; Salerno, Mario Sergio

2018-05-09

Patents and patent portfolios are gaining attention in the last decades, from the called 'pro-patent era' to the recent billionaire transactions involving patent portfolios. The field is growing in importance, both theoretically and practically and despite having substantial literature on new product development portfolio management, we have not found an article relating this theory to patent portfolios. Areas covered: The paper develops a systematic literature review on patent portfolio management to organize the evolution and tendencies of patent portfolio management, highlighting distinctive features of patent portfolio management. Interview with IP manager of three life sciences companies, including a leading multinational group provided relevant information about patent portfolio management. Expert opinion: Based on the systematic literature review on portfolio management, more specifically, on new product development portfolio theory, and interview the paper proposes the paper proposes a reference model to manage patent portfolios. The model comprises four stages aligned with the three goals of the NPD portfolio management: 1 - Linking strategy of the Company's NPD Portfolio to Patent Portfolio; 2 - Balancing the portfolio in buckets; 3 - Patent Valuation (maximizing valuation); 4 - Regularly reviewing the patent portfolio.

Patents: Recent Trends and Puzzles

OpenAIRE

Zvi Griliches

1989-01-01

This paper reviews the historical data on patenting in the United States with special reference to the last 20 years and their potential relation, if any, to the recent productivity slowdown. Two Points are made: Patents are not a "constant-yardstick" indicator of either inventive input or output. Moreover, they are "produced" by a governmental agency which goes through its own budgetary and inefficiency cycles. The paper shows that the appearance of an absolute decline in patenting in the 19...

Experience with Nuclear Medicine Information System

Directory of Open Access Journals (Sweden)

Bilge Volkan-Salanci

2012-12-01

Full Text Available Objective: Radiology information system (RIS is basically evolved for the need of radiologists and ignores the vital steps needed for a proper work flow of Nuclear Medicine Department. Moreover, CT/MRI oriented classical PACS systems are far from satisfying Nuclear Physicians like storing dynamic data for reprocessing and quantitative analysis of colored images. Our purpose was to develop a workflow based Nuclear Medicine Information System (NMIS that fulfills the needs of Nuclear Medicine Department and its integration to hospital PACS system. Material and Methods: Workflow in NMIS uses HL7 (health level seven and steps include, patient scheduling and retrieving information from HIS (hospital information system, radiopharmacy, acquisition, digital reporting and approval of the reports using Nuclear Medicine specific diagnostic codes. Images and dynamic data from cameras of are sent to and retrieved from PACS system (Corttex© for reprocessing and quantitative analysis. Results: NMIS has additional functions to the RIS such as radiopharmaceutical management program which includes stock recording of both radioactive and non-radioactive substances, calculation of the radiopharmaceutical dose for individual patient according to body weight and maximum permissible activity, and calculation of radioactivity left per unit volume for each radionuclide according their half lives. Patient scheduling and gamma camera patient work list settings were arranged according to specific Nuclear Medicine procedures. Nuclear Medicine images and reports can be retrieved and viewed from HIS. Conclusion: NMIS provides functionality to standard RIS and PACS system according to the needs of Nuclear Medicine. (MIRT 2012;21:97-102

Medical irradiation, radioactive waste and misinformation. A press release from the French Academy of Medicine; Irradiation medicale, dechets, desinformation: un avis de l'Academie de medecine

Energy Technology Data Exchange (ETDEWEB)

The, G. de; Tubiana, M

2002-07-01

The Academy of Medicine, worried by the problems that poses for public opinion the medical irradiation, the radioactive wastes and some erroneous information that these subjects give rise to, considers useful to give an advice based on objective data. (N.C.)

In-depth research of domestic nuclear patent information

International Nuclear Information System (INIS)

Mo Dan; Gao Anna; Li Dongbin; Lu Yanjia; Ren Chao

2014-01-01

Based on the domestic patent information, combined with examples, this article makes an in-depth discussion on the domestic nuclear patent information. The author puts forward for the patent information research, the appropriate retrieval of patent documents is the basis,and the correct quantitative statistical analysis of patent documents is the key, and in-depth qualitative analysis of patent documents is the core. It is expected to provide information support and guarantee for the technical innovation and scientific research personnel in the nuclear field through in-depth study of domestic nuclear information. (authors)

Inventing around Edison’s Incandescent Lamp Patent

DEFF Research Database (Denmark)

Howells, John; Katznelson, Ron D.

’s ‘898 patent. Third, by analysis of forward citation to these patents we show that regardless of these inventions’ commercial viability in the incandescent lamp market, some became important prior art for new technological fields and some laid the groundwork for the later successful substitute...... for Edison’s carbon filament. Fourthly, we show that the recent view that Edison’s patent gave the patent holder General Electric (GE) a dominant position in the incandescent lamp market is incorrect: we show that besides commercially-successful invention around the claims of this patent, data for GE...

Inventing around Edison’s incandescent lamp patent

DEFF Research Database (Denmark)

Howells, John; Ron D, Katznelson

’s ‘898 patent. Third, by analysis of forward citation to these patents we show that regardless of these inventions’ commercial viability in the incandescent lamp market, some became important prior art for new technological fields and some laid the groundwork for the later successful substitute...... for Edison’s carbon filament. Fourthly, we show that the recent view that Edison’s patent gave the patent holder General Electric (GE) a dominant position in the incandescent lamp market is incorrect: we show that besides commercially-successful invention around the claims of this patent, data for GE...

Religious coalition opposes gene patents.

Science.gov (United States)

James, J S

1995-05-19

The biotechnology industry is concerned about a coalition of mainstream religious leaders, working with Jeremy Rifkin of the Foundation of Economic Trends, who oppose the patenting of human and animal life forms, body parts, and genes. The coalition called a press conference on May 18 to ask the government to prohibit the current patenting practices for genetic engineering. The biotechnology industry argues that patents indicate that a company's research tool has significant value, and encourages capitalists to invest their dollars in the development of new treatments for diseases. They also argue that the 29 biotech drugs that are on the market have been developed as a result of patents on genes. Although most business leaders are united in opposing restrictions, many scientists are divided, citing both religious and scientific reasons.

Evaluating patent portfolios by means of multicriteria analysis

Directory of Open Access Journals (Sweden)

Xiaolu Wang

2011-06-01

Full Text Available Valuation of intangible assets is a complex topic where traditional methodologies are not always successful. Nevertheless, intangible assets, like patents, have become of great importance to companies, as their value is considered to be relevant economic and strategic information, so it is necessary to evaluate firms’ patent portfolios. The present research introduces an extended goal programming model to calculate the relative importance of the patents of companies in a patent pool. This information may be useful for patent valuation as well as for management purposes. The proposed multicriteria methodology has been applied to the 19 companies in the MPEG2 patent pool, with a total of 770 valid patents, using 7 criteria to obtain a composite measure of the relative position of the firms in the patent pool.RESUMENLa valoración de activos intangibles constituye un área compleja donde los métodos tradicionales no siempre obtienen buenos resultados. Sin embargo, los activos intangibles, entre ellos las patentes, han ganado importancia en las empresas, de forma que el cálculo de su valor se ha convertido en una cuestión estratégica en muchos casos. Este hecho requiere que las empresas valoren la cartera de patentes en su conjunto. La presente investigación presenta un modelo extendido de programación por metas y su aplicación para el cálculo de la importancia relativa de las patentes. Este modelo puede resultar importante tanto para la valoración de las patentes como para la gestión empresarial. La metodología multicriterio propuesta ha sido aplicado a 19 empresas en el sector de las patentes del formato MPEG2, con un total de 770 patentes válidas, y utilizando 7 criterios con el objetivo de obtener una medida compuesta de la posición relativa de las empresas en el conjunto de patentes.

Effect of the economic crisis on the production of immunology patents managed through the Patent Cooperation Treaty agreement from 2004-2011.

Science.gov (United States)

Campos, Elena; Campos, Adolfo

2015-07-01

To determine the evolution of patents in immunology, as a result of research and innovation in the years 2004-2011. The search for patents published internationally in immunology was made by using the SCOPUSTM database. SCOPUS gives information about over 23 million patents. The extracted data from patents were: inventors and applicants; their nationalities; sections, classes and subclasses of the International Patent Classification. 89 countries. Data have been obtained from the database SCOPUS. It has been used for the international patent classification. Patents by country, Productive sectors, Productive areas. A total of 17,281 patents were applied for immunology during 2004-2011 of which 16,811 were from 30 Organisation for Economic Cooperation and Development countries, and 5326 from 28 countries in the European Union. These patents were granted in 89 countries and 13,699 of them were submitted by researchers from only one country. Private entities applied for 62.45% of all patents, universities 17.48%, hospitals 3.40% and public research organisations and private applicants applied for the rest. The university that made more applications was the University of California with 315 and the company was Genentech Inc. (US) with 302. The reduction in the number of applications of international patents in all disciplines of science also affected the area of immunology. Collaboration in immunology between universities, companies and hospitals is hard because their interests are different. It is shown in patent applications that the majority of patents in immunology are applied for by only one entity. Patents in immunology are developed, mainly, in aspects such as medical preparations, peptides, mutation or genetic engineering, therapeutic activity of chemical compounds and analysing materials by determining their chemical or physical properties.

Simultaneous invention and the patent law

DEFF Research Database (Denmark)

Howells, John

inventions they often find this to challenge the idea that patent law (which rewards only the first inventor with exclusive rights) is needed to encourage invention and innovation. We review the empirical evidence alleged to show that simultaneous invention is prevalent for important inventions. In general...... is typical of important pioneer inventions in both survey evidence and alleged illustrative cases of simultaneous invention. We show this in the cases of Edison, the Wright brothers, the Selden automobile patent vis a vis Ford, Watt and the steam engine. We then point out that patent law inherently ensures...... that patent protection is not extended to near simultaneous inventions. There remain a number of simultaneous inventions discovered through interference proceedings but we find the number too small to mount a serious challenge to the general operation of patent law....

The European Patent System: Dealing with emerging technologies.

NARCIS (Netherlands)

Kica, Evisa; Groenendijk, Nico

2011-01-01

In light of recent controversial patent decisions in biotechnology, this article argues that the current European patent examination and opposition procedures do not suffice to balance the patent system These procedures do not provide sufficient guidance for patent examiners to deal effectively with

Travel in the depth of radioactivity; Voyage au coeur de la radioactivite

Energy Technology Data Exchange (ETDEWEB)

NONE

1996-09-01

This educational booklet gives a general presentation of radioactivity: origin of natural radioactivity, characteristics of atoms and isotopes, the radioactivity phenomenon, its decay and measurement units, the radiations and their use in medicine, industry, agriculture and food industry, biology etc.. (J.S.)

Trends in worldwide nanotechnology patent applications: 1991 to 2008

International Nuclear Information System (INIS)

Dang Yan; Zhang Yulei; Fan Li; Chen Hsinchun; Roco, Mihail C.

2010-01-01

Nanotechnology patent applications published during 1991-2008 have been examined using the 'title-abstract' keyword search on esp-cenet 'worldwide' database. The longitudinal evolution of the number of patent applications, their topics, and their respective patent families have been evaluated for 15 national patent offices covering 98% of the total global activity. The patent offices of the United States (USA), People's Republic of China (PRC), Japan, and South Korea have published the largest number of nanotechnology patent applications, and experienced significant but different growth rates after 2000. In most repositories, the largest numbers of nanotechnology patent applications originated from their own countries/regions, indicating a significant 'home advantage.' The top applicant institutions are from different sectors in different countries (e.g., from industry in the US and Canada patent offices, and from academe or government agencies at the PRC office). As compared to 2000, the year before the establishment of the US National Nanotechnology Initiative (NNI), numerous new invention topics appeared in 2008, in all 15 patent repositories. This is more pronounced in the USA and PRC. Patent families have increased among the 15 patent offices, particularly after 2005. Overlapping patent applications increased from none in 1991 to about 4% in 2000 and to about 27% in 2008. The largest share of equivalent nanotechnology patent applications (1,258) between two repositories was identified between the US and Japan patent offices.

Trends in worldwide nanotechnology patent applications: 1991 to 2008

Science.gov (United States)

Dang, Yan; Zhang, Yulei; Fan, Li; Chen, Hsinchun; Roco, Mihail C.

2010-03-01

Nanotechnology patent applications published during 1991-2008 have been examined using the "title-abstract" keyword search on esp@cenet "worldwide" database. The longitudinal evolution of the number of patent applications, their topics, and their respective patent families have been evaluated for 15 national patent offices covering 98% of the total global activity. The patent offices of the United States (USA), People's Republic of China (PRC), Japan, and South Korea have published the largest number of nanotechnology patent applications, and experienced significant but different growth rates after 2000. In most repositories, the largest numbers of nanotechnology patent applications originated from their own countries/regions, indicating a significant "home advantage." The top applicant institutions are from different sectors in different countries (e.g., from industry in the US and Canada patent offices, and from academe or government agencies at the PRC office). As compared to 2000, the year before the establishment of the US National Nanotechnology Initiative (NNI), numerous new invention topics appeared in 2008, in all 15 patent repositories. This is more pronounced in the USA and PRC. Patent families have increased among the 15 patent offices, particularly after 2005. Overlapping patent applications increased from none in 1991 to about 4% in 2000 and to about 27% in 2008. The largest share of equivalent nanotechnology patent applications (1,258) between two repositories was identified between the US and Japan patent offices.

Patent Value: A Business Perspective for Technology Startups

OpenAIRE

Angela de Wilton

2011-01-01

In the last year, news headlines have highlighted record patent infringement settlements, multibillion dollar auctions of large corporate patent portfolios, and ongoing patent battles between key technology industry players. Despite this acknowledgment of the significant value of patents for large corporations, many small technology companies are understandably more focused on the near-term costs of obtaining a patent rather than future value. Costs may seem prohibitive to an early stage tech...

AVC/H.264 patent portfolio license

Science.gov (United States)

Skandalis, Dean A.

2006-08-01

MPEG LA, LLC offers a joint patent license for the AVC (a/k/a H.264) Standard (ISO/IEC IS 14496-10:2004). Like MPEG LA's other licenses, the AVC Patent Portfolio License is offered for the convenience of the marketplace as an alternative enabling users to access essential intellectual property owned by many patent holders under a single license rather than negotiating licenses with each of them individually. The AVC Patent Portfolio License includes essential patents owned by DAEWOO Electronics Corporation; Electronics and Telecommunications Research Institute (ETRI); France Telecom, societe anonyme; Fujitsu Limited; Hitachi, Ltd.; Koninklijke Philips Electronics N.V.; LG Electronics Inc.; Matsushita Electric Industrial Co., Ltd.; Microsoft Corporation; Mitsubishi Electric Corporation; Robert Bosch GmbH; Samsung Electronics Co., Ltd.; Sedna Patent Services, LLC; Sharp Kabushiki Kaisha; Siemens AG; Sony Corporation; The Trustees of Columbia University in the City of New York; Toshiba Corporation; UB Video Inc.; and Victor Company of Japan, Limited. Another is expected also to join as of August 1, 2006. MPEG LA's objective is to provide worldwide access to as much AVC essential intellectual property as possible for the benefit of AVC users. Therefore, any party that believes it has essential patents is welcome to submit them for evaluation of their essentiality and inclusion in the License if found essential.

Patent Ductus Arteriosus Treatment in Very Preterm Infants: A European Population-Based Cohort Study (EPICE) on Variation and Outcomes

NARCIS (Netherlands)

Edstedt Bonamy, A.K.; Gudmundsdottir, A.; Maier, R.F.; Toome, L.; Zeitlin, J.; Bonet, M.; Fenton, A.; Hasselager, A.B.; Heijst, A.F. van; Gortner, L.; Milligan, D.; Reempts, P. Van; Boyle, E.M.; Norman, M.

2017-01-01

BACKGROUND: Spontaneous closure of patent ductus arteriosus (PDA) occurs frequently in very preterm infants and despite the lack of evidence for treatment benefits, treatment for PDA is common in neonatal medicine. OBJECTIVES: The aim of this work was to study regional variations in PDA treatment in

[Risk control of traditional Chinese medicines containing aristolochis acids (AAs) based on influencing factors of content of AAs].

Science.gov (United States)

Tian, Jing-Zhuo; Liang, Ai-Hua; Liu, Jing; Zhang, Bo-Li

2017-12-01

Aristolochic acids (AAs) widely exist in such plants as Aristolochia and Asarum. The renal toxicity of AAs as well as its carcinogenicity to urinary system have been widely known. In 2003 and 2004, China prohibited the use of Aristolochiae Radix, Aristolochiae Manshuriensis Caulis and Aristolochiae Fangchi Radix, and required administering other AAs-containing medicines in accordance with the regulations for prescription drugs. In this paper, we retrieved literatures on the content determination of AAs in recent 10 years in China. It suggested that the AAs content is lower in Asarum herb, especially in its roots and rhizomes, and most of which do not show detectable amount of AA-I. Some of traditional Chinese medicines show fairly small amount of detectable AA-I. The AAs content in Aristolochia herb (including Fructus Aristolochiae, kaempfer dutchmanspipe root) is relatively high; however, there are fewer literatures for studying the content determination of AAs in Chinese patent medicines. There were many factors affecting AAs content, including the parts used, origins, processing methods, extraction process. It suggested that we should pay attention to the toxicity of Chinese medicines containing AAs and use these decoction pieces and traditional Chinese medicines cautiously. In addition, basic studies for the origins, processing methods and extraction process of Chinese patent medicines containing AAs, as well as supervision and detection of AAs content in traditional Chinese medicinal materials, decoction pieces and Chinese patent medicines shall be strengthened for reducing medication risk and guaranteeing clinical medication safety. Copyright© by the Chinese Pharmaceutical Association.

77 FR 269 - Matters Related to Patent Appeals

Science.gov (United States)

2012-01-04

... DEPARTMENT OF COMMERCE United States Patent and Trademark Office Matters Related to Patent Appeals ACTION: Proposed collection; comment request. SUMMARY: The United States Patent and Trademark Office... Matters Related to Patent Appeals comment'' in the subject line of the message. Mail: Susan K. Fawcett...

Areas with higher levels of natural radioactivity. Pt. 5

International Nuclear Information System (INIS)

Sansoni, B.; Technische Univ. Muenchen, Freising

1989-12-01

The maple source I delivers 'radon containing water' for possible cure applications with sufficiently high radon concentrations of about 40 nCi Rn-222/l, extremely low concentration of radium and other solution containing materials, and is exceptional among radon medicinal baths used up to now for radon medicinal cures in the Federal Republic of Germany. Radon balneology is especially important for rheumatic diseases. It concerns a stimulation therapy also for chronic diseases which otherwise do not have any effect on it. From the view of radiation protection, medicinal cures with radon become justifiable if standpoints of radiation protection for artificial radioactivity is transferred correspondingly to natural radioactivity which has not been laid down by legislation up to now. Balneology and medicine are to prove the usefulness of medicinal cures with radon in a way that can stand the limits of statistics. Spa doctor and spa staff have to subject to a normal control for radiation protection. (orig./HSCH) [de

Patentability aspects of computational cancer models

Science.gov (United States)

Lishchuk, Iryna

2017-07-01

Multiscale cancer models, implemented in silico, simulate tumor progression at various spatial and temporal scales. Having the innovative substance and possessing the potential of being applied as decision support tools in clinical practice, patenting and obtaining patent rights in cancer models seems prima facie possible. What legal hurdles the cancer models need to overcome for being patented we inquire from this paper.

The Transformation of Science Into Patented Inventions

DEFF Research Database (Denmark)

Beukel, Karin

This paper presents the results of a grounded theory study of the transformation of scientific discoveries into patented inventions. Using an algebraic interpretive approach, the narratives collected during interviews are analyzed as Bayesian inferences and the developed theory is tested. The fin......This paper presents the results of a grounded theory study of the transformation of scientific discoveries into patented inventions. Using an algebraic interpretive approach, the narratives collected during interviews are analyzed as Bayesian inferences and the developed theory is tested....... The findings recast the relationship between science and patents as a process in which the way the transformation of the scientific invention is handled has an effect on the breadth of the patent scope. Unleashing patent scope surplus is dependent on processes related to abstraction and cognitive variety......, which can be mobilized by patent experts with both an in-depth understanding of the scientific discovery, due to their educational background in the life sciences, and capabilities within the legal framework for patenting. More specifically, the findings reveal previously unreported aspects...

The Patentability of Stem Cells in Australia.

Science.gov (United States)

Petering, Jenny; Cowin, Prue

2015-07-01

The potential therapeutic applications of stem cells are unlimited. However, the ongoing political and social debate surrounding the intellectual property and patenting considerations of stem cell research has led to the implementation of strict legislative regulations. In Australia the patent landscape surrounding stem cells has evolved considerably over the past 20 years. The Australian Patents Act 1990 includes a specific exclusion to the patentability of human beings and of biological processes for their generation. However, this exclusion has received no judicial consideration to date, and so its scope and potential impact on stem cell patents is unclear. Copyright © 2015 Cold Spring Harbor Laboratory Press; all rights reserved.

The management of radioactive wastes from small producers

International Nuclear Information System (INIS)

1996-01-01

Medicine, research and industry generate various type of radioactive wastes which have to be managed by the ANDRA, the French agency for the management of radioactive wastes. This educative booklet explains the missions of the ANDRA with respect to these small producers: collection, selection, conditioning, control and storage of wastes. (J.S.)

Idea on patent ; It is high time to stress quality

International Nuclear Information System (INIS)

2012-03-01

This book deals with patent stressing on the quality, which includes from idea to technical business, It's simple to register the computer program, why do patent lawyer appoint the patent attorney's office? construction of patent right range, a good patent and a bad patent, strong patent and weak patent. It doesn't allow for Dus to use as we like, each patent has different value, Let's write technical specifications, advice on talking for invention with a patent attorney's office and what kind of task do intellectual property division do?

37 CFR 1.14 - Patent applications preserved in confidence.

Science.gov (United States)

2010-07-01

... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Patent applications preserved in confidence. 1.14 Section 1.14 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES General Provisions...

An assessment of the quality of advice provided by patent medicine vendors to users of oral contraceptive pills in urban Nigeria

Directory of Open Access Journals (Sweden)

Ujuju C

2014-04-01

Full Text Available Chinazo Ujuju,1 Samson B Adebayo,2 Jennifer Anyanti,3 Obi Oluigbo,3 Fatima Muhammad,4 Augustine Ankomah5 1Research and Evaluation Division, Society for Family Health, Abuja, Nigeria; 2Planning, Research and Statistics Directorate, National Agency for Food and Drug Administration and Control, Abuja, Nigeria; 3Technical Services Directorate, Society for Family Health, Abuja, Nigeria; 4Family Planning Directorate, Society for Family Health, Abuja, Nigeria; 5Department of Population, Family and Reproductive Health, School of Public Health, University of Ghana, Legon, Accra, Ghana Introduction: In Nigeria about 50% of oral contraceptive pill users obtain their products from proprietary patent medicine vendors (PPMVs. This group of service providers are poorly trained and have very limited knowledge about contraception. This paper investigated the nature of the advice offered to simulated current and potential users of oral contraceptive pills. The main objective was to assess the nature and quality of advice provided by PPMVs to pill users. Method: This study is based on findings from a 'mystery client' approach in which three scenarios related to contraceptive pill use were simulated. Each of the 12 mystery clients simulated one of the following three scenarios: new pill users (new to family planning or switching from condom to pills; user seeking a resupply of pills; and dissatisfied pill users intending to discontinue use. Simple random sampling was used to select 410 PPMVs from a total of 1,826 in four states in Nigeria. Qualitative study using in-depth interviews was also conducted. Results: A majority of the PPMVs had pills in stock on the day of the survey and resupplied pills to the clients. PPMVs also understood the reason and importance of referring clients who were new adopters of oral contraceptive methods to a health facility; 30% of the PPMVs referred new adopters to a health facility. However, demand from clients who do not want to go

The 'new' Radiation Protection Ordinance - marking the difference between application of 'radioactive substances in medical research' (Section 41 StrlschV) and 'radioactive substances or ionizing radiation in medicine and dental medicine' (Section 42 StrlschV)

International Nuclear Information System (INIS)

Roedern, P.

1983-01-01

The main differences in the provisions are to be found under the following aspects: - Observation of dose limits; - Necessity of physical radiation protection surveillance; - Obligation to apply for approval in individual cases; - Selection of test persons/patients; - Scope of conditions governing approval; - Obligation to inform about hazards. The unambiguous definition of procedures and purposes allowed in the field of medical research, and of those in the field of medical therapy (including dental medicine) is of crucial importance, due to its significance with regard to radiation protection, civil law and penal law. Marking the limits between these two fields subject to supervision is a precondition allowing the proper application of relevant laws in the field of use and handling of radioactive substances or ionizing radiation for medical purposes. (orig./HSCH) [de

Patent Value: A Business Perspective for Technology Startups

Directory of Open Access Journals (Sweden)

Angela de Wilton

2011-12-01

Full Text Available In the last year, news headlines have highlighted record patent infringement settlements, multibillion dollar auctions of large corporate patent portfolios, and ongoing patent battles between key technology industry players. Despite this acknowledgment of the significant value of patents for large corporations, many small technology companies are understandably more focused on the near-term costs of obtaining a patent rather than future value. Costs may seem prohibitive to an early stage technology startup. Some software startups question whether patents are relevant to their business. In practice, effective intellectual property (IP strategy and management is dependent on many factors, such as technology or industry sector, size and maturity of the business, technology lifecycle, and the business and market environment. IP strategy must be aligned to business strategy from the outset. By considering IP in the broader context of the overall business plan and the competitive environment, opportunities for generating increased return on R&D investment and added business value through patents or other forms of IP can be recognized early on. This approach ensures that a decision about whether or not to patent is driven by business reasons rather than budget constraints. This article examines the costs and benefits of patents from the perspective of early-stage technology startups and growing businesses, and it provides some general guidance on best practices for developing an IP and patent activity plan and for building a patent portfolio that appropriately supports business objectives.

Trends in worldwide nanotechnology patent applications: 1991 to 2008

Energy Technology Data Exchange (ETDEWEB)

Dang Yan, E-mail: ydang@email.arizona.edu; Zhang Yulei, E-mail: ylzhang@email.arizona.edu; Fan Li, E-mail: fanli@email.arizona.edu; Chen Hsinchun, E-mail: hchen@eller.arizona.ed [University of Arizona, Department of Management Information Systems, Eller College of Management (United States); Roco, Mihail C., E-mail: mroco@nsf.go [National Science Foundation (United States)

2010-03-15

Nanotechnology patent applications published during 1991-2008 have been examined using the 'title-abstract' keyword search on esp-cenet 'worldwide' database. The longitudinal evolution of the number of patent applications, their topics, and their respective patent families have been evaluated for 15 national patent offices covering 98% of the total global activity. The patent offices of the United States (USA), People's Republic of China (PRC), Japan, and South Korea have published the largest number of nanotechnology patent applications, and experienced significant but different growth rates after 2000. In most repositories, the largest numbers of nanotechnology patent applications originated from their own countries/regions, indicating a significant 'home advantage.' The top applicant institutions are from different sectors in different countries (e.g., from industry in the US and Canada patent offices, and from academe or government agencies at the PRC office). As compared to 2000, the year before the establishment of the US National Nanotechnology Initiative (NNI), numerous new invention topics appeared in 2008, in all 15 patent repositories. This is more pronounced in the USA and PRC. Patent families have increased among the 15 patent offices, particularly after 2005. Overlapping patent applications increased from none in 1991 to about 4% in 2000 and to about 27% in 2008. The largest share of equivalent nanotechnology patent applications (1,258) between two repositories was identified between the US and Japan patent offices.

Patent protection for microbial technologies.

Science.gov (United States)

Sherkow, Jacob S

2017-11-01

Microbial technologies often serve as the basis of fundamental research tools in molecular biology. These present a variety of ethical, legal and social issues concerning their patenting. This commentary presents several case studies of these issues across three major microbiological tools: CRISPR, viral vectors and antimicrobial resistance drugs. It concludes that the development of these technologies-both scientifically and commercially-depend, in part, on the patent regime available for each, and researchers' willingness to enforce those patents against others. © FEMS 2017. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Uniform interpretation of european patent law with a special view on the creation of a common patent court

NARCIS (Netherlands)

Luginbühl, SL

2009-01-01

The European Patent Convention (EPC) provides for a common application and examination procedure for European patents. Therefore, European patents are granted on the basis of uniform European law which is applied and interpreted by the EPO, as well as by a great number of national judges and members

37 CFR 11.9 - Limited recognition in patent matters.

Science.gov (United States)

2010-07-01

... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Limited recognition in patent matters. 11.9 Section 11.9 Patents, Trademarks, and Copyrights UNITED STATES PATENT AND TRADEMARK OFFICE, DEPARTMENT OF COMMERCE REPRESENTATION OF OTHERS BEFORE THE UNITED STATES PATENT AND TRADEMARK OFFICE...

Patent Keyword Extraction for Sustainable Technology Management

Directory of Open Access Journals (Sweden)

Jongchan Kim

2018-04-01

Full Text Available Recently, sustainable growth and development has become an important issue for governments and corporations. However, maintaining sustainable development is very difficult. These difficulties can be attributed to sociocultural and political backgrounds that change over time [1]. Because of these changes, the technologies for sustainability also change, so governments and companies attempt to predict and manage technology using patent analyses, but it is very difficult to predict the rapidly changing technology markets. The best way to achieve insight into technology management in this rapidly changing market is to build a technology management direction and strategy that is flexible and adaptable to the volatile market environment through continuous monitoring and analysis. Quantitative patent analysis using text mining is an effective method for sustainable technology management. There have been many studies that have used text mining and word-based patent analyses to extract keywords and remove noise words. Because the extracted keywords are considered to have a significant effect on the further analysis, researchers need to carefully check out whether they are valid or not. However, most prior studies assume that the extracted keywords are appropriate, without evaluating their validity. Therefore, the criteria used to extract keywords needs to change. Until now, these criteria have focused on how well a patent can be classified according to its technical characteristics in the collected patent data set, typically using term frequency–inverse document frequency weights that are calculated by comparing the words in patents. However, this is not suitable when analyzing a single patent. Therefore, we need keyword selection criteria and an extraction method capable of representing the technical characteristics of a single patent without comparing them with other patents. In this study, we proposed a methodology to extract valid keywords from

Wacky Patents Meet Economic Indicators

DEFF Research Database (Denmark)

Czarnitzki, Dirk; Hussinger, Katrin; Schneider, Cédric

2011-01-01

We investigate whether standard indicators can distinguish between “wacky” patents and a control group. Forward citations are good predictors of importance. However, “wacky” patents have higher originality, generality and citation lags, suggesting that these indicators should be interpreted...

When patents matter: The impact of competition and patent age on the performance contribution of intellectual property rights protection

NARCIS (Netherlands)

Maresch, Daniela; Fink, Matthias; Harms, Rainer

2016-01-01

The question whether patenting impacts patenting firms' subsequent financial performance is important for technology-oriented companies. However, relevant research has led to contradictory results. We strive to overcome this impasse by introducing innovation competition and patent age as moderators

El Sistema de patentes en Colombia

Directory of Open Access Journals (Sweden)

Rafael Viana Barceló

2014-01-01

Full Text Available En este documento se realiza un análisis económico del Sistema de Patentes de Colombia. Para ello, se establece el efecto que tienen las patentes concedidas a los inventores foráneos sobre la Inversión Extranjera Directa y el Producto Interno Bruto Nacional, a través de la técnica de regresión de data panel. De igual manera, se identifican los sectores económicos que registran mayores tasas de innovación por parte de los inventores nacionales y extranjeros. Se muestra que el sistema nacional de propiedad intelectual tiene un grado de fortaleza acorde con el resto de países latinoamericanos; para ello, se construye un índice de grado de fortalecimiento de sistema de patente nacional que luego será comparado con el de otros países latinos.Palabras Clave: Sistema de Patentes; Derechos de Propiedad Intelectual; Inversión Directa extranjera; Producto Interno Bruto e innovación tecnológica. The system of patents in ColombiaAbstractIn this document an economic analysis of the System of Patents of Colombia is made. For it, the effect that has the patents granted to the foreign inventors on the Direct Foreign Investment and the Internal Product Gross National, through the technique of regression of data settles down panel. Of equal way, the economic sectors are identified that register greater rates of innovation on the part of the national and foreign inventors.Sample that the national system of intellectual property has a degree of agreed strength with the rest of Latin American countries; for it, an index of degree of fortification of system of national patent is constructed that soon will be compared with the one of other Latin countries.Keywords: System Patent; Rights of Intellectual Property; Foreign Direct Investment; Gross Domestic Product and Technology Innovation.

Exploring gender differences in patenting in Spain

OpenAIRE

Elba Mauleón; Cinzia Daraio; Maria Bordons

2013-01-01

The under-representation of women in science and technology is a matter of current great concern. Obtaining patent-based indicators by gender is crucial to analyse the situation of women in innovation, identify potential cases of gender inequalities, and support policy measures to promote gender balance. In this article we analyse men and women involvement in Spanish patents applied to the European Patent Office during 1990--2004. At least one female inventor is present in 18% of the patents;...

Traditional Knowledge and Patent Protection: Conflicting Views On International Patent Standards

Directory of Open Access Journals (Sweden)

A Andrzejewski

2010-12-01

Full Text Available As diseases continue to spread around the globe, pharmaceutical and biotech companies continue to search for new and better drugs to treat them. Most of these companies have realised that useful compounds for these purposes may be found in the natural resources that indigenous and local communities use. And yet, even though the importance of these biological resources to global health and economic livelihood is well recognised, the legal ownership and control of this traditional knowledge is still very controversial. This article undertakes a comparative analysis of American and European, as well as international legal regulations on patent law and traditional knowledge. Key questions include: What is traditional knowledge? How have the national patent laws of these countries treated the protection of plant variety and plant genetic resources? What are the existing international standards for patents, and what implications do they have for protecting traditional knowledge? And finally, what protection systems are emerging for the future?

Advance in radioactive decontamination

International Nuclear Information System (INIS)

Basteris M, J. A.; Farrera V, R.

2010-09-01

The objective of the present work was to determine if the application of the Na hypochlorite has some utility in the radioactive decontamination, in comparison with the water, detergent and alcohol. Several methods were compared for decontaminate the iodine 131 and technetium 99, the work table and the skin it was carried out an initial count with the Geiger Muller. Later on, in a single occasion, the areas were washed with abundant water, alcohol, clothes detergent and sodium hypochlorite (used commercially as domestic bleacher) without diluting. Observing that the percentage in the decrease of the counted radioactivity by the Geiger Muller, decreased in the following way: It was demonstrated that the Na hypochlorite presents the highest index of radioactive decontamination with 100% of effectiveness. The Na hypochlorite is an excellent substance that can be used with effectiveness and efficiency like decontamination element in the accident cases of radioactive contamination in the clinical laboratories of nuclear medicine. (Author)

37 CFR 1.81 - Drawings required in patent application.

Science.gov (United States)

2010-07-01

... 37 Patents, Trademarks, and Copyrights 1 2010-07-01 2010-07-01 false Drawings required in patent..., DEPARTMENT OF COMMERCE GENERAL RULES OF PRACTICE IN PATENT CASES National Processing Provisions The Drawings § 1.81 Drawings required in patent application. (a) The applicant for a patent is required to furnish...

Advances in CO2 capture technology: A patent review

International Nuclear Information System (INIS)

Li, Bingyun; Duan, Yuhua; Luebke, David; Morreale, Bryan

2013-01-01

Highlights: ► Timely updates on carbon capture technologies: More than 1000 patents on solvent, sorbent, and membrane. ► More patents on solvent and sorbent compared to membrane. ► Environmental and health concerns exist regarding carbon capture technologies. -- Abstract: Carbon dioxide (CO 2 ) emissions are believed to be a major contributor to global warming. As a consequence, large anthropogenic CO 2 sources worldwide will eventually be required to implement CO 2 capture and storage technologies to control CO 2 emissions. In order to guide the establishment of policies for CO 2 removal, we reviewed the current status of CO 2 capture patents and technologies based on the Espacenet patent database and found that more than 1000 patents have been published on sorbent, solvent, and membrane. More than 60% of these patents were published since the year 2000, and a sharp increase in patent numbers was seen in the last several years; ∼25% patents were published in the last 2 years. Substantially more patents on CO 2 removal and separation technologies are expected in the coming years. Meanwhile, the top four major types of patents, which consist of more than 2/3 of these patents, were patents granted by Japan (JP), United States (US), World Intellectual Property Organization (WO), and China (CN), and approximately half of the patents were JP and US patents. Unfortunately, no current technologies for removing CO 2 from large sources like coal-based power plants exist which satisfy the needs of safety, efficiency, and economy; further enhancement and innovation are much needed.

Online Patent Searching: The Realities.

Science.gov (United States)

Kaback, Stuart M.

1983-01-01

Considers patent subject searching capabilities of major online databases, noting patent claims, "deep-indexed" files, test searches, retrieval of related references, multi-database searching, improvements needed in indexing of chemical structures, full text searching, improvements needed in handling numerical data, and augmenting a…

Efficacy of Chinese patent medicine Tian Gui Capsule in patients with polycystic ovary syndrome: a randomized controlled trial.

Science.gov (United States)

Kuek, Susuana; Wang, Wen-jun; Gui, Sui-qi

2011-09-01

Polycystic ovary syndrome (PCOS) is a complex hormonal disorder and one of the most common reproductive endocrinology abnormalities in women. Recently, many studies have been conducted assessing Chinese herbal medicine as an alternative treatment for women with PCOS, it is, therefore, worthwhile to analyze and observe the curative effects of traditional Chinese medicine treatment in PCOS. To evaluate the efficacy of the Chinese patent medicine Tian Gui Capsule, in women with PCOS and compare its effects with metformin and ethinyl estradiol plus cyproterone acetate (Diane-35). A total of 47 PCOS outpatients from the Obstetrics and Gynecology Hospital of Fudan University were randomly divided into 3 groups. Patients in group A (n=19) were given Tian Gui Capsule, patients in group B (n=17) were given metformin, and patients in group C (n=11) were given Diane-35. The 3 groups of patients were treated for 3 months. Serum testosterone (T), sex hormone binding globulin (SHBG) and dehydroepiandrosterone sulfate (DHEA-S) levels, free androgen index (FAI), fasting blood glucose (FPG), fasting insulin (FINS), homeostasis model assessment of insulin resistance (HOMA-IR), insulin sensitive index (ISI) and left and right ovary volumes of the 3 groups were evaluated before and after treatment . After 3 months of treatment, when compared with before treatment data, group A patients showed decreased serum T and SHBG levels, FAI, FINS, and left and right ovary volumes (P<0.05), and increased serum DHEA-S (P<0.05), while the FPG level showed no significant change. Although the level of serum T and FINS among the 3 groups after the treatment were similar, group A demonstrated better results than group B in reducing the FAI and increasing the serum SHBG, but less significant results than group C besides, group B was the only group showed improved insulin sensitivity. Although the level of FPG of the 3 groups after treatment were similar, group C had the most increased FPG. The effects

A patent extension proposal to end the underrepresentation of women in clinical trials and secure meaningful drug guidance for women.

Science.gov (United States)

Hathaway, Cynthia

2012-01-01

Historically, women have been systematically excluded from or underrepresented in human clinical trials of new drugs. Due to fundamental physiological differences between women and men with regard to how drugs work in the human body, testing of drugs in men alone can both deny women the full benefit of a drug and cause them to suffer from increased adverse side effects. Attempts to reform drug development law and agency practices to resolve this problem have met with only partial success. Proposed herein is a patent term extension and for studies in women, modeled upon the pediatric patent term extension, but with several key differences intended to reduce the cost to the public and fund auxiliary programs to address off-patent medicines as well. Such an extension would incentivize this research and provide meaningful guidance to women and their physicians.

U Y 105 standard use of non sealed radioactive sources in nuclear medicine: approve for Industry energy and Mining Ministry 28/6/2002 Resolution; Norma UY 105 uso de fuentes radiactivas no selladas en Medicina Nuclear: Aprobada por Resolucion del Ministro de Industria Energia y Mineria de 28/6/2002

Energy Technology Data Exchange (ETDEWEB)

NONE

2002-06-28

Establish minimal requirements radiological safety for use non sealed radioactive sources in nuclear medicine.The present standard is used in operation or nuclear medicine practices using non sealed radioactive sources with diagnostic and therapeutic purposes in vivo and in vitro.

Safety disposal studies of radioactive and hazardous wastes using cement

International Nuclear Information System (INIS)

Aly, M.M.E.

2000-01-01

radioactive waste is generated from the production of nuclear energy and from the use of radioactive materials applications, agriculture and medicine. the important of safe management of radioactive waste for the protection of human health and the environment has long been recognized. conditioning of radioactive waste is the transform of radioactive waste into a suitable form for storage and disposal. common immobilization methods include solidification of low radioactive waste in cement or bitumen.in order to improve cement properties to decrease the release of liquid radioactive waste into the environment and its dispersion to a level where the risks to individuals, population and the environment

Are patent medicine vendors effective agents in malaria control? Using lot quality assurance sampling to assess quality of practice in Jigawa, Nigeria.

Science.gov (United States)

Berendes, Sima; Adeyemi, Olusegun; Oladele, Edward Adekola; Oresanya, Olusola Bukola; Okoh, Festus; Valadez, Joseph J

2012-01-01

Patent medicine vendors (PMV) provide antimalarial treatment and care throughout Sub-Saharan Africa, and can play an important role in the fight against malaria. Their close-to-client infrastructure could enable lifesaving artemisinin-based combination therapy (ACT) to reach patients in time. However, systematic assessments of drug sellers' performance quality are crucial if their role is to be managed within the health system. Lot quality assurance sampling (LQAS) could be an efficient method to monitor and evaluate PMV practice, but has so far never been used for this purpose. In support of the Nigeria Malaria Booster Program we assessed PMV practices in three Senatorial Districts (SDs) of Jigawa, Nigeria. A two-stage LQAS assessed whether at least 80% of PMV stores in SDs used national treatment guidelines. Acceptable sampling errors were set in consultation with government officials (alpha and beta LQAS has been shown to be a suitable method for monitoring malaria-related indicators among PMV, and should be applied in Nigeria and elsewhere to improve service delivery.

Management of radioactive wastes of iodine therapy

International Nuclear Information System (INIS)

Silva, Andre R.M.; Santos, Helena C.

2015-01-01

The main objective of waste radioactive management is to ensure the protection of man and the preservation of the environment. The regulation that established the basis for the good radioactive waste management was elaborated by the Comissao Nacional de Energia Nuclear (CNEN), in 1985. It is the CNEN-NE-6:05: 'Management radioactive waste in radioactive facilities', which although it an important standard related to radioactive waste management and help largely in the design of a management system in radioactive facilities of radioisotope users, covers the topics in a general way and does not consider individuals aspects of the different plants, as is the case of nuclear medicine units. The main objective of this study is to show the segregation and safe packaging, avoiding unnecessary exposure of professionals involved and public individuals in general

Patent Strategy at the Age of High Technology

Science.gov (United States)

Aoyama, Hirokazu

This paper is a summary of the lecture which the author presented at the 5th Hokuriku Workshop for Study of Scientific and Technological Information Activities on the 17th of January in 1986. The author analyzed the present situation and made some suggestions on them ; (1) the role of patent system has shifted from introduction of foreign technologies to independent technological development at the age of high technology, (2) circumstances of rapidly increasing international patent war, particularly patent conflict between U.S. and Japan concerning U.S. ITC, (3) as the service of soft aspects of economy has been closed up, the new business has come to the fore front, and the move to consider technology as a good has been activated, (4) how patent specification should be written, the way of obtaining and protecting patent successfully, (5) basic pattern of patent strategy and what the strategy should be to respond to the enterprises level, (6) present situation of patent information service, effective use of patent maps and information strategy.

Step-By-Step: Life Cycle Radioactive Waste Management

International Nuclear Information System (INIS)

2014-01-01

Radioactive waste is an unavoidable by-product when nuclear technologies are used for electricity production and for beneficial practices in medicine, agriculture, research and industry. When the radioactivity of the waste is above a certain threshold, the waste requires special disposal methods. Through extensive research, standards and approaches have been developed for safely and securely preparing for and managing radioactive waste disposal. In the course of its journey from the point of generation to disposal, radioactive waste undergoes a number of predisposal management treatment steps to transform it into a safe, stable and manageable form suitable for transport, storage and disposal

ECOLOGICAL AND TECHNICAL REQUIREMENTS OF RADIOACTIVE WASTE UTILISATION

Directory of Open Access Journals (Sweden)

Gabriel Borowski

2013-01-01

Full Text Available The paper presents a survey of radioactive waste disposal technologies used worldwide in terms of their influence upon natural environment. Typical sources of radioactive waste from medicine and industry were presented. In addition, various types of radioactive waste, both liquid and solid, were described. Requirements and conditions of the waste’s storage were characterised. Selected liquid and solid waste processing technologies were shown. It was stipulated that contemporary methods of radioactive waste utilisation enable their successful neutralisation. The implementation of these methods ought to be mandated by ecological factors first and only then economical ones.

Applying patent information to tracking a specific technology

Directory of Open Access Journals (Sweden)

Chen-Yuan Liu

2007-10-01

Full Text Available Patents in general contain much novel technological information. This paper demonstrates that the usage of patent analysis can facilitate a unique scheme for tracking technology development. In this paper, the walking technique of the Japanese biped robot is tracked as an example. The searching method of the FI (file index and F-term classification system developed by JPO (Japan Patent Office was employed in this study, where all the related patent data were searched from the IPDL (Intellectual Property Digital Library. This study investigated an important technique applied to the humanoid biped robot that imitates the walking behavior of the human beings on two legs. By analyzing the patent information obtained, the relative research capabilities, technical strengths, and patent citation conditions among patent competitors were compared. Furthermore, a formulated technical matrix of patent map is established in this paper to indicate that the ZMP (Zero Moment Point control means is the main technology to achieve stabilized walking control of the humanoid biped robot. This study also incorporates relevant academic journal findings and industrial information. Results presented herein demonstrate that patents can function not only as a map for tracking a technology trajectory, but also as a guide to the main development of a new technology in years to come.

Fundamentals of patenting and licensing for scientists and engineers

National Research Council Canada - National Science Library

Ma, M. Y. (Matthew Y.)

2009-01-01

... ...28 3.2 Types of Patents...28 3.3 Patent Dates ...29 viiviii Fundamentals of Patenting and Licensing for Scientists and Engineers 3.4 Eligibility of Priority Date ...30 3.5 Patentability ...32...

The Patent Literature As A Shortcut To Identify Knowledge Suppliers

DEFF Research Database (Denmark)

Søberg, Peder Veng

patents which decreases the time span between a patent is filed and its value can be evaluated when searching the patent literature. A potential benefit thereof could be that the patent literature could become relevant in order to identify potential knowledge suppliers.......The present paper explores characteristics of valuable patents that have been subject to litigation which resulted in some of the largest fines to patent infringers reported in history. The valuable patents are compared with less valuable patents in order to identify new methods of evaluating...

The gene patent controversy on Twitter: a case study of Twitter users' responses to the CHEO lawsuit against Long QT gene patents.

Science.gov (United States)

Du, Li; Kamenova, Kalina; Caulfield, Timothy

2015-08-25

The recent Canadian lawsuit on patent infringement, filed by the Children's Hospital of Eastern Ontario (CHEO), has engendered a significant public debate on whether patenting genes should be legal in Canada. In part, this public debate has involved the use of social networking sites, such as Twitter. This case provides an opportunity to examine how Twitter was used in the context of this gene patent controversy. We collected 310 English-language tweets that contained the keyword "gene patents" by using TOPSY.com and Twitter's built-in search engine. A content analysis of the messages was conducted to establish the users' perspectives on both CHEO's court challenge and the broader controversy over the patenting of human DNA. More specifically, we analyzed the users' demographics, geographic locations, and attitudes toward the CHEO position on gene patents and the patentability of human genes in principle. Our analysis has shown that messages tweeted by news media and health care organizations were re-tweeted most frequently in Twitter discussions regarding both the CHEO patent infringement lawsuit and gene patents in general. 34.8% of tweets were supportive of CHEO, with 52.8% of the supportive tweets suggesting that gene patents contravene patients' rights to health care access. 17.6% of the supportive tweets cited ethical and social concerns against gene patents. Nearly 40% of tweets clearly expressed that human genes should not be patentable, and there were no tweets that presented perspectives favourable toward the patenting of human genes. Access to healthcare and the use of genetic testing were the most important concerns raised by Twitter users in the context of the CHEO case. Our analysis of tweets reveals an expectation that the CHEO lawsuit will provide an opportunity to clear the confusion on gene patents by establishing a legal precedent on the patentability of human genes in Canada. In general, there were no tweets arguing in favour of gene patents

Discriminatory components retracing strategy for monitoring the preparation procedure of Chinese patent medicines by fingerprint and chemometric analysis.

Directory of Open Access Journals (Sweden)

Shuai Yao

Full Text Available Chinese patent medicines (CPM, generally prepared from several traditional Chinese medicines (TCMs in accordance with specific process, are the typical delivery form of TCMs in Asia. To date, quality control of CPMs has typically focused on the evaluation of the final products using fingerprint technique and multi-components quantification, but rarely on monitoring the whole preparation process, which was considered to be more important to ensure the quality of CPMs. In this study, a novel and effective strategy labeling "retracing" way based on HPLC fingerprint and chemometric analysis was proposed with Shenkang injection (SKI serving as an example to achieve the quality control of the whole preparation process. The chemical fingerprints were established initially and then analyzed by similarity, principal component analysis (PCA and partial least squares-discriminant analysis (PLS-DA to evaluate the quality and to explore discriminatory components. As a result, the holistic inconsistencies of ninety-three batches of SKIs were identified and five discriminatory components including emodic acid, gallic acid, caffeic acid, chrysophanol-O-glucoside, and p-coumaroyl-O-galloyl-glucose were labeled as the representative targets to explain the retracing strategy. Through analysis of the targets variation in the corresponding semi-products (ninety-three batches, intermediates (thirty-three batches, and the raw materials, successively, the origins of the discriminatory components were determined and some crucial influencing factors were proposed including the raw materials, the coextraction temperature, the sterilizing conditions, and so on. Meanwhile, a reference fingerprint was established and subsequently applied to the guidance of manufacturing. It was suggested that the production process should be standardized by taking the concentration of the discriminatory components as the diagnostic marker to ensure the stable and consistent quality for multi

Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.

Science.gov (United States)

Gupta, Ravi; Bollyky, Thomas J; Cohen, Matthew; Ross, Joseph S; Kesselheim, Aaron S

2018-03-19

To evaluate whether off-patent prescription drugs at risk of sudden price increases or shortages in the United States are available from independent manufacturers approved in other well regulated settings around the world. Observational study. Off-patent drugs in the USA and approved by the Food and Drug Administration, up to 10 April 2017. Novel tablet or capsule prescription drugs approved by the FDA since 1939 that were no longer protected by patents or other market exclusivity and had up to three generic versions. Number of additional manufacturers that had obtained approval from any of seven non-US regulators with similar standards (European Medicines Agency (European Union), HealthCanada (Canada), Therapeutic Goods Association (Australia), Medsafe (New Zealand), Swissmedic (Switzerland), Medicines Control Council (South Africa), and the Israel Health Ministry). Association with drug characteristics including US orphan drug designation for drugs treating rare diseases, World Health Organization essential medicine designation, treatment area, drug product complexity (that is, with attributes that could complicate establishing bioequivalence or manufacturing), and total Medicaid spending in 2015. Of 170 eligible study drugs, more than half (109, 64%) had at least one manufacturer approved by a non-US regulator and 32 (19%) had four or more. Among 44 (26%) drugs with no FDA approved generic versions, 21 (48%) were available from at least one manufacturer approved by one of the seven non-US regulators, and two (5%) by four or more manufacturers. Across all drugs and regulators (including the FDA), 66 (39%) drugs were available from four or more total manufacturers. Of 109 drugs with at least one non-US regulator approved manufacturer, 12 (11%) were approved for patients with rare diseases and 29 (27%) were WHO designated essential medicines; only 12 (11%) were complex products that might be more complicated to import. The highest numbers of drugs were indicated

48 CFR 1427.201 - Patent and copyright infringement liability.

Science.gov (United States)

2010-10-01

... 48 Federal Acquisition Regulations System 5 2010-10-01 2010-10-01 false Patent and copyright... INTERIOR GENERAL CONTRACTING REQUIREMENTS PATENTS, DATA, AND COPYRIGHTS Patents and Copyrights 1427.201 Patent and copyright infringement liability. ...

48 CFR 27.201 - Patent and copyright infringement liability.

Science.gov (United States)

2010-10-01

... 48 Federal Acquisition Regulations System 1 2010-10-01 2010-10-01 false Patent and copyright... REGULATION GENERAL CONTRACTING REQUIREMENTS PATENTS, DATA, AND COPYRIGHTS Patents and Copyrights 27.201 Patent and copyright infringement liability. ...

A study of fuel cell patenting activity in Canada

International Nuclear Information System (INIS)

Lee, B.Y.; Sajewycz, M.

2004-01-01

'Full text:' A patent application is generally filed shortly after completion of research and development; therefore, patent filing statistics provide insight into the state of innovation of a technology. A study has been conducted on fuel cell patenting activity in Canada. This study examines fuel cell patenting trends between 1989-2003 and specific activity in 2001, identifies the major players in the Canadian fuel cell industry, and examines the patent landscape by fuel cell technology. Our results show that historically, Canadians have been leaders at home and abroad in fuel cell innovation. However, Canadians have recently fallen behind in protecting their patent rights at home, and now rank fourth behind German, American and Japanese fuel cell patent filers in the Canadian patent office. However, our data also shows that a significant number of new Canadian entities have emerged and have been very active filing new patent applications. These new entities as well as established Canadian companies are examined in detail. (author)

Pesticides and the Patent Bargain

NARCIS (Netherlands)

Timmermann, C.A.

2015-01-01

In order to enlarge the pool of knowledge available in the public domain, temporary exclusive rights (i.e. patents) are granted to innovators who are willing to fully disclose the information needed to reproduce their invention. After the 20-year patent protection period elapses, society should be

[Exploration of microcosmic Chinese medicine used by western medicine].

Science.gov (United States)

Zheng, Zhi-jing

2015-02-01

"Microcosmic syndrome", "treatment based on syndrome differentiation", and "combination of disease identification and syndrome differentiation" generally refer to a mode: following the syndrome if with no disease identified, following the disease if with no syndrome type differentiated. For example, Chinese medical treatment of hypertension, high blood lipids, increased transaminase, and so on candirectly use Chinese recipes, but no longer with syndrome differentiation. Clinical application of Chinese patent medicine can also obtain favorable clinical. Western doctors need not follow syndrome differentiation. The invention of artemisinin was screened from more than 40 000 kinds of compounds and herbs, but with no reference of any traditional Chinese medical theory. A lot of folk remedy and empirical recipes have obtained effective efficacy but unnecessarily with profound Chinese medical theories. Various evidences showed that disease can also be cured without syndrome differentiation. I held that it might be associated with the same mechanism of Chinese medicine and Western medicine. Any disease can be cured or alleviated by Chinese medicine is a result from its modern pharmacological effect, which is achieved by improving etiologies, and pathogeneses. I was inspired by whether we can directly use traditional Chinese medicine with modern pharmacological effects to treat symptomatic disease. So I raised an idea of microcosmic Chinese medicine used by Western medicine, i.e., we find and use Chinese herbs with relatively effective modern pharmacological effect to treat diseases targeting at patients' clinical symptoms and signs, as well as various positive laboratory results (collectively called as microscopic dialectical indicators). More Western doctors would use it to treat disease due to omission of complicated and mysterious syndrome differentiation. This will promote extensive application and expansion of Chi- nese medicine and pharmacy, enlarge the team of

Radioactive contamination in the Bologna sewage system due to nuclear medicine examinations

International Nuclear Information System (INIS)

Testoni, G.; Bernardi, T.; Tubertini, O.; Bergamini, B.; Marengo, M.

1988-01-01

Liquid wastes produced by the city of Bologna and surrounding areas are collected by a sewage system, leading to a depuration plant. At present, the capacity of the sewage system is about 230,000 m 3 per day, half of which is treated by the depurator. The incoming flow is fairly constant throughout the year, except for August when, owing to factory shut-down for holidays, there is a decrease of about 60,000 m 3 per day. The treatment of of liquid waste in the depurator is in four phases : primary decantation, active oxidation, active decantation, and disinfection. After treatment lasting 12-13 hours, clarified liquids are discharged into the Navile canal. This leads to the Reno river and then to the Adriatic sea. Muds produced during decantation are further treated and reduced to ashes (within 24-48 hours) that are then stored. Since the sewage system also collects liquid waste from two nuclear medicine departments (Malpighi and Maggiore hospitals), we decided to measure radioactivity in the liquids both at entrance and at exit from the depurator, and in the muds and ashes produced by treatment

48 CFR 2527.7002 - NSF patent policy.

Science.gov (United States)

2010-10-01

... 48 Federal Acquisition Regulations System 6 2010-10-01 2010-10-01 true NSF patent policy. 2527... CONTRACTING REQUIREMENTS PATENTS, DATA, AND COPYRIGHTS Disposition of Rights in Inventions 2527.7002 NSF patent policy. As authorized by the National Science Board at its 230th meeting, October 15-16, 1981, the...

Performance of Patenting Firms in Danish Manufacturing

DEFF Research Database (Denmark)

Madsen, Erik Strøjer; Smith, Valdemar; Nielsen, Anders Østergaard

2000-01-01

Most countries focus on industries with high technology and the governments grant subsidies to innovating firms. However, there has been remarkable few studies of the performance of innovative firms or industries. This study examines the performance of patent active firms compared to the non-patenting...... firms within the manufacturing sector in Denmark. Performance is measured both by growth in employment as well as in the return on equity and profit share in turnover. The results suggest that differences in performance of patenting and non-patenting firms are very small, which questions the political...

Applications of radioisotopes in medicine

International Nuclear Information System (INIS)

Sivaprasad, N.

2012-01-01

The application of radioisotopes in medicine is many folds. They can be classified into two main groups. (a) The radioisotope tagged labeled compounds suitable for safe administration in the body for diagnosis of various diseases of vital organs such as brain, kidney, thyroid etc and for treatment known as radiotherapy (b) The sealed source of radioisotopes for utilizing the radiation emitted from the radioisotope for treatment, particularly for radiation therapy of cancer. The former application of radioisotope in the field of medicine has led to the formation of special branch of medicine termed Nuclear Medicine - the branch of medicine deals with the use of radioisotope in the from of radiopharmaceuticals for investigation, diagnosis and treatment of diseases. Radioisotopes in the form of radiolabelled compound and bio-chemicals that are pharmaceutically and radiologically safe for administration in the body for diagnosis and treatment are called radiopharmaceuticals. The radiopharmaceuticals are the results of world-wide effort to bring nuclear energy in a tangible form for diagnosis and treatment. Radioisotopes as radiopharmaceuticals thus constitute one of the key requirements for nuclear medicine investigation and radiotherapy. In the case of sealed radioisotope source the radiation emitted by the radioactive source is utilized for the treatment and this mode of treatment is called radiation therapy where no radioactive substance is administrated into the body. This does not form the part of nuclear medicine

Ekor - unique material for transportation, containment and disposal of radioactive wastes